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Background Cervical cancer, caused by human papillomavirus (HPV), is a major public health problem. Globally there are estimated to be 528,000 new cervical cancer cases and 266,000 deaths each year[1]. Over 80% of cervical cancer cases occur in women living in low-income countries and lower-middle income countries (LMICs)[1, 2]. Two licensed 
prophylactic	HPV	vaccines	have	high	efficacy	against persistent infection with HPV vaccine genotypes 16 and 18, the cause of over 70% of cervical cancer and related cervical lesions[3]. In 2012 Gavi announced its support for HPV vaccination demonstration projects or national programmes for 73 countries; 49 Gavi-eligible and 24 ‘graduating’ countries[4]. For some other low and middle income countries (L&MICs), demonstration projects or national programmes have been conducted with vaccines provided by the GARDASIL® Access Program (GAP)[5], from manufacturer donations, or other means. There have been no comprehensive systematic reviews of results and lessons learnt from the demonstration projects and introductions conducted to date. This study aimed to collate a wealth of information available in the grey literature, peer-reviewed journals, and reported by country representatives in order to inform future Gavi applications and national programmes. We review the delivery strategies chosen and factors correlated with vaccine coverage, present best practices for project/programme success and provide a summary of costing information. Recommendations for planning and sustaining a national programme are discussed, including how HPV delivery can be more fully absorbed into national immunization programmes.
MethodsForty-six countries, which had completed at least six months of HPV vaccine delivery by 1st May 2016, were selected for inclusion in the review. A systematic literature review of published and grey literature was undertaken. Additional grey literature was requested from representatives of all the included countries, such as evaluation reports from national immunization programmes and international partners. Key informant interviews with project/programme implementers were 
conducted	to	fill	gaps	in	the	data.	Data	were	extracted from literature and interviews onto an excel matrix developed using the WHO’s New Vaccine Introduction Guidelines. Nine countries with high cervical cancer burden that were eligible for Gavi HPV vaccine introduction support, but had not yet submitted 
an	application	to	Gavi,	were	also	identified.	Interviews were conducted with national immunisation teams in these countries, to explore reasons why they had not yet applied to Gavi for HPV vaccine demonstration project funding. 
ResultsAcross the 46 countries with HPV vaccine experience included in this review, data were analysed from 12 countries with experience  of national programmes and 66 demonstration projects undertaken in 44 countries. As projects and programmes varied the delivery strategies and target populations, this represents 15 separate delivery experiences in national programmes and 77 separate delivery experiences in the demonstration projects. Among the 66 demonstration projects, 30 were supported by GAP through Axios Healthcare Development, 20 by Gavi, four by PATH (funded by the Bill & Melinda Gates Foundation, implemented by EPI programs with vaccine donated from either GSK or Merck & Co.) and 12 by other means. Key results are shown below. 
Executive Summary
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Planning
• Political commitment from national authorities provides crucial advantages by increasing interest and support at all levels.
• Planning alongside the education sector can improve acceptability and effectiveness of implementation, for example in choosing school grades 
with	the	highest	female	attendance	(e.g.	confirming	sub-nationally	whether this was grade 5 or 6) and coordinating vaccination with school calendars to avoid examination days or other important events.
• Agreements with national ministries (e.g. MOE) did not necessarily translate into cooperation with sub-national sectoral representatives and, in the case of local departments of education and school authorities, cooperation could often be delayed or problematic if not sought early. 
Vaccine management
• Countries have introduced several new vaccines in the past decade and are accustomed to cold chain assessments and expansions. 
• The HPV vaccine is sensitive to freezing and this is the greatest risk for vaccine wastage.
Staff training 
• Cascade training was the most common method of training staff in HPV 
vaccine	introduction;	however,	a	number	of	countries	identified	issues	around the quality of training for frontline staff.   
• Teachers are trusted in the community and should be included in micro-planning and trained appropriately. 
• The ideal timeframe for training is at least two months before vaccine delivery. 
• Novel	aspects	of	HPV	vaccine	and	its	delivery	requires	specific	training,	although training could be integrated into other vaccination training for nurses and may be conducted less frequently in the future, as processes become more familiar and existing staff become more experienced.
Social mobilisation, acceptability and consent
• General knowledge of HPV, HPV vaccine and cervical cancer is low in communities, and among teachers and health-workers.
• Training	of	influential	stakeholders/	spokespersons	is	needed	at	every	level (i.e. national, regional, district, local).
• Problems occur if social mobilisation begins less than a month before vaccination (e.g. due to late fund disbursement or printing). Time allowed should not be underestimated when planning. 
• Teachers and parents of girls attending urban and private schools often require more information before accepting the vaccine than 
those	elsewhere	and	need	to	be	identified	in	a	communication	plan	as	potentially requiring more intensive messaging.
• Rumours are generally consistent across geographical areas and projects/programmes. 
• Collaboration between MOH and MOE is necessary to tackle rumours as soon as they arise. 
• Strategies to address rumours include tailoring communication 
messages	to	specific	concerns,	announcements	by	high-level	officials,	dissemination of letters detailing WHO or government endorsement, one-to-one or group meetings in communities and utilising social media networks to disseminate clear, accurate information (e.g. Facebook). 
Preparation
Communication
Theme Summary of lessons learnt
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• Face-to-face interaction remains the most effective way of mobilising parents and communities, especially among groups likely to refuse 
vaccination.	Effective	influencers	are	teachers,	health-workers,	and	community leaders (e.g. religious spokespeople). 
• If social mobilisation is delayed due to fund disbursement or bureaucracy, 
activities	can	be	implemented	in	a	stepped	approach	so	that	the	first	
schools	targeted	with	vaccine	are	the	first	to	receive	social	mobilisation.
• The most commonly cited reasons for vaccine acceptance were 
protecting	daughters	from	cancer,	general	benefits	of	vaccines,	and	perceived cervical cancer risk.  
• Complicated consent procedures can decrease consent and thus uptake. The most successful opt-in approach appeared to be sending forms home with girls, which could be coordinated by teachers.
• No problems were reported with opt-out consent, but most projects/programmes testing opt-out processes were government-run, with high involvement of the immunisation programme. Additional procedures may be necessary in private schools or where parents expect more information and autonomy over their child’s health
Delivery strategy
• HPV vaccine delivery strategies including schools were the most common 
and	were	reported	as	being	an	efficient	way	to	capture	most	9-13	year	old girls. However, many projects and programmes found the costs associated with repeat  visits to schools prohibitive and potentially unsustainable. There  was limited experience with health facility only delivery. 
• The selection of delivery strategy often had to balance the feasibility of 
high	coverage	with	country	specific	operational	challenges:	the	human	resources and vaccine transport available, accessibility of vaccination sites, school enrolment and attendance rates, project/programme cost and sustainability. 
• There are limited data on health facility only delivery strategies and no coverage data from ‘routine delivery’ strategies where responsibility for the vaccine delivery is decentralised to health centres to deliver in situ or during routine outreach. 
• Strategies	to	reach	out-of-school	girls	are	difficult	to	evaluate	without	
specific	coverage	data	for	this	sub-group.	A	specific	mobilisation	strategy	for out-of-school girls to encourage them to attend vaccination days or the nearest health centre was generally seen as important. It cannot be assumed that out-of-school girls will attend health centres without 
targeting	them	with	specific	information	on	the	importance	of	HPV	vaccine beforehand. However, if being ‘out-of-school’ is illegal, strategies to identify girls must avoid stigmatisation; house-to-house visits are expensive unless volunteers can conduct them.
• Although different mop-up strategies were conducted, there is not 
sufficient	evidence	to	ascertain	best	practices.	The	scope	of	activities	is	
generally	governed	by	country-specific	factors,	e.g.	school	absenteeism,	perceived ‘adequate’ coverage, and the resources available. A two-stage delivery of each dose can be successful in reaching those girls who initially refused vaccination, especially when implementation of HPV 
vaccination	is	in	its	first	year.	Countries	with	low	school	enrolment	could opt to not conduct mop-up activities in order to focus resources on extensive outreach during the initial vaccination dates.
Delivery
Theme Summary of lessons learnt
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• Although different mop-up strategies were conducted, there is not 
sufficient	information/evidence	to	ascertain	particular	best	practices.	
The	scope	of	activities	is	generally	governed	by	country-specific	factors, e.g. school absenteeism, perceived ‘adequate’ coverage, and the resources available. A two-stage delivery of each dose can be successful in reaching those girls who initially refused vaccination, especially when 
implementation	of	HPV	vaccination	is	in	its	first	year.	Countries	with	low	school enrolment could choose to not conduct mop-up activities in order to focus resources on extensive outreach during the initial vaccination dates. 
• Providing	the	first	dose	to	unvaccinated	girls	at	the	time	of	the	second	dose delivery, and establishing a ‘rolling eligibility criteria’ where girls can become eligible for the vaccine as soon as they turn 9 years of age can create challenges in yearly reporting if this has not been planned. Delivery the subsequent year when a greater number of vaccine doses are needed and vaccination has to stretch over two age groups or grades can be challenging if strategies are not clear before the project/programme starts.
• Drop-out between doses can be minimised if all doses are completed within one school year.
• Given the workload and funding required for HPV vaccination programmes and the limited nature of existing services for this age group, multiple countries questioned the feasibility of adding another new intervention to deliver alongside HPV vaccine.
• Countries need to be aware that although the recommendations for most girls now state that 2 doses are enough for protection against HPV, 
HIV	infected	girls	require	3	doses.	Country	representatives	find	this	impractical and vaccinators often do not know a girl’s HIV status. Health workers are generally providing 2 doses for this reason or to avoid stigmatization of HIV positive girls
Target population enumeration 
• In almost all demonstration projects, estimation of vaccine supply needs 
for	the	first	dose	of	HPV	vaccine	was	a	considerable	challenge.	
• School registries from schools themselves or the MOE, existing population censuses, and surveys of school enrolment rates were unreliable data sources
• Planning and implementation of a census to determine the size of the target population for demonstration projects requires substantial resources and is likely to delay vaccine delivery if not adequately planned.
• Pre-registration of out-of-school girls is important to ensure their 
identification	and	vaccination;	however,	house-to-house	activities	to enumerate and pre-register out-of-school girls are expensive. If volunteers are available this could be more feasible than census or health workers. Peer tracing or use of local civil society groups are other strategies to identify girls, all need to be budgeted for during planning. 
• Accurate determination of the number of eligible girls is more of a 
challenge	for	demonstration	projects	that	implement	in	specific	districts	
and	may	require	specific	activities	such	as	school	pupil	enumeration.
• For demonstration projects, enumeration in urban settings has been 
more	difficult	than	rural	areas	due	to	more	mobile	populations,	and	less	distinct district boundaries.
• Several countries have implemented reliable registries for numbers of 
eligible	girls	after	the	delivery	of	the	first	dose.
Delivery
Theme Summary of lessons learnt
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• National programmes which have started delivery to 9-13 year olds have experienced decreasing target populations year after year as the target group decreases to a single age cohort of 9 year olds. 
• Census data may be more accurate and useful when enumerating the national target population than when attempting to enumerate girls in a demonstration project; however, additional data from school registries is still needed to aid distribution of the correct amounts of vaccine at the sub-national level to the districts and health facilities.
Staff availability
• The level of workload generated by HPV vaccination activities was 
variable;	the	effect	on	routine	services	was	difficult	to	estimate	as	many	demonstration projects were small-scale, resource intensive and were not fully integrated into EPI services. 
• Countries concerned about the impact on routine services can test strategies to mitigate this during demonstration projects but should be aware that some of the strategies are unlikely to be possible during national roll-out unless a staggered vaccine delivery is planned e.g. using staff from other regions or employing temporary staff. Trainee health 
workers	may	prove	useful	to	fill	some	gaps	in	capacity.	
• There was no evidence that changing from a 3-dose to a 2-dose schedule has changed the proportion of experiences that reported an impact of campaign activities on routine health services.
• One strategy to mitigate impact on routine services is to extend the time period of HPV vaccine delivery to transform a campaign-like strategy into a phased delivery over a number of months. There is limited experience of this and no available evaluation data on the impact on staff workload.  
• Coincidental introduction of multiple new vaccines can exacerbate capacity issues at all levels (national, regional, district and local). 
Staff supervision 
• Supervision is necessary when adding another activity like HPV vaccine introduction to health workers’ workload. It can be motivational, can ensure successful implementation and high quality data collection. 
• Supervision was usually carried out in a cascade from national level to frontline staff. 
• Checklists and logbooks can help to ensure supervision activities are completed if these are audited by higher level supervisors. 
Staff remuneration 
• The use of per diems for outreach activities or any activity which involves the health worker leaving their station is widespread. 
• Per diems are a major consideration when countries assess the sustainability of a programme 
• Per diems may be required in demonstration projects which can be seen as ‘special’ and ‘non-routine’ and may not be required in national roll-out when delivering the vaccine can be normalized into health workers routine responsibilities, e.g. routine outreach.
Adverse events (AE) monitoring 
• Non-EPI stakeholders, particularly teachers and parents, were a useful resource in monitoring and reporting AEs.
• There were noticeable differences among projects/programmes in AE reporting procedures.
Theme Summary of lessons learnt
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Factors for success
• High HPV vaccine coverage is feasible in L&MICs; no projects attained 
<50%	final	dose	coverage.	
• It	is	difficult	to	obtain	meaningful	data	on	vaccine	coverage	without	a	well-designed coverage survey.
• Limitations in administrative data need to be realised by national and international agencies.
• Delivery strategies including a school-based component are likely to 
achieve	high	uptake,	completion	and	final	dose	coverage,	due	to	the	relative ease of capturing a large number of girls in one place, gaining consent if required and following up girls. However, these strategies are resource intensive. Data on health facility only strategies is limited and the coverage achievements to date have been highly variable.
• Urban areas may be more exposed to negative media, contain more mobile populations and be harder to enumerate than rural areas; it may be harder to achieve high coverage in urban centres for these reasons. 
• High-level political commitment and the involvement of the EPI team or national immunisation programme and the MOE early in the planning process is critical to obtain good coverage. 
• Early collaboration between EPI and education representatives at 
lower	levels	(provincial,	regional	or	district)	can	ensure	efficient	micro	
planning,	i.e.	the	vaccine	schedule	is	planned	to	fit	into	the	school	calendar, can aid in enumerating school-based target populations, can coordinate an effective response to vaccine rumours within the community and can help to follow up girls who missed doses – all of these functions can help to ensure high coverage. They can also more 
efficiently	identify	potentially	problematic	groups	within	the	target	communities e.g. private schools or vocal anti-vaccination groups. 
• The EPI/national immunisation team involvement can ensure timely vaccine delivery, which is important to maintain interest in vaccination in the community and to reduce drop-out.
• Specific	strategies	are	needed	to	identify	and	mobilise	out-of-school	girls;	
the	absence	of	specific	strategies	can	result	in	low	uptake	if	the	vaccine	is	simply made available at the health centre. 
• The 2-dose schedule achieved high coverage, uptake and completion and was reportedly easier and cheaper to implement when compared to the 3-dose schedule. Only one country attempted a 12 month interval between the 2 doses, rather than 6 months, and stated an annual campaign was easier to implement.  
• Delivery of HPV vaccine simultaneously with another intervention to the same target group did not seem to affect HPV vaccine coverage rates. However, few countries attempted to deliver other services with HPV vaccine. Coverage data from experiences that tested delivery of other interventions were only available for 6 countries. 
Factors for success
• Use of electronic monitoring and reporting systems appeared to reduce 
errors	and,	in	some	cases,	simplified	the	process	of	data	recording.	For example, at least two countries created a database of girls to be vaccinated in advance so that all forms already had names on them, thus simplifying and speeding data recording. Other projects noted logistical 
difficulties	with	paper	forms	(e.g.	insufficient	space	on	forms,	difficulty	in following-up girls who missed vaccinations). 
Coverage 
achievements 
Theme Summary of lessons learnt
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Financing
• Several projects found it challenging to secure funds for implementation costs, especially transportation costs and per diems.
• Countries expressed considerable uncertainty around the ability to 
finance	HPV	vaccination	in	the	future.
• Several countries are considering or have already changed delivery strategy due to concerns over cost and sustainability. 
• Reported	recurrent	financial	costs	of	delivery	(excluding	vaccine	costs)	were between USD 1-9 per dose. 
Scale-up
• Demonstration projects appeared most useful for countries with little experience of rolling-out new vaccines or of vaccinating older children; however, substantial lessons have been learnt during scale-up and national programmes also.
• Some countries indicated they could have gone straight to national or phased national programmes rather than spent time on demonstration projects if funding had been available. 
• Demonstration projects did not appear to be particularly useful in 
influencing	the	decision	of	whether	to	scale	to	national	HPV	introduction,	which was either already decided or was governed by the availability of funding. However, demonstration projects  did appear useful in 
influencing	plans	for	future	implementation	(e.g.	consent,	enumeration	processes, delivery strategies).
• Continuity of access to Gavi funding was a major concern when considering scale-up and longer-term sustainability.
• A	number	of	sources	appeared	unaware	of	the	relative	flexibility	of	the	HPV vaccine dosing schedule (e.g. several did not know it could be given in two doses one year apart), which could have potential logistical and cost implications.
• While Gavi sources indicated that Gavi will continue to offer vaccine at a subsidised price to countries after they graduate from Gavi support, exploration of alternative sustainable funding options could encourage more countries to scale-up HPV vaccination.
Sustainability
• Early and thorough training of health-workers in correct and timely recording, reporting, and monitoring procedures was not always given 
enough	attention,	which	caused	later	difficulties	in	timeliness	and	accuracy of reporting.
• More discussion appears warranted on who should hold vaccination cards (e.g. whether this should be health-workers, schools, or girls).
Theme Summary of lessons learnt
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• When EPI was leading the demonstration projects, integration with routine immunisation activities was usually strong and the regular routine human resources and infrastructure was used to deliver the  HPV vaccine. 
• Smaller scale projects run by entities other than the MOH showed minimal or no integration with routine services, and in some cases were run in parallel to the routine health service, hence limiting understanding of scalability. These projects also ended up using some EPI capacity (e.g. cold chain and logistics), often with minimal or late involvement of EPI, thereby reducing its capacity to integrate activities within the routine programme.
• Many countries used familiar delivery models and therefore the level  of integration into standard processes tended to be high (e.g. (repeated) school-based campaign model, with additional mop-up activities in 
regular	health	centres).	Hence	delivery	shared	practices	specific	to	campaign delivery (limited duration, additional staff, allowances, intensive supervision and reporting). 
• There were only a limited number of unique traits to HPV vaccination that distinguished it from other routine vaccines. These involved the targeting of older girls, the often-complex enumeration process and the repetitive vaccination campaigns in schools for countries without existing school health programmes. 
• Many aspects of integration with the routine immunisation programme process remained challenging to assess because of the small size of demonstration projects. Scale up may produce new challenges and learning curves and result in changes of strategy.
• Despite reporting high workload, negative effects on the routine delivery of other services were rarely commented upon. This may be owing to the small scale of the programmes (Section 7.3.3: Staff workload). 
• A small number of countries had in the past or were envisaging switching in the future from the campaign-style delivery to a health facility based strategy to foster a more cost-effective and integrated approach. One country that made this change reversed to school delivery because of poor coverage. Countries will have to trade-off the high coverage attainable in campaign style delivery with the more integrated approach to childhood routine vaccination and possible lower coverage outcomes.
• An increasing number of countries originally intended to test combining at least one other intervention with HPV vaccination but few have translated this into actual implementation. None have formally evaluated combined delivery.
• Among	the	nine	country	representatives	approached,	five	agreed	to	 
be	interviewed.	All	five	felt	cervical	cancer	was	a	public	health	problem	and were aware of Gavi funding for HPV vaccine introduction. 
• Two countries were aiming to submit applications for funding within  the next year. 
• Two other countries prioritised other new vaccine introductions; an application for HPV vaccine support was thought to be planned for some point in the future.
• One	country	felt	there	was	not	enough	country-specific	data	on	HPV	epidemiology or funding to warrant starting an HPV vaccination project/programme.   
Integration of 
HPV vaccine with 
immunization 
programmes and the 
health system 
Decision not to 
introduce HPV 
vaccine among Gavi 
eligible countries 
Theme Summary of lessons learnt
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Conclusions
Considerable experience in HPV vaccine delivery is available from many contexts. Common lessons have been learnt in different countries. These should make it easier for countries still considering HPV vaccination to plan their projects/programmes and perhaps consider delivering vaccine through phased national delivery. Limited data are available and further evaluation is needed on a number of topics including: catch-up strategies, scale-up to national programmes, delivery of HPV vaccination alongside other interventions, integration with existing health system structures and the key drivers of delivery costs to ensure HPV vaccine programmes are sustainable. 
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1. Background
1.1 HPV vaccination Cervical cancer, caused by human papillomavirus (HPV), is a major public health problem. Globally there are an estimated 528,000 new cervical cancer cases and 266,000 deaths each year[1]. Over 80% of cervical cancer cases occur in women living in in low and middle-income countries (LAMICs)[1, 2]. It is the most common cancer among women between 15 and 44 years of age in many LAMICs. In settings where effective cervical screening programmes are available, the incidence of cervical cancer has markedly decreased[2]. However, in many LAMICs, screening programmes are not in place or are only available on a limited scale, and women frequently present late with the disease, leaving palliative care as the only treatment option. Primary prevention for cervical cancer is now possible through vaccination. Three licensed prophylactic HPV vaccines have high 
efficacy	against	persistent	infection	with	HPV	vaccine genotypes (a necessary pre-requisite for the development of cervical cancer) and related cervical lesions[3]. Two are available worldwide, Cervarix® (GlaxoSmithKline Biologicals) targets HPV types 16 and 18; GARDASIL® (Merck & Co. Inc) also targets HPV 16, 18 as well as HPV 6 and 11, which are the primary cause of genital warts[8]. The World Health Organisation (WHO) recommends targeting HPV vaccination to girls aged between 9 and 13 years, prior to sexual debut, as the 
vaccines	are	most	efficacious	in	those	who	have	not yet acquired HPV[9]. By February 2015, 80 countries and/or territories had commenced national HPV vaccination programmes and another 39 had completed or had ongoing HPV vaccine demonstration or pilot projects. Initial impacts of HPV vaccination on genital warts have been observed in countries that commenced national vaccination programmes early, such as Australia, the United Kingdom, the United States, Denmark and Sweden[10-17].Merck & Co established the GARDASIL® Access Program (GAP) in 2007, when they donated three million doses of HPV vaccine for use in low-income countries. A consultancy company, Axios Healthcare Development, managed the GAP for Merck. The GAP provided free vaccines, but organisations implementing the demonstration projects were responsible for procuring injection supplies, paying customs 
duties	for	the	vaccine	and	for	financing	all	delivery costs [18, 19]. GAP ceased to accept 
new applications when Gavi started to provide support for HPV vaccine demonstration projects in 2012. Demonstration projects allow countries to gain experience in delivering the vaccine to a novel age group and/or alongside other adolescent health interventions[6]. Gavi supports national programmes if the country has prior experience of HPV vaccination. This support is available for 73 countries: 49 Gavi-eligible and 24 ‘graduating’ countries[20]. By mid-2015, 25 countries had been approved by Gavi for demonstration projects and three countries had received approval for support of national programmes (Rwanda, Uganda and Uzbekistan)[21]. In addition to GAP and Gavi, other demonstration projects have been funded by NGOs, manufacturer donations, or other means. For Gavi-supported projects, the Ministry of Health (MOH) is required to lead applications and close collaboration with the Ministry of Education (MOE) is recommended [6]. They are also required to plan a number of mandatory evaluations: cost[22], coverage surveys [23] and a post-introduction evaluation (PIE) [24]. 
There	are	several	identified	gaps	for	countries’	decision-making with respect to HPV vaccine introduction. Although there have been some initial reviews (see section 1.2), there have been no comprehensive systematic reviews of results and lessons learnt from the demonstration projects conducted to date or early scale-up in LAMICs. A wealth of information from sources other than peer-reviewed journals is available, but has not yet been collated in order to inform future Gavi applications and national programmes. A review of the rationale for the delivery strategies chosen, best practices, factors affecting coverage and a summary of costing information will provide crucial information for countries when applying for HPV vaccination demonstration projects or starting national HPV vaccination programmes. Moreover, a number of countries did not deliver HPV vaccine through the national immunization programme during their demonstration phases. As they move to consider national scale-up, recommendations on how HPV delivery can be more fully absorbed by national immunization programmes may assist in planning and sustaining a national programme. Integration into the immunization programme is an important question as school immunization is a relatively new form of delivery for many of the studied countries [25, 26]. Strategies for reaching out-of-school girls 
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also need to be well integrated into the national programme to ensure optimal use of resources [27].This study aimed to address the above gaps and use the synthesis of lessons learnt from demonstration and national programmes in LAMICs to develop recommendations on how HPV vaccine delivery can be successfully designed and integrated into national immunization programmes.
1.2 Previous reviews of HPV 
vaccine demonstration 
projectsTwo reviews have examined vaccine uptake and delivery strategies for 21 GAP-supported demonstration projects covering a total of 
14	countries	[18,	28].	High	uptake	(first	dose	coverage) and completion rates (the proportion of girls who started the vaccine schedule 
and	went	on	to	receive	the	final	dose)	were	reported; all but one project had an uptake rate of >70%. School delivery and short duration of vaccination activity were associated with high uptake and completion rates. The ‘duration of vaccination activity’ referred to the total time 
taken	from	shipment	of	the	vaccine	to	final	dose	
delivery,	which	may	reflect	the	preparation,	organisation and level of bureaucracy involved in each project.    There have There have been two additional publications collating experiences from demonstration projects in multiple countries [29, 30] and three reviews of HPV vaccine delivery strategies and acceptability [31-33]. Different delivery strategies were tested in demonstration projects in Peru, Uganda, India and Vietnam and their coverage and acceptability were analysed [30]. High coverage was documented across the different strategies tested; school-based vaccination strategies gave consistently high coverage whilst integration with existing outreach services gave the lowest 
coverage.	Wigle	et	al.	identified	specific	barriers	to successful HPV vaccine implementation through a literature review and key informants interviews [29]. A review of the acceptability of HPV vaccine in 13 sub-Saharan African countries found consistently high willingness to vaccinate and hypothetical acceptance of the vaccine [31]. A review of the published literature on delivery strategies in nine LAMICs found school-based delivery using grades as eligibility criteria for vaccination attained high coverage [32]. The third review summarised lessons learnt from HPV vaccination in 15 countries and reported on operational, logistical and communication issues [34].  
There have been no comprehensive systematic reviews of results and lessons learnt from all the demonstration projects conducted to date. This study aims to collate the wealth of information available in the grey literature, peer-reviewed journals and reported by country representatives, in order to inform future Gavi applications and national programmes. We review the delivery strategies chosen, correlates and best practices for success or failure to achieve high coverage. Recommendations of how HPV delivery can be more fully absorbed by national immunization programmes may assist in planning and sustaining a national programme.
1.3 Published costing studies of 
HPV vaccine demonstration 
projectsCosts per fully vaccinated girl in developing 
countries	have	been	documented	in	five	articles	to be in the range of $1.5 - $18.9 [28, 35-38]. Demonstration projects in eleven L&MICs are included in these articles: Peru, Uganda, India, Vietnam, Tanzania, Kenya, Cambodia, Honduras, Lesotho, Moldova, Nepal. The methods used to estimate costs and the way results are reported vary across articles, occasionally leading to differing estimates of delivery costs within the same demonstration projects, depending on the analysis. There is a need to review methods used to estimate costs of demonstration projects and national programmes in order to aid future evaluations and create comparable estimates. The relative cost-effectiveness of different delivery strategies within countries can then be modelled and compared.
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2. Objectives
The study had the following three objectives:1 To collate and synthesize lessons from completed HPV vaccine demonstration projects and national programmes for critical themes and determinants of success. 2 To generate insights and recommendations on how HPV vaccine delivery can be successfully integrated into national immunization programmes.3 To use creative mechanisms to disseminate the synthesized lessons/insights and best practices, both for HPV demonstration projects and national programmes.
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3. Methods
3.1 Study countries 
3.1.1 Definitions
Throughout	the	report,	themes	and	findings	
are	described	relevant	to	three	classifications:	1) the country, 2) the project/programme, 3) the delivery experience. One country may have conducted multiple different HPV projects/programmes, which included multiple different 
delivery	experiences.	Definitions	and	examples	are as follows: 
Country One of the countries included in the review  (See Section 3.1.2: Country selection).  
Programme A national-level HPV vaccination programme
Project 
The	activities	funded	through	a	specific	GAP, Gavi or other funder application for a demonstration/pilot project. A distinct project 
was	defined	by	the	funder	and/or	implementer	and grant award details, e.g. GAP awarded Bolivia support for four separate demonstration projects at distinct geographical sites and therefore, for this study, Bolivia was considered as contributing data from four different projects. Gavi awarded Laos PDR support for one demonstration project which was stipulated 
to	span	the	course	of	2	years	and	is	defined	in	this review as one project. Botswana conducted one demonstration project implemented by the non-communicable disease (NCD) department and a second implemented by the national immunisation team; these were counted as  two projects.
Delivery experience 
An	HPV	vaccine	experience	was	defined	by	
the	specific	target	population	(age	range	in	years or school grade) and vaccination venue (health facility-based, school-based, outreach, 
or	a	combination	of	the	three)	within	a	specific	
project/programme	(defined	by	funding	source). One country may have contributed multiple distinct experiences; if a project that spanned two calendar years changed delivery strategy (e.g. from school-based to health facility-based), that project would be counted as contributing two distinct delivery experiences, or if a project simultaneously tested two different delivery strategies in two different populations, this would be counted as contributing information from two different delivery experiences. e.g. PATH 
supported one demonstration project in India which tested two different delivery strategies in the same year, therefore India contributes information from one project and two delivery experiences. Honduras was awarded three GAP demonstration projects; each project implemented one delivery strategy and therefore Honduras contributes data from three projects and three delivery experiences. The logistical requirements, social mobilisation needs, coverage achieved were a-priori 
thought	to	be	heavily	dependent	on	the	specific	delivery experience; therefore these themes 
and	key	findings	are	summarised	by	delivery	
experience.	Planning	and	financing	were	summarised at the project/programme level. 
3.1.2 Countries included in the  
lessons learnt componentIn total 46 countries (18 LIC, 22 LMIC, 5 UMIC, 1 HIC) that had completed at least 6 months of an HPV vaccine project/programme by the 
first	quarter	of	2016	were	included	in	the	study	(Table 1). Upper-middle income countries were only included if they had conducted a demonstration project; they were not included if they went straight to national roll out as the objectives of the review focus on LAMIC demonstration projects. One high-income country, Chile, was included due to its choice of delivery strategy; an annual campaign with a 12-month interval between doses. This was 
identified	as	potentially	exposing	some	good	alternative lessons for low-income countries. The 46 countries included in this study are summarized in Table 1, according to the type 
of	financing	used	to	support	or	implement	the	demonstration projects. Across the 46 countries included in the review, two went straight to national roll-out (Chile, Rwanda), 10 had conducted demonstration projects and had scaled-up to national 
programmes	by	the	first	quarter	of	2016	and	34 had only conducted demonstration projects. In total 66 demonstration projects were conducted across 44 countries; 30 projects (in 22 countries) were supported by GAP through Axios Healthcare Development, 20 projects (in 20 countries) by Gavi, four by PATH (funded by the Bill & Melinda Gates Foundation, implemented by EPI with vaccine donated from either GSK or Merck & Co.) and 12 by other means. 
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Table 1. The 46 countries and donors included in this study
Country Type of financing1 Country Type of financing1
1 Bhutan GAP and national (donation) 24 Mali GAP and Gavi demos
2 Bolivia GAP 25 Moldova GAP
3 Botswana World Bank (WB), MOH 
demos and national (MOH)
26 Mongolia GAP
4 Brazil GAP, MOH demos and 
national (MOH)
27 Mozambique Gavi
5 Burkina Faso Gavi 28 Nepal GAP/ACCF2
6 Cambodia GAP 29 Niger Gavi
7 Cameroon GAP and Gavi demos 30 Papua New Guinea GAP
8 Chile National (MOH) 31 Peru PATH and national
9 Cote d’Ivoire Gavi 32 Philippines Jhpiego
10 Ethiopia Gavi 33 Rwanda National introduction 
(donation and Gavi)
11 The Gambia Gavi 34 Senegal Gavi
12 Georgia GAP 35 Sierra Leone Gavi
13 Ghana GAP and Gavi demos 36 Solomon Islands Gavi
14 Guyana GAP and national 37 South Africa Donations and national
15 Haiti GAP/PIH 38 Tanzania GAP and Gavi
16 Honduras GAP demos and national 
(MOH)
39 Thailand Jhpiego
17 India PATH 40 Togo Gavi
18 Kenya GAP and Gavi demos 41 Uganda PATH, GAP, Merck 
demos and national 
(Gavi)
19 Kiribati GAP/ACCF 42 Uzbekistan GAP
20 Lao PDR Gavi 43 Vanuatu ACCF and national
21 Lesotho GAP and national 44 Vietnam PATH
22 Madagascar Gavi 45 Zambia GAP
23 Malawi Gavi 46 Zimbabwe Gavi
1“Donation” refers to the vaccine being donated directly to the country by the manufacturer
2 ACCF: Australian Cervical Cancer Foundation At least another six countries have started or are planning to start Gavi-supported demonstration projects (Table 2), but did not have data available in time for inclusion in the data review and did therefore not contribute information to this study.
Table 2. Countries starting HPV demonstration projects in December 2015 or later (evaluation results 
were not available in time for this study)
Country Sponsor Years of planned support Vaccine (preferred)
1 Angola Donation NA NA
2 Bangladesh Gavi 2015-16 Cervarix®
3 Benin Gavi 2015-16 Cervarix®
4 Burundi Gavi 2015-16 Cervarix®
5 Liberia Gavi Postponed Gardasil®
6 Sao Tome Gavi 2014-16 NA
‘NA’ indicates data not available
Several countries conducted multiple types of demonstration projects supported by different donors. Guyana, Honduras, Lesotho, Bhutan, Botswana, Brazil, Vanuatu, Peru, Uganda and South Africa had already scaled-up from demonstration projects to national implementation by January 2016. Uzbekistan is 
planning to scale-up to a national programme in 2016-17 and contributed data on plans for the national programme. A detailed description of the countries and projects/programmes included in the review can be found in  Appendix A. 
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3.1.3 Countries included in the 
evaluation of reasons for not 
undertaking a HPV vaccine 
demonstration projectBy January 2015, eight Gavi-eligible countries met the diphtheria, tetanus and pertussis vaccine third dose (DTP3) coverage threshold of >70% required for applications for support for HPV vaccine demonstration projects and 
also	had	significant	cervical	cancer	incidence	
(defined	as	an	incidence	of	>15/100,000	women	years) according to GLOBOCAN 2012 [39], 
but had not yet applied for Gavi support for HPV demonstration projects (Table 3). Nigeria was also included in data collection as it had been awarded a GAP donation for an HPV demonstration project, but the project had never started. Gavi eligible countries that have not conducted HPV vaccine demonstration projects, but were excluded from data collection as they had a DTP3 coverage <70% or a low estimated cervical cancer incidence (<15/100,000 women years) are listed in  Table 4. 
Table 3. GAVI-eligible countries that had not yet applied for HPV funding by January 2015  
included in data collection 
Country* World Bank income 
group1
DTP 3 coverage2 Incidence of cervical 
cancer  
(age-standardized 
rate per 100,000)[39]
Cervical cancer 
mortality rates   
(age-standardized 
rate per 100,000)[39]
Comoros LIC 86%3(WHO/UNICEF) 
73% (HH survey) 
61.3 40.3
Congo, DR LIC 72%3 (WHO/UNICEF) 
89% (National) 
62% (HH Survey 
2010)
33.1 27.3
Djibouti LMIC 81%4(WHO/UNICEF) 
81% (National) 
61% (HH Survey 
2006)
17.3 11.5
Eritrea LIC 99%3(WHO/UNICEF) 
94% (National) 
98% (HH Survey 
2007)
17.4 13.1 
Guinea-Bissau LIC 80%3(WHO/UNICEF) 
90% (National) 
81% (HH Survey 
2010)
29.8 21.6
Kyrgyz Republic LIC 96%3(WHO/UNICEF) 
96% (National) 
85% (HH Survey)
23.7 11.2
Mauritania LIC 80%3(WHO/UNICEF) 
80% (National) 
57% (HH survey 
2007)
29.4 18.8
Nicaragua LMIC 98%3(WHO/UNICEF) 
108% (National) 
95% (HH Survey 
2006)
36.2 18.3
 
*  Nigeria was also included in data collection despite a prior application and approval for a GAP project as the project was never started. 
1 World Bank classifications February 2014: LIC = low-income country; LMIC = lower-middle income country; UMIC = upper-middle income country
2 2012 estimates unless otherwise stated. Source: Gavi website; HH = Household 
3 No directly supporting data (low grade of confidence)  
4 Estimate supported by at least one data source either reported data, UNDP data or survey data,
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Table 4: GAVI-eligible countries that had not yet applied for HPV funding by January 2015 and  
considered ineligible for data collection.
Country World Bank 
income group1
DTP3 coverage2 Incidence of 
cervical cancer 
(age-standardized 
rate per 100,000)
[39]
Cervical cancer 
mortality rates  
(age-standardized 
rate per 100,000)
[39]
Eligible for data 
collection
Afghanistan LIC 71%3 (WHO/
UNICEF) 
87% (National) 
40% (HH Survey 
2011)
8.8 6.9 No, incidence 
<15/100,000
Central African 
Republic
LIC 47%3 (WHO/
UNICEF) 
59% (National) 
32% (HH Survey 
2010)
21.0 15.3 No, DPT 
coverage <70%
Chad LIC 45%3 (WHO/
UNICEF) 
72% (National) 
20% (HH Survey 
2010)
18.8 14.6 No, DPT 
coverage<70%
Guinea LIC 59%3 (WHO/
UNICEF) 
102% (National) 
50% (HH Survey)
38.4 27.9 No, DPT 
coverage <70%
Korea, DPR LIC 96%4 (WHO/
UNICEF) 
96% (National) 
92% (HH Survey 
2008)
12.4 7.2 No, incidence 
<15/100,000
Pakistan LMIC 81%3(WHO/
UNICEF) 
89% (National) 
65% (HH Survey 
2013)
7.9 4.7 No, incidence 
<15/100,000
Somalia LIC 42%3 (WHO/
UNICEF) 
61% (National) 
14% (HH Survey 
2006)
33.4 20.1 No, DPT 
coverage <70%
South Sudan LMIC 59% (WHO/
UNICEF) 
68% (National)
30.4 20.3 No, DPT 
coverage <70%
Sudan LMIC 92%4 (WHO/
UNICEF) 
92% (National) 
59% (HH Survey 
2010)
7.9 5.3 No, incidence 
<15/100,000
Tajikistan LIC 94%3 (WHO/
UNICEF) 
93% (HH Survey 
2011)
9.9 4.9 No, incidence 
<15/100,000
Yemen LMIC 82%4(WHO/
UNICEF) 
82% (National) 
61% (HH Survey 
2006)
3.1 2.0 No, incidence 
<15/100,000
1World Bank classification of income group, February 2014: LIC = low-income country; LMIC = lower-middle income country; UMIC = upper-middle income country
22012 estimates unless otherwise stated. Source: Gavi website 
3No directly supporting data (low grade of confidence) 
4Estimate supported by at least one data source either reported data, UNDP data or survey data,
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3.2 Literature review
3.2.1 Published literature search 
strategy 
Between	4-11	December	2014,	five	databases	were searched for references: Medline, Embase, Global Health, Africa-wide Information and ADOLEC. Search terms related to HPV, vaccine or immunization were combined with terms for countries that were included in the study (see Appendix B: Example search strategy and 
results	from	Medline).	If	the	first	year	of	HPV	vaccine experience was known for a particular country, searches were limited to publications from that year onwards in order to reduce the number of articles retrieved that did not document actual experience during vaccine delivery e.g. hypothetical acceptance studies. No language restrictions were applied in the 
search.	Reference	lists	of	identified	reviews	were checked for papers that may have been missed by the database search. References cited in retrieved papers were also examined and one author was contacted for an unpublished manuscript and references. The search results were then combined and duplicates removed (Figure 1).Due to a number of countries completing or initiating new demonstration projects in 2015, the search was updated on the 4th-6th April 2016. Search terms, with added country terms for the 9 countries that had started their HPV delivery in 2015, were updated and run again in 
all	five	databases.	The	screening	processes	and	exclusion criteria remained the same. Appendix E summarises the data collected in each of the two grant phases (November 2014 - April 2015 and November 2015 - May 2016).  
Figure 1. Published literature search flow diagram
1Exclusion criteria for the published literature were: 1) Not focused on HPV 
vaccination; 2) Not focused on one of our countries of interest; 3) Study does not 
include any results from after the vaccine was delivered; 4) Not focused on, or 
relevant to, the demonstration project or vaccine introduction. 
The	identified	references	were	then	screened,	
first	using	their	title	and	abstract	and	then,	if	not excluded, using the full text. Papers were excluded if they were: 1. not focused on HPV vaccination, 2. not focused on one of the countries of interest, 3. did not include results from after the vaccine was offered, or 4. not focused on, or relevant to, the demonstration project or vaccination introduction itself. The search strategy for this review purposefully excluded studies on ‘hypothetical acceptance’ i.e. acceptability studies or formative studies conducted prior to vaccine delivery. This was in order to focus on real experiences and evaluations of vaccine delivery. Modelling studies were also excluded for the same reason. 
3.2.2 Grey literature search strategy
Grey	literature	is	defined	as	a	range	of	published and unpublished materials, which are 
not	normally	identifiable	through	conventional	bibliographic methods. It can include book chapters, books, conference abstracts, reports, unpublished data, dissertations, policy documents and personal correspondence. Grey literature searches were conducted in two electronic databases; Open Grey and ProQuest. In addition, a number of websites were searched: MOH websites for each country, Global Immunization News (GIN) publications from the WHO, Pan-American Health Organisation (PAHO) newsletters website, and 
scientific	conferences	on	HPV.	Databases	and	websites were searched using search terms for human papillomavirus or HPV vaccine  (Figure 2). Relevant grey literature was solicited from stakeholders involved in demonstration projects/ national programmes. We received Post Introduction Evaluations (PIEs), individual ‘dose reports’ submitted by districts after the implementation of each dose, internal evaluations and presentations, and coverage survey results directly from the countries. Axios Heathcare Development asked for permission from countries with GAP-supported 
demonstration	projects	to	share	final	reports	and, if permission was granted, we received both formal and informal evaluation reports from GAP and country representatives. Exclusion criteria were the same as for the published literature (see 3.2.1).
Records identified through database 
searches (n=4085):
ADOLEC (n=71)
Africa-wide Information (n=894)
Embase (n=898)
Global Health (n=1677)
Medline (n=545)
Additional records 
identified through other 
sources (n=28)
Records after duplicates removed 
(n=2936)
Abstracts screened (1301 + 1635)
Duplicates =37
Excluded (n = 2659)1
Criteria 1 =1946
Criteria 2 =225
Criteria 3 =272
Criteria 4 =216
Full-text articles excluded 
(n = 168)
Duplicate info = 8
No text/ unpublished = 2
Criteria 1 = 20
Criteria 2 = 17
Criteria 3 = 40
Criteria 4 = 67
Review article =14
Full-text articles assessed for 
eligibility (n=240)
Studies included in qualitative 
synthesis (61 articles; 11 published 
conference abstracts)
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Figure 2. Grey literature flow diagram
1 ‘Other’ documents included internal country evaluation reports, district reports 
after each dose, international partner reports, presentations, excel sheets and 
posters.
3.3 Key Informant interviews
3.3.1 Countries with HPV experienceOverall, representatives from 44 of the 46 countries were approached for interview 
in	order	to	fill	gaps	in	the	data	on	their	HPV	vaccine experience in two data collection periods (Figure 3). Countries were selected 
for	interview	if	there	were	significant	gaps	in	the information available from published and/or solicited grey literature. Two countries did 
not	have	significant	gaps	in	information	(India,	Vietnam). Four countries refused interviews (Figure 3). In total, 56 interviews covered experiences from 40 out of 46 countries. Interviews collected information on 59 of the 66 demonstration projects and 11 of 12 national programmes and included information on 83 of the 92 separate delivery experiences. Interviews took place by telephone or in person through country visits or at international meetings.Interviews were sought with focal people from all projects/programmes in a country, in order to gain insight into potentially distinct experiences. If the interviewee had been involved in multiple projects/programmes, experiences from MOH-implemented projects/programmes were prioritized and focused on during the interview. For MOH-run projects/programmes a representative of the MOH was prioritized for interview, although on two occasions partner organisations were interviewed instead, as directed by the MOH (countries 21 and 35). For partner-run projects/programmes, representatives of that organisation were sought for interview. In one case a government representative was interviewed in addition to the focal person within the implementing organisation. Interviews focused on gaps in information and lessons learnt. Where appropriate, additional reports were requested and received. The full interview topic guide is appended in Appendix C. This was adapted for each interview to 
address	the	gaps	identified	by	the	literature	review. 
Ethics approval was received from the LSHTM Ethics Committee.
3.3.2 Countries that had not yet applied 
for support to introduce HPV 
vaccineNational immunization programme staff from the nine countries eligible for Gavi support for HPV vaccine demonstration projects, but that had not yet applied for support, were approached for interview by email and phone call. Five country representatives, national EPI managers or occupants of an equivalent position, agreed to be interviewed. Interviews 
followed	a	pre-defined	topic	guide	(appendix	D) and covered how decisions to introduce vaccines are made in their country, whether recent discussions had included HPV vaccine and the perceived barriers to HPV vaccine introduction/applications for support.
3.4 Data extraction from 
published and grey literature 
and interviewsIn total, 61 published articles, 11 published conference abstracts and 188 grey literature papers and reports were screened and had data extracted. Four researchers completed the data extraction over seven months, from February to May 2015, and from January to April 2016. The Excel-based data extraction matrix was developed using the WHO’s new vaccine introduction guidelines [40]. Topics and themes were further developed by the research team. The matrix was piloted and revised 
twice	before	being	finalised.	The	researchers	involved in data extraction conducted two 
checks	of	consistency;	first	the	same	set	of	ten	articles were read by all researchers, data were extracted and the results were compared and discussed. The exercise was then repeated with 
a	set	of	five	different	articles.Data were extracted on seven thematic areas: 1. National decision making and planning, 2. Service delivery, Health workforce, 3. Monitoring and evaluation, 4. Financial support, 5. Sustainability, 6. Scale up. The themes were further sub-divided into 18 sub-categories. Each sub-category had a set of questions that were used to extract data from published and grey literature. These questions were then used to inform key informant interview topic guides to address any gaps in available information (see Appendix C: Topic guide including full list of questions). Data from 56 interview transcripts were extracted onto the same Excel matrix.
Records identified through  
database searches:
Proquest (n=0)
Open Grey (n=0)
WHO/ other news bulletins (n=8)
MOH websites (n=0)
Gavi applications/  
proposals (n=10
Additional documents solicited 
from country representatives and 
international partners:
GAP final reports (n=16)
Gavi PIE (n=9)
Gavi cost (n=6)
Gavi coverage survey (n=9)
Other PIE (n=2) Other coverage (n=1)
Other1 (n=127)
188 reports from 44 of the 46 
countries
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Figure 3. Key informant interview flow 3.5 Data analysisAll country data from the literature and interviews were analysed together to produce aggregate summaries of the themes in cross-sectional thematic analysis. Themes were 
identified	as:	
• National decision making  and planning, 
• Service delivery, 
• Health workforce, 
• Monitoring and evaluation, 
• Financial support, 
• Sustainability, 
• Scale up. Data on sub-categories for which qualitative data was extracted, from interviews or literature, were analysed thematically. Quantitative data (e.g. coverage, adverse events) were analysed descriptively to enable presentation of frequencies and proportions. Coverage was categorised because some projects/programmes only presented a percentage coverage estimate without the 
numerator/denominator	data.	Pre-defined	points of interest, as well as common themes reported in the data, were selected for cross tabulation with project/programme coverage and/or delivery strategy.Social mobilisation methods were tabulated with coverage data and linked to acceptability data where possible. The level at which the HPV vaccine project/programme was integrated with the EPI/national immunisation system was assessed across individual components of health system functions. When a parallel/separate process was created to manage the delivery and monitoring of HPV vaccine, this meant a lower degree of integration. Country/project case studies were developed for particular challenges and/or successful strategies for each topic. Where country data was in the public domain, 
countries	were	identified	in	the	analysis;	data	from grey literature or interviews that were not in the public domain were anonymised.
37 countries (55 demonstration 
projects, 8 national programmes; 
72 delivery strategies) with HPV 
experience
Data collection period: November 2014 – April 2015
Data collection period: 
November 2015 – 1st May 2016
31 countries (47 demonstration 
projects, 8 national programmes; 
72 delivery strategies) 
approached for interview due to 
gaps in information
27 interviews conducted 
covering experiences from 23 
countries, 29 demonstration 
projects, 3 national programmes; 
39 delivery strategies
9 additional 
countries 
approached 
(Burkina Faso, 
Cote d’Ivoire, 
Chile, Ethiopia, 
Gambia, Senegal, 
Solomon Is., 
Togo, Zimbabwe)
Re-approach 21 
countries of the original 
37: 
11 countries for second 
interviews where 
another year of data was 
available or new projects/ 
programmes had started 
(Botswana, Ghana, 
Kenya, Laos, Madagascar, 
Malawi, Niger, Tanzania, 
Uganda, Honduras, 
Cameroon)
8 countries unresponsive 
or unavailable in original 
data collection timeline
2 countries where 
international crises had 
resolved. 
Countries not 
approached 
for interview 
(16 countries): 
Sufficient data 
in first round of 
data collection 
and no changes 
to projects/
programmes 
(13 countries);  
refused interviews 
(3 countries: 
Georgia, 
Philippines, 
Thailand)
Interviewees 
in 2 countries 
unavailable for 
second interviews 
(Tanzania, Niger)
1 country 
representative 
remained 
unresponsive 
(Guyana)
Second interviews 
(n=9/11)
New interviews (n= 9/10)
First interviews 
conducted (9/9 
countries)
Total: 56 interviews conducted covering experiences from 40/46 
countries; 59/66 demonstration projects and 11/12 national 
programmes.
2 countries refused: 
Philippines, Georgia.
8 unresponsive or 
unavailable in the time 
frame: Guyana, Peru, 
Rwanda, Brazil, Lesotho, Mali, 
Mozambique, Zambia.
Countries not approached for 
interview (4 countries,  
6 projects): 
No significant gaps in 
information (2 countries: 
India, Vietnam)
Concurrent public health 
emergencies (2 countries: 
Nepal (earthquake), Sierra 
Leone (Ebola))
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Across the 46 countries with HPV vaccine experience included in this review, data were analysed from 12 national programmes and 66 demonstration projects that had completed at least six months of implementation by May 2016. This represents 15 distinct delivery experiences in the 12 national programmes and 77 separate delivery experiences in the 66 demonstration projects (Figure 4). Among the 66 demonstration projects, 30 were supported by GAP through Axios Healthcare Development, 20 by Gavi, four by PATH (funded by the Bill & Melinda Gates Foundation, implemented by EPI with vaccine donated from either GSK or Merck & Co.), and 12 by other means (Figure 5: Map). See Appendix A for details of countries’ projects/programmes and delivery experience characteristics. Appendix E has a summary of the countries and data collected in each of two data collection periods. For all sections of the report, we have only used information from projects/programmes and delivery strategies with at least 6 months of experience. However, in addition, countries supplied some data on future plans: one country planned to start a third demonstration project in late 2016, one country planned to start national programmes in the near future and two others planned changes in their delivery strategy for the existing national programmes.Not all projects/programmes reported target population data. Among the 69 delivery experiences that reported target population size, 1,750,000 girls were targeted with HPV vaccine. The target population was estimated 
for 11 delivery experiences using the number of doses received and coverage rates and/or previous years’ cohort sizes (23 strategies remained with missing data). Among the 56 delivery experiences that reported the number of girls who received the 
final	vaccine	dose,	1,400,000	girls	received	
the	final	dose	of	HPV	vaccine.	The	number	
receiving	the	final	dose	was	estimated	for	13	further delivery experiences using coverage estimates and estimated target populations (36 experiences remained with missing data).Twenty-one delivery experiences had implemented at least 6 months of a 2-dose HPV vaccine schedule by 1st May 2016 (0, 6 months). Only 10 of these reported two-dose coverage. All other projects/programmes implemented a 3 dose schedule. The dose schedule recommendation change in April 2014[41, 42] 
left	insufficient	time	for	more	data	on	two-dose schedules to become available within this study’s timeline.The main themes are presented in the following way:
• A description of country experience and reported lessons learnt from country reports and representatives.
• Key lessons and conclusions interpreted from the data.
• Recommendations developed after independent cross-country analysis of each theme.
4. General results
Demonstration project 
experience only1:
34
66 demonstration projects defined 
by donation and implemeter
12 national programmes  
≥1 year
77 delivery experiences 
92 delivery experiences
15 delivery experiences
Demonstration project 
experience + ≥1 year of 
national roll-out:
10
National roll-out 
without  
demonstration  
project:
2
Countries
Projects/ 
Programmes
Delivery 
Experiences
Countries with demonstration projects or national programmes: 46
1Additional data was received from three countries planning to scale-up to national rollout from their demonstration project in 2015-16, and four other programmes had planned 
to change delivery strategy in 2015-16. These are not included in the figure or the main synthesis for this review as they had not yet completed one year of implementation by the 
time of writing. 
Figure 4. Countries, projects/programmes, delivery experiences included in the study
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The number of countries and delivery experiences contributing to each topic is summarised in Table 5. A number of 2-page briefs were developed from the results of this study, for dissemination to national and international stakeholders. The information that contributed to each brief is listed in Table 6. The reported lessons learnt are frequently presented adjacent to the number of countries and/or projects/programmes that made the same, or a similar, statement. This is intended 
to inform, but not to govern, how we interpret the information. The number of countries, projects/programmes or delivery experiences displayed in this way is most likely an under-representation of the number of projects/
programmes	that	could	have	identified	the	
specific	point	or	lessons	because	the	level	of	reporting and available information varied greatly across countries.
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Figure 5: Map of countries included by project/programme and donor type1
1Data displayed is the status as of 1st May 2016. Botswana, Uganda and Uzbekistan started or were planning to start national programmes in 2015-16; solid fill is that of most 
recent project/programme, hatching indicates previous projects in-country. 
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Table 5. Summary of the number of countries and delivery experiences with available data on each theme
Report Section Data collection phase 1  
(Nov 2014 - April 2015)
Data collection phase 2  
(Nov 2015 - May 2016)
Countries
(N=37)
Experiences1 Countries
(N=46)
Experiences1
No. % No. %
5 Preparation
Selection of districts 26 30/72 42% 40 53/92 58%
Planning processes 33 37/72 51% 36 59/92 64%
Enumerating target population 37/72 51% 45 60/92 65%
Vaccine transport  31/72 43% 35 49/92 53%
Cold chain management 48/72 67% 35 48/92 52%
Vaccine wastage 16/72 22% 11 16/92 17%
Waste management procedures  28/72 39% 33 43/92 47%
Health workforce training 15 27/72 38% 30 42/92 46%
Training timing and duration 15 27/72 38% 27 30/92 32%
Health workforce allocation 22 22/72 31% 28 29/92 32%
Staff cadre 17 17/72 24% 19 38/92 41%
6 Communication
Social mobilisation materials/ 
methods
30 47/72 65% 40 87/92 95%
Consent process 24 50/72 69% 34 71/92 77%
Acceptability 25 32/72 44% 28 37/92 40%
7 Delivery
Delivery strategy 34 67/72 93% 43 89/92 97%
Workforce supervision 13 19/72 26% 28 33/92 36%
Workforce remuneration 17 17/72 24% 32 35%
Adverse events 34 45/72 63% 44 56/92 60%
8 Achievements
Uptake2 26 42/72 58% 36 56/92 61%
Completion2 27 48/72 67% 30 45/92 49%
Final dose coverage2 30 49/72 68% 34 60/92 65%
Monitoring and evaluation 21 28/72 39% 30 42/92 46%
9 Sustainability
Financial support 37 78/79 99% 46 92/92 100%
Scale-up to national programme 19 51% 34/44 77%
1Delivery experiences which had completed at least 1 year by January 2015 (phase 1) or 6 months by May 2016 (phase 2) are the denominator. 2Uptake: proportion of the target 
population who received the first dose; Completion: proportion of those who received the first dose who went on to complete the dose schedule; Final dose coverage: proportion of 
the target population who received the final dose. 
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Table 6: The results sections that contribute to each 2-page brief in the study dissemination materials
2-page brief Themes Results sections
Preparation Planning, including microplanning 
Decision-making and leadership
District selection
Integration with EPI
Vaccine management / transport
Cold chain
Staff training 
Section 5 
Section 7.2-7.3
Section 10
Communications Social mobilisation
Communication materials
Consent
Rumours
Acceptability
Section 6 
Section 10
Delivery Strategy (school, health facility, other)
Target population
Estimating target population
Timing/ frequency (campaigns, routine, fixed period)
Mop-up, outreach
Human resources/ work load/ supervision/ remuneration
Adverse events (recording, reporting)
Section 7
Section 10 
Achievements Uptake 
Completion 
Drop out (between doses)
Coverage 
Data recording and reporting (M&E)
Section 8 
Section 10
Sustainability Costs (review of literature)
Scale up to national
Section 9 
Section 10
Value Commentary on the value of demonstration projects Section 11
Pitfalls Summary of challenges from the above themes Section 12
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5. Preparation
5.1 Planning 
5.1.1 Leadership and decision-makingAmong 60 experiences in 32 countries that contributed data on leadership, no single institutional actor routinely took the lead in the decision to conduct a demonstration project. The MOH was most frequently mentioned as leading or contributing to a project, often in partnership with donors or technical advisors. The lead programme within the MOH appeared as likely to be related to cancer or sexual/reproductive health as to be EPI. In a few cases, private or teaching hospitals received funding for small pilots that were planned without government input. These appeared to be most common in earlier demonstration projects (e.g. those funded by the GAP) and were generally more ad-hoc, with government departments not always aware of them. GAVI-funded projects were led by MOH through the national immunisation programme. Among 69 experiences in 40 countries with 
data	on	factors	influencing	the	decision	to	introduce HPV vaccination, the information 
most	commonly	mentioned	as	influencing	the	decision to initiate a demonstration project was high national reported cervical cancer burden (29 countries) and availability of free vaccines 
and	other	financing	(15	countries),	followed	by reports of successful implementation in other countries or initial formative research results (11 countries). More than one source 
of	information	was	reported	as	influencing	the decision to introduce the vaccine for most countries. Little information was found about why Rwanda, which went straight to national 
implementation, had not elected to conduct an initial demonstration project. Interview data indicated that decision-makers perceived no need for a demonstration project. This may have been due to a combination of high-level political support, previous positive experiences 
introducing	other	vaccines,	and	a	sufficient	supply of donated vaccine to make national implementation feasible (e.g. due to the country’s relatively small population size). Many comments related to leadership and ownership of decision-making. While most indicated that the MOH should take the leadership position, there was more debate about which department within MOH should lead (e.g. reproductive health, non-communicable disease or the national immunisation programme), in projects/programmes where this was not pre-determined by the funding partner (e.g. Gavi after 2012). The need for EPI decision-makers to feel ownership of HPV demonstration projects was stressed in several countries.
5.1.2 Selection of districts for 
demonstration projectsAmong 53 experiences in 40 countries with data on the areas selected for demonstration projects and their characteristics in comparison to the rest of the country, selection was based on four main approaches (Table 7). Of the 10 projects that selected areas that were convenient, i.e. close to the capital, previously used for research, and/or accessible; 2 project areas were simultaneously representative of national performance. 
Table 7: District or area selection approaches for 53 demonstration projects
Selection approach Example Number of projects (%)
Typical Representative of average performance when compared to 
national averages, e.g. DTP3 coverage, primary education rates and 
transport/infrastructure
15 (28%)
Convenient Convenient for monitoring and supervising demonstration 
activities (e.g. were close to the capital city and/or had good 
transport links), or were situated close to existing partners, or had 
been research sites previously
10 (19%)
Variable Variable conditions so that more than one environment/population 
could be tested at a time, e.g. representative of both urban and 
rural areas
16 (30%)
Challenging Particular challenges that required additional testing and practice 
e.g. nomadic/ religious groups, hard-to-reach areas
7 (13%)
Outstanding Better than average performance e.g. in DTP3 coverage, school 
attendance, cold chain facilities, infrastructure
5 (10%)
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Three projects had selected areas that were convenient and attained better than average EPI performance. Hence, these 3 projects did not gain experience of HPV vaccine delivery in districts representative of the nation.
5.1.3 Planning committees and 
processesAmong the 59 experiences in 36 countries for which planning processes were mentioned, 
findings	from	eight	Gavi-supported	countries	and 25 others indicated the existence of planning committees or inter-agency coordination committees, although these were rarely discussed in any detail. Gavi funding required the creation of a planning committee [6, 21] and leadership of the national immunisation programme (NIP) and therefore Gavi-supported projects were generally well integrated with EPI planning processes. Despite this, or perhaps because of assumed knowledge of EPI structures and processes, minimal information was provided on planning processes (e.g. length of planning, planning partners, technical support) in either Gavi-supported or alternatively supported projects.The 55 experiences in 33 countries for which planning committees were explicitly mentioned, described committees at national and sub-national levels, with sub-national committees responsible for micro-planning and funding requests which were then forwarded to the national committee for approval and oversight. Examples of sub-national level committees include regional representatives forming working groups on: logistics, social mobilisation, training, monitoring and evaluation. One non-governmental implementer mentioned an internal committee but no details were provided. Among the few committees for which membership was mentioned, most had broad inter-sectoral involvement, including representatives from sexual/reproductive health, child health division (e.g. EPI), health promotion and education (school health programme), central medical stores, environmental and occupational health (injection safety), national cancer programme, MOE with international partners - particularly WHO - providing technical assistance. The importance of timeliness (e.g. of decision-making, information and funding disbursements) was frequently mentioned, 
usually	to	indicate	that	insufficient	time	had been allowed for project development and planning such that coordination and implementation had suffered accordingly. Only one country mentioned that HPV demonstration 
planning	created	difficulties	for	other	EPI	planning activities. Several Gavi-supported 
countries noted that the planning timeline was lengthy, but that had this not been the case, 
more	difficulties	could	have	occurred	(e.g.	as	found in smaller or non-governmental projects).Sources indicated that to be effective, microplanning needed to involve teachers and school administrators as well as health representatives. Issues to be considered in planning included low education/literacy among parents, low awareness of risks and prevention of cervical cancer, women’s health having a lower priority in some families and communities, political instability and geographical diversity.
5.1.4 Integration of planning with other 
sectors and programmesAmong 40 experiences in 27 countries for which any detail on planning integration was mentioned, minimal information was provided about how planning was integrated into other sectors. The most frequently mentioned way was through involvement of the education sector in planning for HPV vaccine delivery and shared planning responsibilities between the education and health sectors. In a few countries, community development/social welfare sectors were also mentioned. Four countries indicated that no integration with other sectors had occurred, mainly as the project had been a small or non-governmental pilot project. The style of integration initiatives may have depended more on style of governance and politics than on anything particular to HPV vaccination. In most cases, if mentioned at all, it was as an ad hoc discussion. For example, 
five	countries	mentioned	HPV	vaccination	as an addition to an existing school health programme. Although the integration with the school health programme seemed attractive, it was also noted by one country that this required a high level of engagement from MOE and a long time for negotiating partnership agreements.Collaboration between health, education 
and	finance	sectors	was	noted	as	crucial	to	successful implementation. An initial lack of involvement of the MOE had, in some cases, led 
to	difficulties	in	the	planning	and	subsequent	implementation phases of HPV vaccine demonstration projects (e.g. enumeration, timing of vaccination in school year). The involvement of MOE at the national level was 
often	identified	as	a	facilitator	or	pre-requisite	for engaging local MOE and school authorities. When cooperation was good it was often mentioned as a critical factor for high coverage in school-based models. Collaboration with and support from the Ministry of Finance 
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(MOF) was noted as crucial, yet was sometimes overlooked during decision-making and planning. Integration with national cancer programmes was mentioned by 37 experiences in 25 countries, while another three indicated that no integration had yet occurred. WHO, which provided technical support for many countries, advocates that HPV demonstration projects be implemented within the guidelines of a four-pronged national cervical cancer strategy, including prevention, promotion, screening and treatment [42]. However, capacity and development of national cancer programmes and cervical cancer strategies appeared to vary considerably, despite WHO initiatives and their development being required for all Gavi-supported countries. Details of national cervical cancer strategies were not available, although sources noted that some Gavi-supported countries were still at the stage of developing these strategies. Only one non Gavi-supported country mentioned integration with a national cancer strategy. No differences were explicitly noted over time. 
5.1.5 Key lessons learnt and 
conclusions
Based	on	the	findings	above,	lessons	related	to	planning included: 
• Political commitment from national authorities provides crucial advantages by increasing interest and support at all levels.
• Funding and technical support by development partners can be very useful during preparation and planning.
• Planning across the ministries of health, 
education	and	finance	is	necessary	for	success, including harmonizing policies, regulations and protocols to support institutional and technical sustainability.
• Planning alongside the education sector can improve vaccine acceptability and effectiveness, for example in choosing school grades with the highest female attendance 
(e.g.	confirming	sub-nationally	whether	this was grade 5 or 6) and coordinating vaccination with school calendars to avoid examination days or other important events.
• Agreements with national ministries (e.g. MOE) did not necessarily translate into cooperation with sub-national sectoral representatives and, in the case of local departments of education and school authorities, cooperation could often be delayed or problematic if not sought early. 
5.1.6 Key recommendations
Based	on	findings	related	to	planning,	we	recommend that:
• Strong inter-sectoral coordination is facilitated from the beginning, so that all decision-making and planning includes, at a minimum, national-level decision-makers from MOH, MOE, and MOF.
• Sufficient	time	must	be	allowed	in	project/programme timelines for decision-making and planning at national and sub-national levels (e.g. this can take at least 9 months).
• While EPI does not have to lead each demonstration project/ national programme, EPI must feel ownership of the project/programme, as its active support and participation in planning and delivery phases is necessary for effective vaccine delivery.
5.2 The decision not to implement 
HPV vaccine By January 2015, nine Gavi-eligible countries were eligible to apply for HPV vaccine project funding but had not (i.e. they met the DTP3 coverage threshold of >70% required and had 
significant	cervical	cancer	incidence,	for	this	
study	defined	as	>15/100,000	women	years	according to GLOBOCAN 2012 [39]). These countries were: Comoros, DRC, Djibouti, Eritrea, Guinea-Bissau, Kyrgyz Republic, Mauritania, Nicaragua and Nigeria. Nigeria had applied for GAP support for a demonstration project, but it had never started and no application for Gavi support had been made at the time of data collection.
Representatives	from	five	national	immunization teams were available to be 
interviewed.	All	five	representatives,	reported	that cervical cancer was a public health problem in their country; four mentioned it as 
an	important	problem.	All	five	representatives	were aware of Gavi funding for the introduction of HPV vaccine and had experience of Gavi funding for other vaccine introductions.In four countries, in-country data was stated as the factor which most informed the decision to introduce new vaccines. Two countries gave details about the committees which were formed to discuss new vaccine introductions. These were multi-stakeholder groups with very 
similar	membership	as	to	those	identified	by	countries who have already introduced HPV vaccine. One country stated that they used information from their last PIE to inform their decision.
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 “Our decision to introduce the new vaccine is based on the PIE from the past vaccines introduced, which give lessons for future vaccine introduction. The 
final	decision	is	arrived	at	and	the	ICC	approves for the new vaccine” 
Country D representative.Decision-making processes appeared to be very similar to countries with HPV vaccine experience. However, competing priorities were stated as the main reason for not yet applying for Gavi support.  Two countries were planning to submit an application to Gavi within the next year (Nigeria and country A). Nigeria had delayed introducing the HPV vaccine, despite high-level interest in its introduction since 2010, mainly due to fears that HPV vaccination would affect coverage of other routine infant vaccination, including polio vaccine. It was felt that a vaccine targeting girls of reproductive age would exacerbate existing rumours around vaccines causing infertility and sabotage any previous gains in polio vaccine coverage. “To go and bring a vaccine which is targeting only girls in that reproductive age group was dangerous. We felt we needed to take some time, sort out the problem of polio and proceed gradually.  I think we have got to that stage now”
Nigeria representative.One country (Country B) had discussed the addition of HPV to their schedule and was soliciting help from technical partners to discuss delivery feasibility. However, along with a second country (Country C), competing priorities with rotavirus, rubella, PCV13, meningitis A and measles second dose vaccine introductions had delayed discussions around 
HPV	vaccine	introduction.	The	fifth	country	
(Country	D)	stated	that	there	was	insufficient	funding at the moment to discuss HPV vaccine, not enough information on who would lead the introduction and monitor it and a lack of experience and support, and therefore 
insufficient	political	will	to	take	it	forward. “The country was introducing a number of vaccines from 2012. We didn’t consider cervical cancer as much of a public health importance in the country. There were sentinel sites monitoring rotavirus, and rubella, meningitis and measles instead – hence the delays in introducing the HPV vaccine.” 
Country C representative. 
5.3 Vaccine Management 
5.3.1 TransportInformation on the supply and transportation of HPV vaccines was available from 49 experiences in 35 countries. National programmes and over half of demonstration projects for which information was available used the routine immunisation programme transport system to supply health facilities with HPV vaccine. Of the seven experiences where regular EPI processes were not used, three were GAP projects not 
led	by	the	MOH,	one	was	financed	directly	by	Merck, one by a provincial health department, 
one	by	ACCF	and	one	was	financed	by	GAVI.	In	some countries, the transport timetable of the routine vaccines did not correspond with that of the HPV vaccines and separate transport had to be arranged. In some of these projects, the implementers had originally assumed that the HPV vaccine would be transported together with other EPI vaccines, but in reality this proved problematic to organise, due in some part to the timing of the demonstration project not aligning with quarterly delivery schedules. Moreover, some demonstration projects were not planned in close coordination with the routine vaccination programme. In one instance, transport quality of the HPV vaccine was seriously compromised due to inadequate cold chain support (Country 25).If nurses from health centres delivered the vaccine in schools, school vaccination teams generally collected the vaccine from health centres or district vaccine storage using  vaccine carriers.
5.3.2 Cold storageIn total, 48 delivery experiences in 35 countries provided information about whether a cold chain assessment was completed before the HPV vaccine demonstration project was implemented. In many instances, assessment was part of a large, national cold chain assessment. Based on these assessments, additional refrigerators and cold boxes were procured in advance for several of the demonstration projects. However, some countries reported limited cold storage space at either national, regional or district cold stores. In some countries, the storage space was only 
gradually	expanded	after	the	first	HPV	dose	had been delivered. In one country, some of the vaccine supply was kept at district level due to limited refrigeration storage capacity at some health facilities. This was reported to have resulted in lower than expected coverage in those facilities. The key informant attributed this to having a resultant ‘pull’ rather than ‘push’ system of vaccine supply where health 
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workers had to collect the vaccine when stock ran out at the health facility level. Information on cold storage equipment used for the HPV vaccine was available from 36 demonstration projects. In 34 of these, the usual EPI cold storage equipment was used. The two projects that used separate cold storage equipment were both GAP projects. In both of these projects, new fridges were procured especially for the HPV vaccine, which 
were	installed	in	project	offices	or	project	pharmacies and not in EPI central stores or health facilities. In one case this was at the request of EPI because there was no space at regional storage facilities. In the other project, it was not possible to procure vaccine carriers and therefore cardboard boxes with refrigerants were instead used when carrying the vaccine to schools.   There were reports of lack of temperature monitoring in several countries, but this was not only an issue for the HPV vaccine.  
5.3.3 Vaccine wastageAmong 16 experiences in 11 countries providing information on HPV vaccine wastage and vials (i.e. either single or two-dose vials) used, only one reported considerable wastage, due to accidental freezing of the vials. This resulted in the demonstration project being halted halfway through third dose implementation. The other 15 projects reported marginal vaccine wastage (e.g. between one and 42 doses wasted per project), as one/two dose vials reduced wastage considerably In general, great care was taken not to waste HPV vaccines. Project teams were aware that the vaccine was relatively expensive and often only a limited amount was supplied. The HPV vaccine was often viewed as a precious commodity, with the demonstration project seen as the only chance of getting the vaccine. 
5.3.4 Waste managementInformation on waste management of used syringes and needles was available from 43 experiences in 33 countries. All of these reported that used syringes and needles were disposed of in a similar manner to other 
syringes used by the EPI programme. For most projects, it was simply stated that “usual EPI procedures were followed”. Other approaches included:
• waste kept in a secure place at the schools until collected for incineration at designated waste disposal sites;
• waste transported in sharp boxes back to the health facilities for incineration;
• private waste management companies contracted by district health management teams to collect and dispose of waste at appointed dates and times. While no projects reported issues with waste management that were particular to HPV vaccines, it was apparent that systems for waste management were weak in many of the settings. For instance, one key informant stated:“Waste management was also the same. The problem is however that we have a national policy for waste management, but don’t have funding to implement it.  So waste is just burned in secured tanks because we don’t have funding for incinerators”
Country 17 representative.
5.3.5 Key lessons learnt and 
conclusionsIn relation to vaccine management, key lessons included: 
• Countries have introduced several new vaccines in the past decade and are accustomed to cold chain assessments and expansions. 
• The HPV vaccine is sensitive to freezing and this is the greatest risk for vaccine wastage.
• If EPI systems for vaccine transport, cold storage and waste management are weak, this also affects HPV vaccine.
5.3.6 Key recommendationsIn relation to vaccine management we recommend that:
• HPV vaccines should be transported together with the other EPI vaccines. This reduces the 
risk	of	temperature	fluctuations	by	using	established EPI systems and integration is 
cost	efficient.	HPV	vaccine	delivery	timing	needs to be coordinated with routine EPI vaccine delivery timings.
Photo courtesy of D. Watson-Jones 
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• Implementers of demonstration projects outside of the EPI should not assume that the EPI cold chain is adequate and working optimally, or available to be used for HPV vaccine.
• Waste management procedures should be regularly reviewed and strengthened.
5.4 Staff training
5.4.1 Training approachIn total, 42 experiences in 30 countries provided information on staff training. HPV vaccination training was commonly conducted in a cascade manner, with the national immunization team being trained initially, sometimes alongside the provincial teams. National or provincial representatives then trained district representatives, who then trained the frontline staff. In total 37 experiences in 26 countries, including six national programmes with data, reported using cascade training (e.g. Countries 3, 12, 15, 17, 21, 22, 26, 28, 30, 31, 33, 36, 37). Almost all of these projects/programmes were led by the MOH and therefore used EPI staff. The transfer of information between levels in the cascade was reported to be of variable quality by four countries, who recommended that cascade training should be monitored and evaluated by national level staff to ensure consistency of messages (Countries 2, 3, 12, 17). This was especially pertinent in one country where HPV vaccination training was combined with measles campaign training to reduce costs. Limited supervision resulted in most staff reporting only receiving training on measles and this was reported as the reason for their delay in starting to deliver the vaccine despite having it available at the health facility (Country 33; see Section 10: Integration). Three countries used a centralized training model, where the national team trained frontline vaccinators either when visiting districts or inviting all vaccinators to train at a central venue (Countries 8, 16, 35).  Just one country reported an alternative approach to training and developed a successful distance learning module to train health professionals and teachers; completion of the module took 40 hours (Country 4). Most training sessions were developed and/or coordinated by international partners in conjunction with the MOH. Where the cost of training was a problem for countries, one country recommended cutting the number of national level team members who were trained in order to concentrate on the service delivery personnel (Country 21). 
Training activities were generally focused 
specifically	on	HPV	vaccination,	combining	knowledge about cervical cancer and the HPV vaccine with reminders about EPI standard processes. Responses from three countries indicated that HPV vaccination warranted 
specific	training,	as	it	involved	targeting	a	
specific	age	group	and	gender,	awareness	raising about cervical cancer (baseline knowledge was low), potentially new practices relating to consent, and vaccination in schools (Countries 3, 12, 15). 
5.4.2 ParticipantsAmong 38 experiences in 30 countries mentioning training participants, these included a wide range of stakeholders: national, provincial and district-level stakeholders in vaccination from both the education and health 
sectors,	nurses,	health	education	officers,	lay	counsellors, pharmacy technicians, community health workers, teachers, school health teams, hospital nurses, head teachers, hospital doctors and community mobilizers.One country recommended that pharmacists should participate in training if they have a role in cold chain management, in order that they feel ownership and can advise on supply chain logistics if/when necessary. Non- EPI staff, e.g. reproductive health staff, were rarely mentioned as being the target of the HPV vaccine training. However, all health workers, not only those delivering HPV, were seen as needing detailed knowledge of HPV, the vaccine, HPV-associated cancer and reasons for the target age and population, in order to allow them to become consistent and reliable sources of correct information in the community (Countries 3, 12, 31, 36). Only one country stated that additional HPV vaccination training was unnecessary, because of past experience in vaccination (Country 6).Teachers were key partners in most HPV vaccine projects/programmes; every delivery strategy accessed school-age children even if it was not utilising a school-based delivery strategy. Teachers were seen as being reliable conduits of information about the vaccination project/programme, if well-mobilised (Countries 3, 15, 18, 24). In three countries, it 
was	reported	that	one	day	briefing	of	teachers	
was	insufficient	and	that	teachers	requested	more training on cervical cancer, the vaccine and the biology of HPV. In one country where no training was provided to teachers, the scope of the social mobilisation of school girls was limited. 
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Two countries suggested that separate training for health workers and teachers ensures the respective roles are clear. However, it was then useful to join the groups to consolidate roles and relationships and develop a micro-plan for delivery (Countries 12, 33). 
5.4.3 Duration, timing, refresher 
sessions Among 30 experiences in 27 countries including data on training duration or timing, the duration of HPV vaccine training sessions for health workers varied from less than a day to three days. Often duration was reported to vary as training cascaded down from national to community level, or depending on the recipient group e.g. health workers, teachers or local leaders. For health workers, one day of training was the most common, although recipients in two countries reported that this was too short. HPV vaccination training was generally conducted separately, rather than being integrated into other trainings (See Box 11; Section 10: Integration for one example where this was not the case). The interval between the training and the start of vaccine delivery varied from just one day, to a few months. In three instances, where training occurred between one day and two weeks prior to vaccine delivery, health workers reported that the interval was too short and that this was too rushed as ideally training would have occurred before the social mobilisation campaign (Countries 3, 15, 31). If training was delayed, it impacted on how well communities 
were	mobilized	by	the	key	influencers	(health	workers and teachers). The ideal interval was 
specified	by	one	country	as	one	to	two	months	before vaccination started. Refresher training between doses was not mentioned or not deemed necessary 
in	most	countries	in	the	first	year	of	their	demonstration projects, but was reported as a factor to ensure good completion of the vaccine schedule in seven countries, including one implementing a national programme (Countries 8, 12, 15, 21, 26, 30, 33). One country stated that the intensity of training could decrease over time (as years of the programme passed) and perhaps just a reminder to healthcare workers and teachers prior to the second and/or third doses would be adequate after a few years of the programme (Country 33). 
5.4.4 Training content and materialsAmong nine experiences in seven countries that provided data on training content and/or materials, relatively little detail was included (Countries 12, 14, 18, 21, 25, 31, 33). Only four of these projects/programmes mentioned that participants were trained on adverse events (Countries 14, 21, 31, 33). Another stated that a seminar was held on handling ‘minor and major incidents’ (adverse events) but attendance was not mandatory (Country 25). 
There	were	insufficient	data	to	link	training	on adverse events with the data on adverse events experienced. Topics covered in training generally included: 
• Cervical cancer and its prevention
• HPV immunization schedule 
• Target group
• Administration technique
• Stock taking
• Messages for girls and parents
• The consent process 
• Information, education, communication (IEC) materials and role-play 
• Handling adverse events following immunisation (AE)
• Micro-planning
• Calculating coverage and targeting efforts on low coverage areas
• Cold chain requirements and management
• Safe injection proceduresThree countries reported that training materials need to be delivered in a timely way so as not to delay training and/or social mobilisation activities, Those trained also requested materials to take away at the end of the session (Countries 3, 23, 30).A participatory approach (demonstrations, role plays, and active learning) and the use of visual training materials were reported as being effective by three countries (Countries 12, 26, 30). One country reported that training materials developed during a previous demonstration project were useful for training for national roll-out (Country 3).
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5.4.5 Key lessons learnt and 
conclusions 
In	relation	to	staff	training	the	key	findings	included: 
• Cascade training was the most common method of training staff in HPV vaccine introduction; however, a number of countries 
identified	issues	around	the	quality	of	training for frontline staff.   
• All health workers, not only those delivering HPV vaccine, need knowledge of HPV, the vaccine, the cancer(s), and reasons behind the eligibility criteria, so that they are able to answer questions from the community and help to mobilise girls.
• Teachers are trusted in the community and can greatly enhance consent and acceptance rates through social mobilisation – they should be included in micro-planning and trained appropriately. 
• The ideal timeframe for training is at least two months before vaccine delivery, in order that health workers and/or teachers can conduct social mobilisation activities in good time before vaccination days. Materials should be planned well in advance so their delivery does not delay the start of training. 
• Novel aspects of HPV vaccine and its 
delivery	require	specific	training,	although	training could be integrated into other EPI training for nurses and may be conducted less frequently in the future, as processes become more familiar and existing staff become more experienced.  
5.4.6 Key recommendations In relation to staff training we recommend: 
• General knowledge of HPV and cervical cancer is low among healthcare workers and the community. Careful training is necessary 
in	order	to	explain	the	efficacy	of	the	vaccine,	the eligibility criteria and appropriate social mobilisation messages. 
• Adequate training is needed in order that staff can resist pressure to deviate from eligibility criteria and to ensure that coverage estimates are accurate. 
• Cascade	training	is	likely	to	be	more	efficient	and less expensive than a centralized training session (where all frontline staff are trained by a national ‘trainer’). However, cascade training should be monitored and evaluated to ensure consistency of messages. 
• Teachers and some healthcare workers, including those not delivering the vaccine, should be included in training. 
• Training should be conducted at least two months before vaccine delivery. 
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6. Communications
6.1 Social mobilisation
6.1.1 Formative research
Only	seven	countries	specifically	mentioned	in post-delivery evaluation reports that formative research informed their mobilisation strategies (Countries 12, 22, 23, 26, 30, 31, 33). Other countries may have conducted formative research but not mentioned its 
influence.	Formative	research	was	used	in	these	seven countries to identify particular social mobilisation challenges (e.g. literacy levels 
in	Country	23),	to	define	effective	messages	and to develop communication strategies. The importance of formative research or prior experience was emphasised in two countries, one of which had learnt to allow more time to develop and pre-test IEC materials, after confusion over messages during a previous vaccine introduction (Country 22).
6.1.2 Messages  For most projects/programmes, mobilisation messages were tailored for a target audience 
(e.g.	health	and	education	officials,	teachers,	communities, families, girls) and focused on providing key information about:
• Cervical cancer, including the importance  of HPV vaccination in prevention;
• Vaccination logistics, including doses required, timing and venues, consent procedures;
• HPV	vaccine	safety	and	efficacy,	MOH	and	MOE endorsement (if applicable), length of protection, potential side effects;
• Countering misinformation and rumours, including the message that HPV vaccination does not affect fertility or cause long-term adverse effects. Messages were developed to address 
community	concerns	identified	regarding	
HPV	vaccine	safety,	efficacy,	schedule	and	eligibility. Endorsement of HPV vaccination by the government and/or relevant authorities (e.g. WHO) was highlighted in messages in some countries in order to increase target 
audience	confidence	in	the	project/programme.	Published formative research from Soweto in 
South	Africa	identified	that	mothers’	desire	to protect their daughters from sexually transmitted infections (STIs) was a major driver of acceptability, in an environment which they felt was high risk for gender-based violence and rape [43]. This was the only documented experience of increased acceptability when 
framing the vaccine as an STI vaccine rather than a cancer vaccine.In general, HPV vaccine as a cancer prevention method was more frequently emphasized than its role in STI prevention. The reason for this was two-fold. The public often had little to no knowledge of HPV and were more familiar with the concept of cervical cancer. There were also concerns at the policy level that framing HPV vaccination together with STIs and reproductive health may increase stigma around the vaccine and decrease parental acceptance, or may cause confusion about HIV versus HPV prevention messages.   All reported mobilisation messages generally targeted the whole community, including 
boys.	Messages	specifically	targeting	girls	aimed to raise awareness of the importance of protecting girls and encourage them to get 
the	vaccine,	and	the	lack	of	specific	messages	for boys  was not mentioned by any country or project/programme as effecting community acceptance of the vaccine. Two countries stated explicitly that boys were interested in how to protect their mothers and sisters (Countries 6, 25). The media in one country criticised the exclusion of boys (Country 30); boys were sometimes included in integrated simultaneous interventions, e.g. deworming and tetanus toxoid booster administration (see Section 10: Integration). One country reported that boys requested the vaccine (Country 15). 
6.1.3 Information dissemination 
approachesInformation on IEC materials and methods was available for 40 out of 46 countries, covering 87 out of 92 different delivery experiences. Various approaches were used to disseminate information and messages. Inclusion of an interactive approach to communication was mentioned by 46 out of 87 experiences: 
Interactive approaches included: (i)  One-to-one/group meetings at schools, health facilities or outreach sites. (ii) Direct contact with teachers, health-workers, community health-workers, and communicators.(iii) Home visits by health-workers. 
Non-interactive approaches included: (i)  Announcements on local media, including radio and television spots social media internet sites(ii) Announcements at religious services. (iii) Loud-speaker announcements. 
(iv)	Distribution	of	leaflets	and	posters
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Evidence from four countries indicated that interactive approaches were more effective in increasing community acceptance and mobilising girls (Countries 26, 31, 33, 36). 
Information	sources	were	defined	as	the	people	or IEC materials delivering the messages. The top three information sources accessed by parents were reported by coverage and acceptability surveys in ten countries covering 13 delivery experiences (Countries 12, 13, 17, 18, 28, 31, 33, 36, E, G; Table 8). Meetings with health-workers and/or teachers, held in school or community locations were by far the most common information source reported. In Tanzania, parents who reported attending a teacher-parent vaccination 
meeting	were	significantly	more	likely	to have a vaccinated daughter than those reporting not attending these meetings [44].
Communication was most effective when 
delivered	by	‘credible	influencers’	within	
communities.	Credible	influencers	were	
primarily	identified	as	health	workers	and	teachers/school directors (head teachers), 
while	parents	in	five	countries	also	mentioned	
community	and	religious	leaders	or	influential	family members (Countries 12, 17, 18, 33, 
36).	Example	of	prominent	influential	leaders	included: First Ladies and royalty (Queens) (Countries 1, E, 13, 28, 31, 37), high level 
ministerial	officials	(Countries	30,	E,	15,	37,	I)	and Media and TV celebrities (Countries 4, 30). 
In	Tanzania,	parents	who	first	learnt	about	HPV	vaccination from a project source were slightly more likely to have fully vaccinated daughters than those who had heard about it elsewhere [44]. 
Two	countries	identified	plans	to	add	HPV	vaccine information to the school curriculum alongside existing health education sessions (Countries 25, 34). In Uganda, 63% of interviewed girls stated that they wanted HPV vaccine included in the curriculum [45]. In addition to information, an incentive such 
as promotion T-shirts (Country 4), bookmarks for being vaccinated (Country 11), transport refund for follow up visits (Countries 13, 19) and bracelets were given in one country in some areas to girls after each dose (Country 35). However, this was only evaluated in one country where coverage was high even in areas without the incentive and incentives were stopped after 
the	first	year	(Country	35).	Countries reported very little about best practices on how to engage media. Those that did provide some information reported:
• Communication may require extensive media engagement so as to leave no room  for misinterpretation (Country 1).
• Specific	media	sessions	with	journalists	and	pre-prepared press kits for local media were more effective than merely providing media briefs (Countries 12, 26).Three countries mentioned using their government social media network to increase awareness of their national HPV vaccination programmes and to combat emerging rumours on social media (Countries 4, 30, B). However, 
Table 8. Main sources of HPV vaccine information cited by parents 
Information sources Score1 Number of country 
surveys  
Interactive meetings with teachers and/or health-workers 25 11 
Radio 10 5 
Local media (e.g. TV) 7 4 
Posters 5 3 
Pamphlets 4 2 
Other verbal communication (e.g. relatives, girls, church) 4 3 
Internet 1 1
Loudspeaker 1 1
1The most commonly reported source from each survey was given a score of 3, the second most commonly cited source of information was given a score of 2 and the third most 
common was given a score of 1.
HPV vaccine cultural troop, Tanzania (Photo courtesy of D. Watson-Jones)
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Table 9: Timing of social mobilisation prior to vaccination and coverage achieved
Timing Countries in which 
projects/ programmes 
reported timing data
Project/
programme 
coverage 
Comments
1-2 weeks Countries 18, 15 90%, 89% Country 18: Representatives reported 
sensitization was “too short” due to the late 
disbursement of funds for the printing of 
materials and activities. 
Country 15: no comments made
2-3 weeks Countries 3, 11, 31, 30, 12, 
26, C, 13.
>90%, NA, 
90%, NA, 
78%, 83%, 
NA, 82%
Country 3: At national level, announcements 
started early but community-level engagement 
started 2-3 weeks prior to vaccination. 
Country 30: Delays in getting final agreement 
of the national education officials delayed 
messages being sent to schools: “it was too short 
a timeline”. 
4 weeks Countries 4, 14, 33, E. 85%, NA, 
NA, 87%
Country 33: Teachers thought the notice given of 
vaccination activities starting was too short. 
Country 4: 1 month pre-vaccination day billboards 
and TV programmes were arranged. An Education 
week at school was organised 2 weeks pre-
vaccination and parent meetings were held then.
8 weeks  Countries 13, 21, 28. 83%, 65%, 
NA
No comments  reported by countries
2-4 months Countries 6, 31. 90%, 78% Country 31: Sensitization meetings began 2 
months prior to vaccination: meeting with 
administrative area committees (31 meetings), 
meetings with teachers (one per school), meeting 
with parents-teams team (1 per school), 5 village 
council meetings. These were preceded by 36 
stakeholders meeting conducted 4 months prior 
to vaccination.
NA indicates coverage data was not available. 
all mentioned this was challenging: “It is hard for the government to appear trustworthy on social media” 
KI Country B.
6.1.4 Timing and duration of social 
mobilisationTiming of social mobilisation activities was reported by 19 delivery experiences and coverage data were available for 13 of these. Timing did not seem to correlate with coverage achieved and optimal timing was probably 
dependent	on	the	specific	local	context	 (Table 9). Very few experiences explicitly described the frequency of social mobilisation activities (i.e. 
whether social mobilisation was repeated before each dose or only conducted once at the start). Only one experience stated that mobilisation activities were carried out “before each vaccination session” (Country 5). Another stated that social mobilisation 
was	only	conducted	before	the	first	dose	due to restricted funding (Country 17). The necessity for messages to be given repeatedly to 
counter	newly-arising	rumours	was	identified	explicitly by two projects (Countries 25, 37). One country stated that the extent of social mobilisation activities decreased in the second year of the programme as the vaccine became more familiar in the community (Country 33) and another reported that the intensity of 
mobilisation	activities	in	the	first	year	could	not	continue due to funding gaps (Country 1).
6.1.5 Managing rumours Rumours were reported in 19 of the 46 countries, and their effects could span over multiple projects/programmes. The consequences of not including measures to prevent rumours or adequately control their spread could be serious and in one instance resulted in the project stopping after just one year (Country 12). Negative media discouraged politicians from further demonstration projects or scaling up to national programme in one 
country (Country 21). The range of rumours reported was limited with the majority focused on the effects of HPV vaccination on fertility and/or causing adverse events (Table 10):1. The vaccine is experimental/ being tested.2. The vaccine leads to fertility problems.3. The vaccine causes adverse events/long-term effects.4. There is “another cure” for cervical cancer.
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Table 10: Reported rumours and responses
Rumours Country experience and response
The vaccine is 
experimental/untested 
Country 3: rumour generated as result of opt-in consent; consent was changed to opt-
out. 
Country 6, F, I: The words ‘trial’ or ‘demonstration’ were perceived as indicating an 
experiment and were substituted by ‘study’ or ‘pilot’. Fears were compounded by the 
use of opt-in consent.
Country 12: government and experts should have engaged with the rumours early on. 
Vaccination project was stopped after 1 year. 
Country 24: social mobilisation was considered inadequate; coverage in urban areas 
was low (<70%).
Country 37: the emphasis during campaign was the vaccine is also being delivered in 
other countries in the world.
Countries mentioned that tailoring messages to these rumours (e.g. by adequately explaining the limited extent of potential side effects of the vaccine) may help minimise their impact. One country stressed that allowing the media access to accurate information from an independent government source (e.g. high-level government 
official,	respected	public	health	body)	was	vital to managing rumours (Country 37). One country found that inadequate training of staff and teachers meant that they could not answer parents’ questions, which contributed to rumours about HPV causing sterility in a few schools (Country 3). Two countries found that rumours could cross national boundaries (Countries 1, 20). Two countries noted that expensive TV programmes did not seem to have the biggest impact on awareness or preventing 
rumours	and	that	rumours	could	influence	acceptance despite a well-organised and extensive mobilisation strategy (Countries 12, 21). While three countries stated that a strategy to address rumours should be part of their communications plan (Countries 1, 20, 30), none 
specified	having	a	crisis	communication	plan	for	this purpose. Three countries reported that rumours were perpetuated on social media networks and used government social media sites to combat these rumours, with limited success (Countries 4, 30, B). The use of social media by parents of children who suffered adverse events following immunisation and anti-vaccine lobbyists 
‘drastically	affected	uptake’	and	is	difficult	 to reverse:“Recovering the trust of the target population is proving extremely challenging, despite involvement of 
major	national	figures	both	in	the	field	of medicine and entertainment/social programmes” 
KI Country 4.
Strategies to manage rumours included: 
• Engaging with rumours early and using technology, such as email and SMS messages, and social media to easily reach large audiences with the correct information (Countries 35, 4, 30, B).
• Holding face-to-face meetings with institutional and religious leaders who expressed concerns (Countries 12, 17, H).
• Identifying opposition groups and lobbyists and providing them with additional communication and targeted information (Country 14, F).
One experience illustrates the many different challenges that can reduce the ability of national governments to effectively manage and combat rumours: “[MOE] participation in social mobilisation was delayed, they had to wait for the committee’s authorisation - this limited the ability to carry out social mobilisation in schools. The launch of the family planning guidelines and in particular increased information on contraceptive implants in the same period as HPV vaccine introduction negatively impacted acceptance of HPV vaccine in some communities. A televised launch by the MOH appeared to mediate some concerns but the biggest challenge was anti-vaccine lobbies on social media (facebook), email and SMS.”
 KI Country 30. 
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6.2 Acceptability and consent
6.2.1 Increasing acceptability Data on acceptance and refusal of HPV vaccine was available for 37 delivery experiences in 28 countries (34% of 92 experiences and 13% of 46 countries); 26 delivery experiences had a documented acceptance rate or numerical value associated with acceptance (e.g. ‘acceptance was high, apart from one school which refused vaccination’). All acceptability studies included in the review were conducted post-vaccination. HPV vaccine refusals occurred among individual girls or parents, at the community level and at the school level, especially in private and faith-based schools (Table 11; Box 1). Some projects noted that persistent sensitization 
through	community	influencers	increased	vaccine acceptability, even in communities demonstrating initial reluctance (Countries 14, 35, 37). An information letter signed by 
MOE	and/or	MOH	officials,	inviting	parents	to vaccinate their daughters, allayed many 
parental	concerns	and	had	a	significant	impact	on vaccine acceptance. It was clear from at least four countries that hesitancy in health workers, who were not involved in the vaccination 
programme (e.g. family doctors), to recommend the vaccine induced parental refusal, this supports the importance of broad education of health professionals, even in specialties not related to vaccination: “Some parents still refer to their paediatrician or their doctor, and when the doctor does not seem to have been informed, it does not support a favourable opinion in the parents. If the doctor says “I’ll think”, “I will give you information in 2 days” - it causes vaccine hesitancy. The national HPV organising committee included paediatricians so they eventually publicised their opinion and the missing girls [whose parents had initially refused] could catch up on their schedule.” KI Country H.It is important to note that simply measuring acceptability using dose 1 uptake, without adequate context, has major limitations; the low uptake reported in some projects could have been due to logistical issues as well as refusals e.g. vaccination teams attending sessions on 
The vaccine leads to 
fertility problems
Country 8: a crisis response had to be organised with a meeting with the community 
(reactive response) Since this occurred, a risk communication group has been set up. 
Country 17: a religious spokesperson spread internet rumours and only stopped after 
intense mobilisation. 
Country 21: anti-vaccine lobbyists attained media exposure despite a well-organised 
social mobilisation campaign. Media training was needed for MOH staff to deal with 
future rumours.
Country 24: social mobilisation was inadequate
Country 31: messages around side effects and future fertility needed to be built into 
parent-teacher meetings.
Country 16: high-level parliamentarians “actively advocated for cervical cancer 
prevention and vaccination and helped to quickly reverse rumours before they got out 
of hand”
Country 16: two vials, one of the injectable contraceptive (Depo-Provera) and one of 
the HPV vaccine, were shown at the public meeting for people to see the two vials are 
different 
Country 28: no information on response to rumours
Country F: imams, chiefs, and community liaison officers publicised their support for 
the vaccine 
Country I: no specific responses used
The vaccine causes 
adverse events/long-
term effects 
Country 28: no information on response. 
Country 33: no information on response to rumours.
Country 35: 2 girls reporting adverse events (AE) were visited and after investigations 
their mothers were reassured AE were not due to vaccination
Country 26: specific sessions should involve journalists to enable them document the 
appropriate information and counter rumours
Country H: a crisis management team was established to deal with rumours, press 
releases were done and question and answer sessions were organized with health 
workers.
There is “another cure” 
for cervical cancer
Country 35: rumours that seaweed cured cervical cancer were tackled immediately 
with an email newsletter and parent meetings.
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Table 11: Countries with groups unwilling to accept HPV vaccination
Groups unwilling to accept the vaccine  Countries
Community/groups of parents 7 (Countries 1, 5, 6, 10, 14, 18, 23)
Schools (private, faith-based) 8 (Countries 23, 24, 31, 35, 37, F, H, I)
Churches and religious groups 7 (Countries 3,13, 28, 37, B, F, I)
Human rights groups, academics 2 (Countries 12, 30)
Health-workers 4 (Countries 4, 6, 23, H)
Box 1: Specific issues in ‘private’ or non-government schools 
1  Private schools have different term-times compared with government schools; this meant that the vaccines schedule fell on non-school days (Country 23,37).
Solution: Engage private school representatives in local planning processes and plan to avoid delivering vaccine in close proximity to holiday periods.
2  Private school leaders or representatives were not fully aware of the programme, became aware too late, or had heard rumours about the programme and therefore refused vaccinators to enter the premises (Country 23, 24, 35, 37, 31).
Solution: Engage private school leaders early and provide detailed information; allow school directors time to consult with parents and decided the consent process
3  Private school representatives were afraid that they would be held responsible for adverse events experienced after vaccination, or refused vaccination as they thought parents would not agree with it (Country 23, 31)
Solution: Information needs to be provided on the number and severity of adverse events expected and how to report adverse events to the relevant health facility. Teachers and parents should be mobilised in joint meetings to ensure that they receive the same information and to support teachers if they are challenged by parents.
4  Private school teachers and parents require more intensive social mobilisation than those in government schools. 
Countries reported that effective mobilisation strategies included:• Using	high-level	local	officials,	community	leaders	and	religious	leaders	as	effective	mobilisers in meetings with community members, parents and the media (Country 31, 37)• Holding question and answer sessions at schools, led by health workers, to address teacher and parent concerns (Country 23)• Targeting	school	nurses	or	medical	officers	with	detailed	information	so	that	they	could become a reliable source of information for parents and teachers (Country 23)• General increased awareness over time and successful vaccinations in schools/communities participating early in the project led to higher acceptance at subsequent vaccination sessions and increased demand for dose 1 either during a second opportunity to receive dose 1, or at the time of delivery of dose 2 (Country 23, 31)
Issues in private/non-government schools and reported solutions:
a different day from that previously planned and therefore not gaining as high attendance at vaccination as expected (see Section 8: Achievements). A longitudinal study in Kenya that ascertained baseline acceptability and subsequent HPV vaccine uptake reported a high parental consent rate of 88% but very low 
first	dose	uptake	of	33%.	Practical	barriers	to	
attending	the	first	vaccination	session	with	their	daughters were mentioned as the reason for low uptake by 51% of parents of unvaccinated 
daughters.	Parents	found	it	difficult	to	leave	
work and/or transport themselves to the  health centre to be present (as required)  for the vaccination [46].
6.2.2 Reasons for HPV vaccination 
acceptance and refusalIn total, 29 projects/programmes reported the reasons for parental acceptance. Twelve post-vaccination acceptability studies or surveys of parents or caregivers, including questions on reasons for acceptance or refusal, were conducted in eight countries covering 17 
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Table 12. Reasons for vaccination acceptance (12 surveys)
Top 3 parental reasons for acceptance of the HPV vaccine Score1 Number of surveys2
Vaccine is “good for health” 31 12
Protection from cancer  30 12
Protection from infection/diseases 16 9
Perceived risk or susceptibility to cervical cancer 8 3
Have enough information/Information convincing 6 3
Vaccine is safe 5 2
Following others’ advice 5 3
Informed about the programme 4 2
Vaccine is free 3 2
Perceived severity of infection and consequences 3 2
To avoid shame/ stigma of an STI infection 2 2
Expression of interest in HPV vaccine and education 2 1
Heard of cancer/ knowledge of someone with cancer 1 1
School providing to every child 1 1
The vaccine is effective 1 1
1Reasons were scored, ‘3’ if they were the most common reason given by parents in the survey, ‘2’ for the second most common reason, ‘1’ for the third most common reason. 
Scores were then combined for each reason across surveys and the number of surveys in which the reason appeared as one of the top three was also noted. 
2The number of surveys reporting the listed reason as one of the top 3 reasons cited by parents for accepting the vaccine (all surveys had at least as option of answering an 
open-ended question).
delivery experiences. These were conducted for PIEs, international partner evaluations and/or research purposes. Parental acceptance rates 
were	measured	by	consent	rate,	uptake,	final	dose coverage and willingness to recommend HPV vaccination to others. All the surveys included at least an option for an open-ended answer as to why parents accepted vaccination. Results are summarised in Table 12. The most common reasons cited by parents for accepting the vaccine were to protect their child from 
cancer,	a	belief	in	the	benefits	of	vaccines	and	a	perception that their daughters were at risk of cervical cancer. Reasons for not starting or not completing HPV vaccination, were cited in eight of the studies/surveys from 11 countries, and are presented in Table 13. The three most common parental reasons could be categorised as ‘lack of motivation’, ‘lack of information’ and ‘systems barriers’. Parents stated: fear of adverse effects and vaccine safety, lack of project/programme awareness, that their daughter was absent on vaccination day. Reasons for not starting or not completing the vaccine schedule were often presented together. Other reasons cited in the literature and/or interviews, but not linked to an acceptability study/survey are summarised in Table 14. These include reported parental reasons for acceptance or refusal as perceived by health workers, or anecdotal evidence mentioned in reports, with no numerical information as to the frequency or relative importance of the statements.  
Only	two	studies	specifically	reported	reasons	relating to completion separately from reasons for not starting vaccination. In Brazil, where 39 of 1377 initially vaccinated girls did not receive 
the	final	dose	(3%),	reasons	for	this	included:	moving away and lost to follow-up (31 girls, 79%), unexplained parental decision (3 girls, 8%), girl’s refusal (one girl, 3%), pregnancy (2 girls, 5%) and non-serious adverse events reported by the family (2 girls, 5%). Completion was slightly more likely in private than public school (98.9% vs 96.7%)[47]. In Tanzania, qualitative interviews revealed the main reasons for non-completion were absenteeism, transferring schools and not knowing that the vaccine was available at nearby health centres if doses were missed at school [48]. One project assessed completion rates obtained with different delivery strategies and found that mixed delivery (i.e. both schools and health facilities) provided better completion rates (Country 23) (See Section 8: Achievements for more information on the effect of delivery strategy on uptake, completion and coverage rates). Other reasons for non-completion cited in project/programme reports included: 
• Absenteeism, transfer/withdrawal from school (Countries 20, 31, 35)
• Emergence of rumours or negative media exposure
• Logistical	difficulties	with	travel	to	vaccination site or related costs
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Table 13: Parental reasons for not starting or completing HPV vaccination doses 
Top 3 parental reasons for refusal of the HPV vaccine Scores1 Number of surveys2
Lack of motivation 
Fear of adverse effects and vaccine safety 16 9
Girls or parents do not want vaccine 8 4
May encourage early sex 6 3
Interfere with fertility 5 2
Cancer is perceived as low priority disease/low risk 5 3
Concern about vaccine effectiveness 4 2
Undisclosed reasons 3 1
Perceived low risk of infection 2 1
Not good for a child 2 2
Lack of information 
Not aware of the programme 25 10
Insufficient information 12 6
Systems barriers 
Absenteeism (girl was away during vaccination day) 21 11
Difficult to determine age eligibility (parents didn’t know if girl was 
eligible)
9 7
Location and time not convenient 5 3
Vaccine not available or not in stock 4 3
Health provider didn’t recommend 1 1
1Reasons were scored, ‘3’ if they were the most common reason given by parents in the survey, ‘2’ for the second most common reason, ‘1’ for the third most common reason. 
Scores were then combined for each reason across surveys and the number of surveys in which the reason appeared as one of the top three was also noted. 
2The number of surveys reporting the listed reason as one of the top 3 reasons cited by parents for accepting the vaccine (all surveys had at least as option of answering an 
open-ended question).
Table 14. Parental reasons reported in literature and interviews for acceptance or refusal of HPV vaccine
Reasons for accepting1 Reasons for refusing1
Vaccine is safe and effective Concern about vaccine safety, AE and rumour of 
fatalities after immunization
Persuaded by influencers; teachers,  
relatives and health workers
Not having enough information about the vaccine, 
including not being aware of the programme
Vaccine is good for health and offer  
protection against infections 
Fear that the vaccine can affect girl’s fertility or make 
girls sterile
The vaccine is available at no cost Logistic, travel and other vaccination related costs 
The vaccine is a government programme  
and therefore safe
Vaccine is new, a trial, research, or experimental
Protection from cervical cancer Do not believe in the vaccine 
Knew someone who had  
cervical cancer
Advised not to vaccinate on religious grounds, advice by 
physician or nurses 
Questions around signing of consent e.g. accepting 
responsibility
Absenteeism during HPV vaccination days
Vaccine could make girls sexually active or promiscuous
Parents/partners/girls refusing to be vaccinated
Others: perceived low risk, lack of time, too many 
vaccines, wait until next time
1These were cited in the literature but not identified as originating from a survey.
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Table 15: HPV vaccine consent procedures by delivery strategy
Delivery Strategy Number of experiences by consent process1 Total
Opt-in Opt-out Changed 
from opt-in 
to opt-out
Mixture 
(opt-in and 
opt-out
School-based 16 4 1 5 26
School + health facility 7 6 4 0 17
School + health facility + outreach 6 5 1 3 15
School + outreach 2 3 1 1 7
Health facility 3 0 0 0 3
Health facility + outreach 0 1 0 2 3
Total 34 19 7 11 71
1Consent processes divided into mutually exclusive categories. 
• Timely/scheduled availability of vaccine and personnel (“girls lost interest if the third dose was delayed”) (Countries 2, 5, 23)
• Address changes (Country 11)
• Travel, school holidays, examinations at time 
of	final	dose	(Country	21)
• Administration of the 3 doses was not completed in the same academic year  (7 countries)Strategies to ensure the delivery of mop-up doses, including whether or not outreach was performed, are described in Section 7.1.6: Mop-up strategies. Strategies employed to improve completion are in Section 8.1.4: Correlates of coverage.
6.2.3 ConsentConsent policies for HPV vaccine were generally 
aligned	with	country-specific	national	policies.	
Thus,	when	opt-out	was	an	official	policy	for	other vaccines administered to older children/adolescents, it was also the consent choice for HPV vaccination. However, several countries that did not previously cater for this age group in any vaccination programme introduced opt-in consent initially. In many cases they switched to opt-out consent in subsequent rounds due to implementation challenges and/or the emergence of rumours that the vaccine was ‘experimental’ or unsafe (Countries 1, 2, 11, 35). Projects/programmes generally designed new consent forms if written consent was used because this was a new target group and/or existing consent forms had not been adapted to include HPV vaccination at the time of the project.In total, 71 out of 92 delivery experiences reported the consent procedure used (Table 15). Almost half of them reporting using opt-in, in which parents had to complete a form, or provide verbal consent in two countries (Countries 18, 24), before girls 
could be vaccinated (Table 15). Three countries required girls to be accompanied by their parents to be vaccinated (Countries 5, 13, 28). This was mentioned as a problem, resulting in lower uptake than expected in two countries (Countries13, 28). The use of verbal assent by girls, in conjunction with written parental consent, was not described in detail, though assent was mentioned in 12 project/programmes from six countries (Countries 12, 26, 33, 36, 31, 30). Opt-out was used in 19 of 71 experiences (27%), as this was the routine EPI approach and in some countries there was concern that opt-in consent would lead to suspicion that this vaccine was different in some way. Opt-out consent was conducted by either requesting community agreement, through community leaders or meetings, or by educating parents about the vaccination project/programme and then advising parents to keep their daughters at home on the vaccination day or to specify to a teacher if they did not want their daughter 
vaccinated.	Results	from	five	demonstration	projects (Countries 4, 8, 26, 31, 33) indicated that several girls chose to be vaccinated even if parents refused. Whereas other projects (Countries 13, 14, 23, 31) noted girls refusing despite parental consent (e.g. due to fear of injections). On a few occasions (Countries 4, E), school principals and chiefs signed the consent forms on behalf of parents. Some MOHs recommended using opt-in written consent despite it not being the norm because the HPV vaccine was new and was only implemented in selected districts. However, 13 experiences reported that using opt-in consent raised suspicion that the vaccine was experimental (Countries 1, 2, 3, 8, 11, 13, 14, 21, 23, 25, 26, 30, 35). Social mobilisation teams in 
these	countries	advised	that	forms	be	simplified	or the approach changed to opt-out. Seven countries changed to opt-out during or after one year of implementation (Countries 1, 3, 8, 11, 
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13, 25, 35). Two countries using consent sheets for receipt of other school health interventions suggested acceptance would increase when HPV vaccine was added to this form, as the vaccine would appear to be routine and the logistics 
would	be	simplified	(Countries	30,	35).	Of the 15 experiences reporting problems caused by the use of opt-in consent, 
five	reported	specific	rumours	around	vaccine introduction (that the vaccine was experimental, caused AEs or loss of fertility). Eleven of the 15 experiences had data on uptake 
rates;	five	reported	uptake	between	64-70%	(Countries 3, 6, 21, 30, 35), the remainder had uptake >70%. One found uptake increased from 77% to 99% when they switched from opt-in to opt-out consent, although many other programme factors also changed in this time period (Country 3). One country actively compared uptake with opt-in and opt-out strategies and switched to opt-out as it drastically increased uptake (Country 25).  
Eleven experiences used a mixture of consent procedures, some private schools insisted on signing written consent forms whereas public schools used the opt-out process. In one country (Country 6), one community was comfortable signing the consent form whereas another used opt-out.
6.2.4 Reported lessons learnt by 
projects/programmesReported lessons on social mobilisation, acceptability, consent are detailed in Table 16. 
Table 16: Reported lessons learnt on social mobilisation, acceptability and consent
Reported lessons 
Mobilisation 
Strong mass mobilisation should target specific rumours to avoid or reverse the effect of negative media coverage 
and anti-vaccine campaigns
Collaboration between the MOH and MOE is necessary when conducting mobilisation activities.  Health care 
workers, teachers, and community and religious leaders are the greatest influence on parental decision-making. 
Teachers and community leaders should be engaged early and encouraged to mobilise girls. Girls can aid 
identification and mobilisation of peers.
A communication strategy should be developed to inform the mobilisation activities
Early start of mobilisation and adequate availability of funding for mobilisation is critical - early engagement of 
public
Messages should be appropriate, clear and concise, and translated into local languages
IEC materials are most effective when they include participatory methods, are interactive, are pretested and/or 
informed by formative research and/or developed with expert advice 
Letters of endorsement from the government (MOH and/or MOE) or WHO, local authorities, or political and local 
leaders can increase acceptability. 
Collaboration across regional (international geopolitical regions) and national/ local media is important to identify 
and address rumours. Prompt responses to criticisms/ rumours are critical and a press kit could be useful. 
General knowledge of HPV vaccine among health professionals is low. Training and orientation of health workers 
should be intensified.
Projects/programmes should put measures in place to adequately mobilise and address institutional refusals such as 
schools and churches
Mobilisation is logistically easier if integrated into other community activities
Consent
A lengthy process of signing consent accounted for some girls missing an opportunity to be vaccinated
Opt-in consent can cause problems as it raises suspicions if not routinely used for other vaccines
Acceptability 
Initial high refusal rates may decrease over time as the community becomes more familiar with the vaccine. Projects 
and programmes should take this into account and allow time for girls and parents to change their minds 
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6.2.5 Key lessons learntIn relation to social mobilisation, the key lessons learnt included:
Preparation
• General knowledge of HPV, HPV vaccine and cervical cancer is low in communities, and among teachers and health-workers.
• Training	of	influential	stakeholders/	spokespersons is needed at every level (i.e. national, regional, district, local).
• Problems occur if social mobilisation begins less than a month before vaccination (e.g. due to late fund disbursement or printing). Time allowed should not be underestimated when planning. 
• Teachers and parents of girls attending in urban and private schools often require more information before accepting the vaccine than those elsewhere and need 
to	be	identified	in	a	communication	plan	as potentially requiring more intensive messaging.
Dealing with rumours
• Rumours are generally consistent across geographical areas and projects/programmes. 
• Collaboration between MOH and MOE is necessary to tackle rumours as soon as they arise. 
• Strategies to address rumours include tailoring communication messages to 
specific	concerns,	announcements	by	
high-level	officials,	dissemination	of	letters detailing WHO or government endorsement, one-to-one or group meetings in communities and utilising social media networks to disseminate clear, accurate information (e.g. Facebook). 
Messages
• Key messages need to focus on cervical 
cancer	prevention,	safety	and	efficacy	of	the vaccine, government endorsement, vaccination timing and venues, the need to return for a second dose, the vaccine does not affect fertility, lack of long-term adverse effects. 
Delivery
• Face-to-face interaction remains the most effective way of mobilising parents and communities, especially among groups likely to refuse vaccination. Effective 
influencers	are	teachers,	health-workers,	and community leaders (e.g. religious spokespeople). 
• Letters of endorsement from the MOH, 
MOE and WHO can increase community 
confidence.
Timing
• Social mobilisation should be continuous or repeated to counter newly emerging rumours.
• It is likely that social mobilisation activities 
can	be	reduced	after	the	first	few	years	of	a	national programme as the vaccine becomes ‘normalized’.
• If social mobilisation is delayed due to fund disbursement or bureaucracy, activities can be implemented in a stepped approach so 
that	the	first	schools	targeted	are	the	first	to	receive social mobilisation.In relation to acceptability, lessons learnt included:
• The most commonly cited reasons for vaccine acceptance were protecting 
daughters	from	cancer,	general	benefits	of vaccines, and perceived cervical cancer risks.  
• The most commonly cited reasons for vaccine refusal were fear of adverse effects, vaccine safety, lack of awareness and absence on vaccination day.   
• Reasons for non-completion were largely absenteeism and/or logistical reasons.In relation to consent, lessons learnt included:• While many tested opt-in consent with or without child assent, this was noted to cause logistical problems and increase rumours if different from EPI norms. • Complicated consent procedures can decrease consent and thus uptake. The most successful opt-in approach appeared to be sending forms home with girls, which could be coordinated by teachers.• No problems were reported with opt-out consent, but most projects/programmes testing opt-out processes were government-run, with high EPI involvement. Additional procedures may be necessary in private schools or where parents expect more information and autonomy over their child’s health.
6.2.6 RecommendationsIn relation to social mobilisation, acceptability and consent, we recommend: 
• A communication plan should be developed 
during	preparation,	to	include	specific	strategies to ensure messages are delivered to out-of-school and hard-to-reach girls and their parents and communities.
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• Teachers, health-workers, and community leaders should be trained to mobilise girls. Social mobilisation training should occur well before vaccination. 
• Face-to-face mobilisation meetings should be prioritised where possible. 
• Social mobilisation in communities should begin at least one month before vaccination, earlier if possible, especially for new projects/programmes. Time required (e.g. funds disbursement, printing) should not be underestimated. 
• Specific	strategies	to	prevent	and	manage	rumours should be outlined in the communication plan. 
• High-level	officials	from	MOH	and	MOE	should address rumours as quickly as possible.
• Schools, health-workers, community groups and media should be engaged with in the early stages of planning, as knowledge about HPV and vaccination may be low. If feasible, press kits and media sessions can be useful to engage the media. 
• Additional formative research may not be needed to identify key messages due to the consistency in the use of messages across projects/programmes that attained high coverage.
• Message development should focus on: cervical cancer prevention; safety and 
efficacy,	including	lack	of	fertility	impact	or long-term adverse effects, government endorsement, delivery timing and venues and the need to return for a second dose. 
• Consent should be opt-out where feasible, ensuring consistency with existing EPI consent policy. If opt-in consent is chosen for HPV vaccination, processes should be streamlined and reasons clearly explained to parents and communities. An example of a streamlined process might be to implement a school health programme consent form at enrolment for all interventions delivered in schools.
• Countries may want to consider whether the use of different consent processes in public and private schools may cause confusion and potential future concerns in the community around equity of information and choice.
• Intensity of social mobilisation should be 
assessed	after	the	first	year	and	potentially	reduced, if high acceptance has been achieved in targeted communities.
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7. Delivery
7.1 Delivery experiences
7.1.1 Country experience of HPV 
vaccine deliveryThe 46 countries implementing HPV vaccination between 2007 and May 2016 accumulated 120 years of implementation experience. As of May 2016, 39% of the countries (N=18) had 2-3 years of experience while 35% (N=16) had one year of experience (Table 17). Twelve countries had four or more years of experience. Experience with two-dose schedules is increasing, with 19 countries completing at least one year of this by May 2016 (21 2-dose delivery experiences). Accurate detail on which delivery strategy was used was available for 89 of the 92 delivery experiences known to have completed at least 6 months of implementation by May 2016. School-based delivery and a combination of school and health facility delivery with or without outreach were the most common strategies (78/89=87.6%; Table 17). In almost all of these experiences, the predominant delivery sites were reportedly schools and vaccine supply in health facilities and/or during community outreach was designed to increase vaccination coverage of school absentees or out-of-school girls. Eleven experiences were reportedly health facility-only strategies or health facility based strategies with some routine outreach to community (and sometimes school) sites. At the national level it was unclear whether the relative mix of outreach and health facility delivery was truly known. In some cases the national team simply set the coverage targets and left the districts to decide feasible strategies.  Six countries (3 national programmes in countries 1, 4, 33) and three demonstration projects (countries 22, 31, H)) stated that their delivery strategy included a mixture of school, facility and outreach sites; however, the choice of strategy and planning was decentralised to the district, municipality or facility level. Facilities chose the strategy most feasible in their locality but the central team did not specify, or necessarily know, whether this was predominantly school or facility based delivery. None of these experiences had evaluated the mix of delivery strategies used and the differences in cost, time, or coverage achieved. One country representative explicitly stated 
they avoided specifying school delivery to avoid requests for extra per diems (Country 33). One demonstration project stated this allowed teams in districts with greater vaccine hesitancy to conduct more outreach compared 
to	fixed	delivery	sites	(Country	22).	Another	country, which had well-established health infrastructure and human resources, stated simply that facilities knew the most effective strategy and the decentralised approach achieved good coverage: “[The choice of delivery strategy] was left to the municipalities to organise… The Ministry of Health was supportive but not directive in terms of making the vaccine available in schools, which should only occur provided adequate emergency measures are in place at these schools [to deal with adverse events]” 
KI Country 4.
7.1.2 Target populationAmong the 75 delivery experiences with information on their school-based component, 52% (39/75) of experiences vaccinated a 
specific	age	group	of	girls	and	31%	(23/75)	selected a school grade(s). A further 17% (13/75) selected a school grade but only vaccinated girls of a certain age within that grade (Table 17). In out-of-school delivery, the eligibility criterion was always age. Determining girls’ age was a problem in many countries where birth records had not been routinely available or kept by the parent (almost all countries in sub-Saharan Africa), or where school registers were inaccurate (Countries 8, 31). In one country registers were inaccurate due to a government incentive to report that all girls in the primary school were below 13 years of age. Parent/ guardian interviews with the 
use	of	peer	group	comparisons	and	significant	historical events were reportedly used in 7 countries to estimate year of birth (Countries C, E, F, H, 29, 31, 33). 
Only	one	country	stated	specifically	targeting	HIV positive girls and women aged 9-45 years 
old	in	their	national	programme	and	specifically	delivering 3 doses to this group (Country 4).  Targeting different populations in school and out of school e.g. a grade in school and an age cohort out of school, although potentially logistically quicker during delivery, created substantial problems in target population 
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enumeration and coverage calculations in almost all countries that did it. For example, one national programme estimated the target population of 10 year olds using census data; for ease of delivery the vaccination teams then vaccinated all of grade 4 in school (of which an estimated 90% are 10 years old) and targeted age 10 out of school. Administrative coverage estimates of doses delivered divided by the estimated target population were therefore overestimates of the coverage within 10 year old girls; and given the reports that girls who were in other grades who wanted the vaccine went to out of school vaccination sites with no validation of age, the age range that was vaccinated in reality is unclear. The coverage and the equity of delivery is also uncertain (Country 33). This is reiterated in Section 8: Achievements.“Girls in other grades could decide to present at community outreach sites or the health facility to get their vaccine” 
KI Country 33. 
7.1.3 Strategies to access out-of-school 
girls Among the 89 experiences with data, 24 (27%) did not have a strategy in place to reach out-of-school girls (Table 17). Strategies to reach out-of-school girls most commonly relied on girls attending health facilities for vaccination (35%), with varying intensities of activities to mobilise out-of-school girls. Three countries reported low uptake of vaccine at the health facility. 
Outreach	is	defined	by	WHO	as	any	type	of	health service that mobilizes health workers to provide services to the population or to other health workers, away from the location where they usually work and live [49]. Some vaccination during outreach into the community was included in 34/89 experiences (38%) in 28 countries (Box 2: Examples of outreach). Thirteen projects/programmes reported the use of community leaders and community health workers to identify, mobilise and trace out-of-school girls and bring or direct 
them	to	the	health	facility	or	fixed	outreach	sites, or to aid door-to-door vaccination activities. Community health volunteers and community leaders were reported to be 
incredibly	important	in	identification	of	out	of school girls and to increase coverage in this group. However, active tracing and outreach are resource-intensive strategies.
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Table 17. HPV vaccination delivery strategy experiences
Country experience Description Number of countries (N=46) % 
Total number of years of experience as 
of May 2016
1 year 16 38%
2 - 3 years 18 41%
4 or more years 12 22%
Delivery strategy1  Number of experiences 
examined2 (N=89)
Delivery strategy combining strategy 
for in-school and out-of-school girls
(Total 72 experiences; 5 missing data)
School only 24 33%
School + health facility 21 30%
School + health facility  
+ outreach
25 16%
School + outreach 8 7%
Health facility only 6 8%
Health facility + outreach 5 4%
Strategies for in-school girls N=75
Target population in school (if schools 
were included in the delivery strategy)
Age 39 47%
Grade 23 35%
Age within a school grade(s) 13 18%
Strategies to access out-of-school girls N=89
Delivery strategy for out-of-school girls None 24 33%
Vaccine supplied at local health 
facility (with active tracing 
of girls and bringing them to 
health facility (n=5))
31 37%
Health facility + outreach 26 13%
Outreach only 4 10%
Vaccine available at school, 
health facility + outreach 
4 6%
Changes in delivery experience N=46
Countries in which the national (MOH) 
implementer changed or tested >1 
delivery venue or target population3 
(N=37)
Change in delivery venue 11 22%
Test of >1 delivery venue 2 5%
Change in target population 12 22%
Test of >1 target population 2 5%
1 Distinct delivery experiences were defined by target population or delivery venue or both within a particular implementer/funder demonstration project or programme
2 92 delivery experiences had sompleted 6 months of implementation by May 2016; 89 had accurate and complete data on delivery strategy, 3 were missing data. 
3 Countries where the MOH was involved in the project/programme, which tested >1 delivery venue or target group (either simultaneously or sequentially). Two countries both 
changed target population and tested different target populations so appear in both categories.   
Box 2: Examples of outreach during HPV vaccine delivery
• Active search for eligible girls using community  health workers (CAWs). CHWs then brought girls to the health facility (5 countries: Country 1, 17, 22, 26, 28).
• Mobile	Clinics,	churches,	fixed	community	sites	and	gathering	points,	especially	in	areas	without health facilities or schools, to access eligible girls who used mobile vaccine sites (Countries 2, 7); eight used permanent vaccination sites in the community in addition to mobile clinics (Country 4, 6, 9, 11, 29, 31, 33, 35).  
• Health	workers	conducted	door-to-door	home	visits	in	previously	identified	communities	
known	to	have	out-of-school	girls.	Girls	were	vaccinated	at	the	house	or	sent	to	fixed	vaccination sites in the community that were open during school vaccination times (Country 21, 24, D, E).
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Table 18. Changes in vaccination venues with reported reasons
Original strategy Change in strategy Countries Reasons for changes
School Health facility Country 1 High level of resources required for 
outreach visits to schools.
Health facility School Country 1 HPV coverage was low in health 
facility delivery.
School + health facility + 
outreach
School + health facility Country 28 Outreach had proven resource 
intensive, with logistical difficulties 
and only incremental gains in 
coverage.
School School + health facility +/- 
outreach
Countries 3, 23, 
8, 35
To increase equity of HPV vaccination 
by including out-of-school girls.
Health facility Health facility + outreach Country 7 To increase HPV vaccination coverage.
School + health facility Health facilities and 
integrated into routine 
outreach
Countries 13, 
31, 33 
High level of resources required for 
school-based strategy & concern over 
sustainability.
School + health facility + 
outreach
School Country 26 Difficult and costly to identify out 
of school girls and calculate the 
denominator, simpler to vaccinate 
grades at school as most girls in 
school
7.1.4 Changing delivery strategy - 
vaccination venues  MOH representatives in eleven countries were involved in decisions to change strategies based on evaluation reports. This did not include countries with distinct pilots implemented by different groups (Table 18). MOH representatives in two countries tested different delivery strategies simultaneously (Uganda and Vietnam [50]).There are a number of reasons why countries changed vaccination venues within their delivery strategies (Table 18). Four countries changed from school-based delivery to integration of HPV vaccine into the routine immunisation schedule at health facilities, due to the high level of resources required for outreach visits to schools. In one of these countries, the health facility strategy was tested for three years. When it became apparent that coverage had decreased from >90% to 60-70%, school delivery was re-instated and coverage increased (Country 1). The strategy is pending evaluation in the other three countries (Countries 13, 31, 33). Plans stipulated that if coverage is low at the health facility, visits to schools would be integrated with routine monthly outreach activities, and supervised during quarterly visits from district supervisors.After initially only utilising a school-based strategy, four countries added a strategy to reach out-of-school girls. This was done by offering vaccinations at health facilities (Countries 3, 23), outreach sessions (Country 35), or both (Country 8). An outreach strategy was also added to a routine health facility-based delivery model. The rationale for this 
is not known, but may be due to the low 
coverage	achieved	in	the	first	year	(Country	7). The relative success of these strategies is 
difficult	to	evaluate	as	coverage	was	either	maintained at >90% (Country 23, 28) or data are not yet available after the strategy change was implemented (Countries 8, 26, 35, 7). One country reported increased coverage after adding a strategy for vaccinating out-of-school girls at the health facility (Country 3). In Vietnam, where school enrolment and healthcare utilisation is high, a school-based strategy and a health facility-based strategy tested simultaneously in different geographical areas both attained >90% coverage with no apparent difference [50].Four countries stated that they planned to change from a school-based strategy to a health facility based strategy in the future, due to:
• The high level of resources required for 
school	visits,	specifically	the	transport	and	staff per diem costs. HPV vaccine will be integrated into the routine immunisation schedule and delivered at health facilities and routine community outreach visits (Countries 8, 33, 31). 
• The low acceptability of the school-based strategy; health workers and the community did not accept schools as a vaccination venue (Country 20). One country stated that, in the future, they would try to ‘normalize’ HPV vaccine outreach activities to be part of health workers’ routine outreach activities in order to reduce the cost of per diems (Country 18)(Section 7.5: Staff remuneration).
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Table 19. Changes in target populations and reported reasons (12 countries)
Original target population Change to target 
population 
Countries Reasons for changes
Age Grade Countries 1, 2, 
24, 31, 33
Identifying eligible girls by age was 
difficult if exact birth date/year was 
not known or documented. 
Grade Age Country 31, 33 It was thought to be unacceptable to 
separate some girls from their class-
mates and select them to receive the 
vaccine while other class members 
were not vaccinated (Country 24).  
Grade Age Country 8 It is easier to explain to the 
community and aligns with routine 
EPI, which used age cohorts
Grade More appropriate grade Countries 8, 3, 
33, 31 
To purposely assess a different 
strategy in the second year of the 
project.
Age 10 out-of-school Age 9-13 out-of-school Country 18 A higher concentration of eligible girls 
were in a higher/lower grade
Wide age range Narrowed age range Countries, 4, 
16, B
As part of the national programme a 
wide age range was eligible at first, 
like a catch up campaign up to 13 and 
this was then reduced to a single age 
cohort
Age within a grade Age Country 26 Easier to estimate the denominator/ 
target population even if girls are 
spread in different grades
7.1.5 Changing delivery strategy - 
target populationEight countries changed target population (vaccine eligibility criteria) (Table 19). In addition, two countries simultaneously tested age and grade eligibility criteria (Tanzania [51], Uganda [50]); one other country changed eligibility criteria after one year in order to purposefully test a different approach (Country 8). Changes in eligibility criteria were not necessarily a result of a change in the vaccination venue. An age-based criterion for the target population for vaccination was changed to grade-based in two countries, and a further two countries which tested both approaches subsequently adopted a grade-based approach. Grade-based 
identification	was	preferred	because	identifying	
eligible	girls	by	age	was	difficult	and	time	consuming when the exact birth date/year was not known or documented and/or school enrolment meant that one age group stretched across multiple school grades (Countries 1, 2, 31, 33). “Age-based delivery was messy; we switched to just vaccinating one grade  as it is easier and quicker” 
KI Country 1. “Grade-based vaccination was more practical”  
KI Country 33.
Although grade-based delivery was tested and found to be logistically simpler and quicker to implement by some countries, a subsequent demonstration project used the grade criterion for just one year (Country 31). Country representatives stated that the project was planning to change to an age-based strategy in year 2 because it was easier to explain and more acceptable to the community. In areas where the range of ages within each grade was high, they reported that communities did not agree with one grade receiving vaccination if girls 
were	≥9	years	old	in	that	grade,	with	≥9	year	olds in other grades having no opportunity to get vaccinated.In contrast, one country that initially planned to use an age-based approach, both in school and out-of-school, found that in the initial phases of the demonstration project it was unacceptable 
and	difficult	to	explain	to	teachers	and	parents	that some girls in a class would be selected for vaccination and others in the same class would not be vaccinated. The eligibility criterion was therefore changed to the school grade that had the majority of 11 year old girls. A different grade was selected for urban and rural areas because girls in rural areas generally enrolled in school later (Country 24). Three countries conducting national programmes opted to start with an age range of 
9-13	years	in	the	first	year	and	systematically	reduce it year on year afterwards to age 9 only. This provided an effective small catch-up campaign up to age 13 (Countries 4, 16, B).
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7.1.6 Duration of activity to deliver 
each doseHPV vaccine was delivered in a ‘campaign style’ in almost all projects/programmes included in 
this	review,	i.e.	there	were	specific	days	of	HPV	vaccine activity which were simultaneously timed across all the involved geographical areas, rather than the vaccine being incorporated into routine services and being always available. Only 31 out of 92 delivery experiences had data on the duration of delivery for each dose; this ranged from 2-3 days to 1 month for campaign style delivery. The majority of experiences delivered each dose over the course of one week (Table 20) and activity was synchronized/carried out in the same calendar week across the area/district/country.  Two delivery experiences allowed health workers a window of a month in order to deliver each dose, vaccine delivery essentially remained 
a	campaign	but	the	specific	campaign	days	for visiting schools were spread over a longer time period than 1 week (Countries 11, 30). Two other delivery experiences allowed health workers 6 months to deliver each vaccine dose at health facilities, not in a campaign, through ‘routine delivery’ i.e. vaccine was technically available every day at the health facility (Countries 31, 33).
Among school-based delivery strategies, the time allowed for delivery of each dose ranged from 2-3 days to 1 month (Table 20). The duration of activity for each dose was stated to vary and depended on the distance to the 
schools, the size of the schools and the number of schools allocated to each vaccination team. The average number of schools reached per vaccination team was only reported by 4 projects/programmes and ranged between 2 and 10 (Countries 3, 13, and 31[48]); most projects/programmes simply stated that the number of schools per vaccination team varied. The number of eligible girls within each school was also highly variable and reported by 2 countries as anything between 2 and >100 (Countries 1, 31). One national programme noted that the time required to deliver vaccine in a school varied from a few hours per school to 2-3 days per school, but on average each dose was delivered by each vaccination team to all the schools allocated to them over 2-3 days (Country 1). A further 2 demonstration projects allowed one full working week for each vaccination team to deliver each dose to all of the sites in their catchment area, including mop-up activities (Countries 8, 14). Two national programmes conducted a school-based campaign over 20 days for each dose. 
This	allowed	health	workers	to	fit	vaccination	activities around their routine activities and aimed to minimise the impact on other routine services (Countries 11, 30). Among delivery strategies which utilised both school and health facilities with/without 
outreach,	in	five	delivery	activities	for	each	dose took one week including mop-up (Country 3, 17, 28, 31) and took 1-2 weeks for six other projects/programmes (Countries 3, 6, 19, 37, 89, 90). Generally school delivery was completed in 
the	first	week	and	part	or	all	of	the	second	week	was used for mop-up doses. Only one health facility delivery strategy, a small project with little EPI involvement, had data on time allocated to deliver each dose and administered each dose for a period of a week at the health facility (Country 5). Two further projects delivered each dose integrated into ‘routine’ delivery of other EPI vaccines at the health facility and during routine outreach services over 6 months for each dose  (Countries 31, 33). 
HPV vaccine delivery to primary schoolgirls, Tanzania (photo courtesy of Deborah 
Watson-Jones)
Table 20. Time allocated to deliver each dose
Time per dose Number of delivery experiences with data  
(final dose coverage estimate for each delivery strategy)
Total
School only +/- outreach School + Health facility 
+/- outreach
Health facility only 
2-3 days 1 (>90%)  1
4 days – 1 week  6 (52%, 81%, 82%; NA) 5  (69%, 80%, 93%, 94%, 
96%, 99%; NA)
1 (NA) 12
1-2 weeks 3 (84%, 93%; NA) 6 (59%, 65%, 79%, 79%, 
97%, NA)
9
20 days - 1 month 2 (91%, 99%) 2
6 months - routine 
delivery
2 (NA) 2
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Coverage data were available for some projects/programmes that provided information on the time allocated to deliver each dose. There was no obvious relationship between delivery strategy, duration of vaccine delivery activities per dose and HPV coverage.Three projects offered doses at more than one distinct time point in ‘staged delivery’ (Countries 31, 12, 30) (detailed in Section: 7.1.6: Mop-up). For details on the effect of introducing HPV vaccination on the staff workload and routine services see Section 7.3.3: Staff workload.The delivery of two doses rather than three doses was reported as logistically easier to 
fit	in	to	the	school	year	and	cheaper	by	all	countries that had changed vaccine schedule (10  countries had some experience of both two- and three-dose schedules by May 2016 out of 19 countries with 2-dose delivery experience). One country used an extended interval of 12 months between doses and reported this made enumeration and delivery in a single campaign each year easier:“It is much easier to go to one grade one year and the following one the next year”
KI Country B. Concern was raised in one country by health workers who had delivered three doses in a previous demonstration project and were now asked to deliver only two doses to girls. Vaccination stopped whilst health worker concerns that girls would not be protected were 
addressed.	Official	letters	of	communication	
from	the	MOH	rectified	the	issue	(Country	33).	One country explicitly stated that two doses were more acceptable than three (Country 18). Only one of the 19 countries that had 
implemented	two	dose	schedules	had	a	specific	strategy for HIV positive girls (Country 4), who are currently recommended to remain with the three-dose schedule[42]. Other key informants either did not realise or had forgotten that HIV positive girls needed 3 doses or simply did not see how they could practically implement the different schedules. There was concern 
identification	of	HIV	positive	girls	during	vaccination would stigmatise them or induce rumours around the vaccine being linked to HIV: “HIV positives are vaccinated with 2 doses alongside all other girls – we can’t separate them”
KI Country 16.
7.1.7 Mop-up strategies Strategies to follow up girls who were absent on vaccination day were described for 37 countries (44 delivery experiences). ‘Mop-up’ doses were delivered in a number of ways (Table 21): 
• Vaccine was provided at return visits to the schools and/or other vaccination sites 1-2 
days	after	the	first	vaccination	day.	In	some	countries the vaccine was also available at the health facility (Countries 3, 18, 23, 26, 31, 37, A, E, G, H); however, this was not always the case e.g. Country 29 vaccine was stored at the district due to health facility space constraints, other countries only operated school-based campaigns (Countries 8, 13, 14, 25, 30).
• Vaccine was made available at the local health facility only with no reminders, outreach, or active search (Countries 5, 6, 33, 34, B).
• Active	search’	by	CHWs	identified	girls	who	had missed doses and girls were either given reminders to go to the health facility for their dose, or they were taken to the local health facility for vaccination by the CHWs (6 countries: 3, 5, 17, 19, 26, 35) or girls were vaccinated on home visits (4 countries: Country 21, 22, D, F).  
• Three countries explicitly stated they did not perform mop-up vaccination activities in order to save funds; all 3 of these countries performed outreach activities in the community during the initial vaccination days (Countries 24, C, I).In addition, some countries gave opportunities to receive the vaccine to girls who had missed 
the	first	or	second	dose	in	a	staged	delivery	where vaccinators returned to schools 1 month 
or	more	after	the	first	vaccination	day:	
• Vaccine was provided at a second visit to the 
schools	the	following	month	after	the	first	visit, in a 2-stage planned delivery of either 
just	the	first	dose	or	every	dose	of	a	3	dose	series) (Tanzania[48], Countries 12, 30)
• Dose 1 was provided during dose 2 delivery at schools for those girls who had missed the 
first	dose	(Countries	18,	22,	31,	21).	
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Table 21: Mop-up strategies and the coverage and completion rates achieved
Mop up Strategies Number of 
experiences
Coverage (%) Completion (%)
Return visits to schools only 6  81, 82, NA, NA, 85, 91  94, NA, NA, NA, 100, 
100
Return visits to schools +/- vaccine 
was available at health facility 
14 72, 90, 105, 94, 99, 72, 
79, 59, 80 NA, 79, NA, 
NA, NA
83, 90, 100, 99, 97, NA, 
88, 91, 70, 87, NA, NA, 
NA, NA
Available at health facility only (no 
reminders or outreach)
7 65, 88, 61, 90, 100, 83, 
NA
88, 100, 94, 87, 88, NA, 
NA
Available at health facility and some 
outreach activities
3 66, 94, 100 73, 96, 100
Active search and reminders to go to 
health facility
3 98, NA, NA 97, NA, NA
Active search by CHWs who brought 
girls to health facility
4 69, NA, 87, 85 85, NA, 90, 93
Active search + door-door 
vaccination 
4 65, NA, NA, 79 84, NA, NA, NA
None 3 52, NA, NA 71, NA, NA
NA indicates coverage or completion data was not available for the project/programme. Completion is the proportion of girls who received the final dose, having initiated 
vaccination and received dose 1.The duration of time allowed for return visits for mop-up activities was reported by just 4 projects, all reported return visits were conducted over 1-2 days after the main vaccination activities were concluded (Countries 8, 14, 28, 31). The number of return visits to any particular school was reported by 3 projects and varied from a policy limiting activity to just one return visit (Country 30), returning 2-3 times if schools were easily accessible or urban (Country 25), to health workers returning up to 4 times if necessary (Country 26). The number of return visits depended on the need (e.g. school absenteeism 
rates)	and	resources	to	finance	the	transport	and staff costs. Only one project in Tanzania mentioned the duration of time that the vaccine was available at the health facility for mop-up doses. In this case, vaccine supply was available for 2-4 weeks after the dose was delivered in school due to constraints with the cold chain capacity [51]. One country reported that provision of vaccine 
doses	at	the	health	facility	was	more	efficient	than return visits to schools, and that active tracing of defaulters was resource intensive and unsustainable for the incremental gains in coverage (Country 26). However, 4 countries reported that uptake of mop-up doses at health facilities was low (Tanzania [51], Countries 15, 33, 21). Six projects/programmes reported a two-stage delivery of doses (purposefully returning to schools a month or more later), or delivery of dose 1 to girls who missed it during dose 2 delivery, allowed girls and parents to change their mind(s) and accept vaccination after witnessing no major adverse events in girls’ peers. This was particularly important in 
the	first	year	of	project/programme	(evidence	
from 6 projects/programmes: Countries 18, 22, 31, 30, 21). In Tanzania, offering each dose on 2 occasions at schools achieved higher gains in coverage than making the vaccine available at the health facility [51]. Two countries recommended that return visits to schools should only be completed if coverage was low (e.g <80% at that school) (Countries 30, 18).In some countries, dose 1 was supplied during the delivery of dose 2, not only to girls who had been missing during dose 1 but also to girls who had become eligible in the intervening period of time, e.g. had turned 9 years old. This created some issues in calculating yearly coverage and in coordinating supply of vaccine the following year to a target population which then bridged multiple year groups or grades (e.g. Country 31). In one country, offering a second cohort vaccine in the same year may have altered 
the	denominator	and	artificially	lowered	that	year’s coverage rates by not accounting for the fact that some girls would only complete their schedule the following year (Country 1). One programme sent SMS reminders to girls if they had missed doses or were due doses at the nearest health facilities; no formal evaluation data were available (Country 35). Another two projects commented that girls who were vaccinated could be instrumental in tracing their absent peers (Countries 6, E).There was no correlation between mop-up strategies and reported coverage or completion (Table 21).
7.1.8 Catch-up campaigns Three national programmes conducted catch-up vaccination in older age groups (Bhutan, 
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Table 22: Reported lessons on vaccine delivery
Reported Lessons Denominator (N) Delivery 
experiences  
reporting the 
lesson 
%
Delivery strategy – vaccination venue 
School-based delivery can take advantage of high school 
attendance and good coordination with teachers which can 
lead to help in mobilisation and registration, preparation 
of vaccination areas, crowd control, assistance with paper 
work, monitoring adverse events and following up absent 
girls. 
Experiences with any 
school component (75)
20 27%
Vaccination campaigns through schools require extensive 
resources, especially in rural areas.
Experiences with any 
school-based approach 
(75)
14 19%
There are some advantages of using a health facility delivery 
strategy e.g. availability of cold chain, EPI and other staff, 
and ability to respond to AE if they occur.
Experiences with any HF 
component (57)
2 4%
Accessing out-of-school girls
Vaccine delivery through outreach (alongside community 
sensitization) could increase HPV vaccination coverage  in 
areas of poor school enrolment 
All that did outreach 
(38)
11 29%
Accessing hard-to-reach areas, and tracing of out-of-school 
girls or defaulters, required more intensive planning and 
increased budget per girl compared to that for in-school 
girls.
All that did outreach 
(38)
13 34%
Eligibility criteria/ target population
Among projects/programmes which used age as an eligibility 
criterion, it was difficult to determine girls’ age, especially 
in communities where age was not routinely documented 
or where age was not accurately documented on school 
registers.   
Age and age in grade 
criteria (52)
17 33%
Grade based criteria were simpler to implement than age 
criteria.
Grade criteria (23) 3 13%
Planning and timing 
To achieve good vaccine completion rates, projects/
programmes should aim to deliver all doses in one school 
year. This often depends on timely availability of vaccine and 
funding for mobilisation activities.
Experiences with any 
school-based approach 
(75)
17 24%
Rwanda, Vanuatu); details were not well reported. One country delivered vaccine to girls up to the age of 15, another country up to the age of 18. The third country vaccinated the second and third grades of secondary school in addition to the delivery to 9-13 year olds in primary schools. All catch up strategies lasted 
for	just	the	first	1-2	years.	No	evaluation	results	were available. As detailed previously in section 7.1.5, a number of countries chose to start national programmes with a wide age range of eligibility (e.g. 9-13 year old girls) and then narrow vaccine delivery down to target a single age cohort. This was reportedly logistically easier in situations where some girls did not know their exact age, but also acted as a small catch up campaign in these countries e.g. Countries 3, 4.  
7.1.9 Reported lessons learnt  Lessons that were documented by projects/programmes are summarised in Table 22.School-based delivery was reported as simpler to implement than any other delivery; a large numbers of girls in the eligible target group could be accessed and coordination with teachers was helpful (evidence from 13 projects/programmes, 13 countries). Schools 
that	have	not	yet	been	officially	registered	and new schools should be included in micro planning as well as registered schools.  All ten of the nineteen countries that had experience delivering both 3-dose and 2-dose schedules reported that the two-dose schedule was easier and cheaper to implement than the three-dose schedule. Almost all countries implementing a 2-dose schedule reported some confusion over how to vaccinate HIV+ girls (18/19 countries).
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7.1.10 Key lessons learnt and 
conclusionsIn relation to delivery strategy, key lessons included: 
• HPV vaccine delivery strategies including a school-based component were most common 
and	were	reported	as	being	an	efficient	way	to capture most 9-13 year old girls. However, many countries found the costs associated with repeat visits to schools prohibitive and potentially unsustainable.
• The selection of delivery strategy often had to balance the feasibility of high coverage 
with	country	specific	operational	challenges:	the human resources and vaccine transport available, accessibility of vaccination sites, school enrolment and attendance rates, project/programme cost and sustainability. 
• There is limited data on health facility only delivery strategies and no coverage data from ‘routine delivery’ strategies where responsibility for the vaccine delivery is decentralised to health centres to deliver in situ or during routine outreach.  
• Strategies to reach out-of-school girls 
are	difficult	to	evaluate	without	specific	
coverage	data	for	this	sub-group.	A	specific	mobilisation strategy for out-of-school girls to encourage them to attend vaccination days or the nearest health centre was generally important. It cannot be assumed that out-of-school girls will attend health 
centres	without	targeting	them	with	specific	information on the importance of HPV vaccine beforehand. However, if being ‘out-of-school’ is illegal, strategies to identify girls must avoid stigmatisation, house-to-house visits are expensive unless volunteers can conduct them.  
• Although different mop-up strategies 
were	conducted,	there	is	not	sufficient	information/evidence to ascertain particular best practices. The scope of activities is 
generally	governed	by	country-specific	factors, e.g. school absenteeism, perceived ‘adequate’ coverage, and the resources available. A two-stage delivery of each dose can be successful in reaching those girls who initially refused vaccination, especially when implementation of HPV vaccination is 
in	its	first	year.	Countries	with	low	school	enrolment could choose to not conduct mop-up activities in order to focus resources on extensive outreach during the initial vaccination dates. 
• Providing	the	first	dose	to	unvaccinated	girls at the time of the second dose delivery, and establishing a ‘rolling eligibility criteria’ where girls can become eligible for the 
vaccine as soon as they turn 9 years of age can create challenges in yearly reporting if this has not been planned. Delivery the subsequent year when a greater number of vaccine doses are needed and vaccination has to stretch over two age groups or grades can be challenging if strategies are not clear before the project/programme starts. 
• Drop out between doses can be minimised if all doses are completed within one school year. 
• Given the workload and funding required for HPV vaccination programmes and the limited nature of existing services for this age group, multiple countries questioned the feasibility of adding another new intervention to deliver alongside HPV vaccine.
• Countries need to be aware that although the recommendations for most girls now state that 2 doses are enough for protection against HPV, HIV infected girls require 3 
doses.	Country	representatives	find	this	impractical and vaccinators often do not know a girl’s HIV status. Health workers are generally providing 2 doses for this reason or to avoid stigmatisation of HIV positive girls. 
7.1.11 Key recommendations In relation to delivery strategies, we recommend: 
• Countries should select a delivery strategy 
based	on	a	combination	of	country	specific	factors:  the proportion of the target group enrolled in school, absenteeism, operational costs, desired/adequate coverage, and sustainability. 
• Including a component of school-based delivery can yield high coverage. 
• Projects/programmes should be evaluated periodically in order to monitor the performance of the chosen delivery strategy and test different approaches in terms of coverage and cost.
• A combination of delivery strategies rather than a single strategy alone is essential to achieve high coverage if school enrolment is low. Conversely, countries with high school enrolment and limited resources may decide to minimise outreach if it does not give 
significant	additional	impact.
• If school-based delivery is planned, microplanning should include an exercise to enumerate all schools including non-registered schools. Vaccination should be planned to coincide with school calendars and harvest times.
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• A	specific	mobilisation	strategy	for	out-of-school girls to encourage them to attend vaccination days at schools, outreach sites or the nearest health centre should be implemented. 
• If resources allow, active follow up of girls who missed doses can yield high coverage and successfully use mobile phones or utilise teachers and CHWs. However, during planning, the expense and time required must be realised. 
• Poorly executed mop-up activities can cost 
more	than	their	incremental	benefit	justifies.	When planning with limited resources, the cost-effectiveness of mop-up activities should be assessed; a threshold of coverage is a transparent strategy in which to limit mop-up activities to those areas where they 
will	be	the	most	efficient	e.g.	only	conducting	a return visit to a school if <80% of girls 
received	the	dose	on	the	first	day.	However,	an opportunity for all girls who have missed doses to obtain vaccine should be provided – social mobilisation should include messages on the nearest health centre where the vaccine can be accessed.
• Staff should be trained on how to deal with the presentation of newly eligible girls at the vaccination site when returning to deliver the second/ third dose. 
• If resources allow, planning a two-stage delivery of each dose can be successful in reaching those girls who initially refused vaccination, especially if implementation of 
HPV	vaccination	is	in	its	first	year.
• Countries need to be aware that HIV infected girls require 3 doses and should develop 
specific	strategies	to	offer	them	the	3-dose	regimen. 
• Whilst funding from international partners is available it may be worthwhile to maintain a wide age range of eligibility criteria for 
the	first	few	years	of	national	programmes	
e.g.	9-13	year	old	girls.	The	first	few	years	of implementation can act as a small catch up campaign; subsequent years would then reduce to a single age cohort of 9 year olds. 
7.2 Enumerating target 
populations and vaccine 
needsInformation on enumeration methods used and challenges encountered was available from 43 demonstration projects and ten national programmes in 45 countries. 
7.2.1 Country evidence - Demonstration 
projectsFor the large majority of demonstration projects, the estimation of the target population (number of girls targeted to receive the vaccine) to produce a denominator for vaccine provision and coverage, was a major challenge. This was the case for all delivery strategies; school-based, health facility-based and outreach. In some of the early GAP projects, no attempts were made to determine the size of the target group. Instead, a certain number of vaccines were procured and these were delivered until the stock was used up. For some of the projects, a census was undertaken in advance to determine the number of girls to be targeted. However, it was reported that these censuses demanded considerable time and resources, which might have been better spend on implementing the demonstration project. Three different methods were most commonly used to determine the number of girls targeted 
in schools:1. School registers2. Data from the MOE on children enrolled in different schools 3. Combining data from the most recent population census with data on school enrolment rates
A	few	projects	undertook	a	specific	census	in advance of vaccination to determine the number of girls to be targeted. However, it was reported that these censuses demanded considerable time and resources, which might have been better spend on implementing the demonstration project (Country 22). Estimates of the population of out-of-school girls were most commonly estimated from the most recent census, combined with estimated school attendance rates. In these cases the census and enrolment data were not disaggregated by district but national averages were used which could not be validated. Four countries reported using local NGOs or literate community leaders or social workers to advise on where out-of-school girls reside (Countries 3, 6, E, F). Eleven demonstration projects reported using community volunteers (Countries A, D, F), community health workers (Countries 17, 18, H) or other agents including health workers themselves (Countries C, E, I, 19, 29) to conduct house-to-house visits to enumerate out-of-school girls. This strategy proved expensive, formed a large proportion of delivery costs and had often not been budgeted. See section 9.1 for 
further	details	on	financing.		
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In almost all settings, none of these sources for in-school or out-of-school girls gave accurate estimates or ineligible groups were vaccinated leading vaccination teams uncertain as to whether the target group was larger than estimated (despite a house to house census in one country, Country C) or eligibility criteria were just not systematically implemented. 
Eligibility	criteria	were	often	difficult	to	assess	
given	the	lack	of	birth	certificates,	or	they	were	not understood, or implementation was variable and not supervised leading to vaccination of ineligible populations: There was no way of verifying age so many more could present on vaccination day and were vaccinated than were actually eligible” 
KI Country H. The example summarised in Box 3 shows the 
difficulties	encountered	in	one	of	the	projects.Thirteen demonstration projects reported 
significant	shortages	of	vaccine;	examples	included: 
• The discovery of unregistered schools, many of them private schools, led to the addition of schools to the vaccine delivery schedule 
during	the	first	dose	delivery	(Countries	29,	37). In addition, the extent of urbanisation of the population since the last census was underestimated and due to a decline in amenities such as electricity supply in the rural areas the population of the district capital was almost double that estimated (Country 29). The subsequent headcount of the population proved to be just within the buffer stock ordered. 
• WHO/UNESCO, Education Management System, and census estimates proved to underestimate the target population by almost half in 3 countries. Stock-outs were only avoided due to the fact that vaccine orders were based on a 3-dose schedule and recommendation changes allowed a 2-dose schedule by the time of delivery (Countries 6, 13, E). One government had to procure extra vaccine doses (Country 13). Target populations proved to be 141-157% of that initially estimated. Two projects reported excess vaccine e.g. 
Country	D	which	identified	and	vaccinated	92% of their estimated target population but 
were	unable	to	find	out-of-school	girls	despite	a	house-to-house census. In almost all settings during implementation of 
the	first	dose,	girls	in	targeted	schools	and	those	
identified	to	be	out-of-school	were	counted	and numbers were adjusted in preparation for delivery of the second and/or third dose. 
In most countries, this count was done a few weeks before vaccine delivery was scheduled and again during the delivery. In one country where the Gavi demonstration project was led by the reproductive health (RH) department, the EPI teams could not get the estimates of school target populations in advance of vaccination day. The inexperience of coordination between the MOE and RH 
at	national	level	significantly	impacted	the	distribution of correct numbers of vaccine doses at district level (Country 6). Three demonstration projects reported 
enumerating	urban	areas	was	more	difficult	than rural areas as children could live in a different district to that which they attended school (Countries A, 26, 37). This was a particular problem for demonstration projects where district boundaries were not distinct.  Additionally one project mentioned street children could not be enumerated at school or at home and that some teachers had counted 9 year old boys and girls during the headcount in schools due to misunderstanding eligibility criteria and inadequate training (Country 37). 
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Box 3: Example of challenges incurred when estimating the number of vaccine  
doses needed for a demonstration project in ‘Country 18’ 
• When the application to Gavi was prepared, the latest census was used to estimate target population, adjusted for the percentage of girls in school
• When reviewing the implementation plans, districts were asked to develop registers of eligible girls
• Numbers found in the community (out-of-school) were far below those expected. In schools, registration numbers were higher than the census estimate. Fewer doses than needed had therefore been requested from Gavi. 
• Three options were proposed to Gavi
 − Increase the number of doses
 − Allow implementation in one district only (not ideal as the plans purposefully included different districts and the comparison would be lost)
 − Allow vaccine delivery to the rural district and only to the urban centre within the second district (experience would still be obtained in urban and rural delivery
• Gavi agreed the third option
• The registered numbers were not correct when it came to implementation
 − Some teachers had enumerated the whole class, including boys, or counted unisex names as girls
• A	new	headcount	was	required	to	get	definitive	numbers.	For	this,	the	coordination	team	
talked	to	teachers	directly,	not	just	to	the	district	education	officer.	The	final	number	of	
vaccines	required	was	only	confirmed	after	this	headcount,	just	prior	to	delivery
• The	number	needed	for	the	second	dose	was	informed	by	the	first	dose
Experience from Country 18 (sub-Sarahan Africa):
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7.2.2 Country evidence and challenges - 
National programmesThe ten national programmes with information available used different enumeration methods:• In three countries, data from the most recent census were used. However, forecasting was compromised due to the census being delayed in one country, whereas in the second it gave accurate numbers. Another used an estimate of 2.2% of the total population from the census. This percentage estimate was arrived at from experiences in a demonstration project; however, there were stock-outs of vaccine during the delivery of dose 1. There could be a number of explanations for the stock-out: there was no way of verifying a girls age at delivery and many ineligible girls could have presented for vaccination; 
it	was	reported	as	difficult	to	estimate	how	to distribute the vaccine across districts and this could have been inaccurate; or poor calculation of target population  (2.2% is an underestimate). • Three countries used data from school registers, two countries used school only strategies therefore these estimates proved accurate, the third country utilised a mixed delivery strategy of schools and 
health	facilities	for	which	local	influential	community members and NGOs helped to identify out of school girls in each district. • Two countries used MOE statistics to estimate the number of girls enrolled in the particular grade, coupled with visits to schools to verify numbers. One country added a 10% buffer stock to account for potential discrepancies in these data and this was successful in preventing stock-outs. • One further country combined educational statistics and provincial estimates. However, the EPI coordinator tended to distribute vaccines based on the provincial estimates rather than the educational statistics. • The	final	country	combined	census	and	enrolment data in a school based strategy and has reported this has been accurate and the target population is decreasing as 9-13 year olds have been vaccinated and the new cohorts of unvaccinated girls are only 9 year olds. 
7.2.3 Key lessons learnt and 
conclusions In relation to enumerating the target population, key lessons included:
• In almost all demonstration projects, estimation of vaccine supply needs for 
the	first	dose	of	HPV	vaccine	has	been	a	considerable challenge. 
• School registries from schools themselves or the MOE, existing population censuses, and surveys of school enrolment rates have all been unreliable data sources. 
• Planning and implementation of a census to determine the size of the target population for demonstration projects requires substantial resources and is likely to delay vaccine delivery if not adequately planned. 
• Pre-registration of out-of-school girls is 
important	to	ensure	their	identification	and vaccination; however, house-to-house activities to enumerate and pre-register out-of-school girls are expensive. If volunteers are available this could be more feasible than census or health workers. Peer tracing or use of local civil society groups are other strategies to identify girls, all need to be budgeted for during planning.  
• Accurate determination of the number of eligible girls is more of a challenge for demonstration projects that implement in 
specific	districts	and	may	require	specific	activities such as school pupil enumeration. 
• For demonstration projects, enumeration in 
urban	settings	has	been	more	difficult	than	rural areas due to more mobile populations, and less distinct district boundaries.
• Several countries have implemented reliable registries for numbers of eligible girls after 
the	delivery	of	the	first	dose.	
• National programmes which have started delivery to 9-13 year olds have experienced decreasing target populations year after year as the target group decreases to a single age cohort of 9 year olds. 
• Census data may be more accurate and useful when enumerating the national target population than when attempting to enumerate girls in a demonstration project; however, additional data from school registries is still needed to aid distribution of the correct amounts of vaccine at the sub-national level to the districts and health facilities. 
7.2.4 Key recommendationsIn relation to enumerating the target population we recommend:
• Given	the	data	difficulties,	it	should	be	accepted that there are considerable uncertainties with the number of doses needed. If good records are kept for the 
Lessons learnt from human papillomavirus (HPV) vaccine demonstration projects68
first	dose	and	there	are	clear,	well-utilised	eligibility criteria, vaccine needs can be adjusted for the second dose and for future cohorts.
• Countries should allow for a buffer stock when ordering vaccines so that underestimation of eligible girls does not result in restricted access to vaccine.
• As many schools are not registered by the MOE, local validation of the number of schools and the number of pupils is needed.
• A system of pre-registration of girls at school is useful a few weeks before vaccine delivery to ensure that the vaccination team brings the appropriate number of doses. 
• Pre-registration of out of school girls may be important in order to identify and vaccinate them; however, this can be expensive if there are no available volunteers to conduct house-to-house visits and needs to be budgeted for accordingly. 
• If teachers or CHWs are asked to count girls, clear instructions need to be given to them on the eligibility criteria. 
• School absenteeism rates should be accounted for in the estimates of vaccine doses required.
• Enumeration is easier if the target population in and out of school is the same i.e. an age cohort. 
7.3 Availability of staff for  
vaccine delivery
7.3.1 Team sizeDuring vaccine delivery outside health facilities, vaccination team size varied between 1-6 persons. Among 28 countries (29 projects/programmes) with any data on human resource allocation, the most commonly used vaccination team size was 3-4 persons (18 countries), generally comprising two healthcare workers, one crowd controller/ mobiliser and/or one teacher/ school/ community representative. Only two countries stated that this team size 
would	be	difficult	to	maintain	during	national	implementation (Countries 3, 33) and one country stated that vaccination team size would need to increase in the future to deal with the multiple other interventions that will be delivered in outreach sessions (Country 14). One country stated using teams of 4-6 people, including two vaccinators, minimised disruption at large schools (Country 21). Six countries stated that team size depended on school size (Countries 1, 15, 21,15, 35, 37) and 
it was reported as important to vary team size depending on school size or the number of schools necessary for each team to visit in order 
to	maintain	efficiency	(Countries	15,	21,	25).			
7.3.2 Staff cadreIn almost all projects/programmes with MOH involvement and data on staff, the healthcare workers who delivered HPV vaccine were those already employed by the MOH who delivered routine immunisations. Only one country used a different strategy. Here the HPV vaccination workforce was comprised of trainee nurses and 
vaccinators	who	were	specifically	recruited	for	the demonstration project from medical/ health colleges. This was done because of a severe shortage of existing trained staff (Country 24).  Among 19 countries with information on the cadre of staff used to deliver the vaccine, only one country used community health workers (CHWs) (Country 18), one used auxiliary nurses (Country 12) and the remaining 15 used 
fully	qualified	nurses	or	unspecified	‘nurse	vaccinators’.  In some countries it was necessary 
to	use	qualified	nurses	to	ensure	trust	in	the	delivery of a new vaccine. Countries utilised CHWs in vaccine delivery, to aid the smooth-running of the vaccination day, to follow up missing girls, or to reach out-of-school girls, and countries stated the positive outcomes of the strategy included ease of access to hard-to-reach areas and nomadic groups and lower health worker workload (Countries 13, 16, 18, 28, 1, 17, 22, 26, D).  
7.3.3 WorkloadThe school-based ‘campaign’ approach, the level The school-based ‘campaign’ approach, the travel to schools, additional visits to schools for ‘mop-up’ activities or for staged delivery of each dose and the level of social mobilisation necessary were all reported to lead to high workload for health workers. Of 31 delivery experiences that had data on the duration of activity for each dose; the majority of experiences delivered each dose over one week; the range of the time allowed for delivery of each dose ranged from 2-3 days to 20 days (See Section 7.1.6 Duration of activity for each dose). Health worker workload depended on the number of schools per vaccination team (reported by 3 projects and ranged between 2 and 10) and the number of eligible girls within each school (highly variable and reported by 2 countries as anything between 2 and >100 (Tanzania, Country 1)). Actual workload was 
difficult	to	quantify	but	anecdotal	evidence	suggested that smaller schools were quick to vaccinate. Teams vaccinating multiple small schools and attending 1-2 schools per day 
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may have conducted vaccination activities for a shorter time per day but over more days, compared to a team which was allocated one or two large schools: “The campaign took 5-7 days normally but some facilities took longer as there were limited team members, health workers, and they had to cover a wide area” 
KI Country E.Among 20 countries with any data on the impact of HPV vaccine activity on routine health service provision, no impact was reported by 10 countries (2 national programmes, 8 demonstration projects). However; 5 of the 10 countries reporting no impact had planned and implemented strategies to mitigate impact in advance of delivery (examples of strategies are listed below). One of the demonstration projects conducted HPV vaccination as a 
vertical	programme	with	a	specific	workforce	within the MOH but separated from the routine health systems, so by nature it did not disrupt the routine activities (Country 11). Another demonstration project reported that all health workers were routinely trained in immunization so that they could rotate when to conduct outreach and therefore this mitigated the impact of new vaccine introductions on other services (Country 26). In addition, the experience within a country was not homogenous: in one country which reported overall no disruption of routine services, a third of health centres reported disrupted activity and two-thirds did not (Country 33):  “Disruption of services was reported at about 25 - 27% of the facilities, some areas reported new temporary hire (to mitigate impact)” 
Country 33 report. Ten countries (3 national programmes, 7 demonstration projects) reported that HPV vaccine activities did affect daily routine services due to a shortage of manpower, especially in remote health centres with only 1-2 full time staff (Countries 3, 6, 11, 12, 13, 14, 18, 28 33, H) “60% of auxiliary nurse midwives said their routine work was affected, 23% said it was affected to a large extent. Activities affected included antenatal care and postnatal care, monthly reporting etc.” 
KI Country 12.
“The low capacity of health workers is a matter of concern, even before the vaccination starts. Most health facilities and reproductive health units are understaffed. Therefore, supplying staff for the outreaches to schools can be overwhelming to the workers”
 KI Country 31. “Capacity is a challenge - the same HWs need to do all the jobs. Districts form teams assigned to 3-4 schools and that nurse on the team is not able to do any other activities at the health centre. At health posts (staffed by only 2 nurses) if 1 nurse is out it leaves just 1 staff to do everything.” 
KI Country 3.“A shortage of staff at the health facilities was noticed on the vaccination day, some facilities remained closed, but it’s just a week” 
KI Country 13.A number of strategies were described by 13 of the 46 countries to minimise the impact of the HPV vaccine outreach activities on health centre activities (Countries 12, 15, 18, 24, 26, 28, 30, 33, 36, 37, A, C, I). These were reported whether the country reported any data on the impact of the vaccine activities on routine services or not:
• Integration into existing outreach days or community visits reduced delivery costs, increased project/programme sustainability 
and	utilised	staff	more	efficiently	(evidence	from 6 countries). 
• Longer working days were implemented to help deal with workload and prevent delays to other community activities or staff having to work additional days (4 countries).
• Redeployment of staff from other areas of the country and/or other services (e.g., antenatal care) (7 countries), or employment of temporary, trainee or previously retired staff (3 countries) increased the workforce available during HPV vaccine delivery. 
• Task shifting to CHWs to aid with routine activities/ campaign vaccinations helped to manage the high workload and lack of human resources (3 countries). 
• Delivering HPV vaccine doses over a longer time period enabled planning of outreach days around existing workloads (2 countries).Two countries reported that, although the initial workload was heavy in part due to intensive social mobilisation and work to identify eligible girls, workload decreased over 
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time due to greater familiarity with procedures and fewer communications activities (Country 23, 36).  Despite the heavy workload, 3 projects implementing a school and health facility delivery model reported that the introduction of HPV vaccination had improved their routine EPI programme, awareness of cervical cancer and enhanced the relationship between health workers and the community in implementation areas (Countries 6, 15, G). The impact of HPV vaccination projects/programmes on school activities was rarely reported. Five countries noted some negative impact on school activities (Countries 13, 30, 33, 36, I), but two of these countries reported the disruption had been worthwhile to get the girls vaccinated (Countries 33, 36). Some school staff suggested arrangement of vaccination days before holidays or during out-of-school hours may reduce the impact of vaccination programmes on school lessons (Country 36). In one country 75% of teachers reported disruption to the school day, 6% said it was severe, and the next demonstration project will test routine style delivery at health centres during school holidays (Country 13).  
7.3.4 Key lessons learnt and 
conclusionsIn relation to the availability of staff key lessons included: 
• If school size is large, large teams can complete vaccination activities very rapidly, minimizing the disruption at the school; however, with small school sizes or house-to-house outreach activities it becomes 
inefficient	and	expensive	to	send	large	teams. 
• The level of workload generated by HPV vaccination activities was variable; the effect 
on	routine	services	was	difficult	to	estimate	as many demonstration projects were small-scale, resource intensive and were not fully integrated into EPI services. 
• Countries concerned about the impact on routine services can test strategies to mitigate this during demonstration projects but should be aware that some of the strategies are unlikely to be possible during national roll-out unless a staggered vaccine delivery is planned e.g. using staff from other regions or employing temporary staff. Trainee health workers may prove useful to 
fill	some	gaps	in	capacity.	
• There was no evidence that changing from a 3-dose to a 2-dose schedule has changed the proportion of experiences that report an impact of campaign activities on routine health services. 
• One strategy to mitigate impact on routine services is to extend the time period of HPV vaccine delivery to transform a campaign-like strategy into a phased delivery over a number of months or a more ‘routine approach’ integrated with existing outreach services. There is limited experience of this (Countries 30, 12, 31, 33) and no available evaluation data on the impact on staff workload or HPV coverage.  
• Coincidental introduction of multiple new vaccines can exacerbate capacity issues at all levels (national, regional, district and local). 
7.3.5 Key recommendations In relation to the availability of staff we recommend that:
• Vaccination team size should be decided during microplanning, after a human resources capacity assessment in each area. Team size should vary depending on the size of schools in the catchment population, or the number of schools necessary for each 
team	to	visit,	in	order	to	maintain	efficiency.
• Teams can include teachers, CHWs and trainee health workers in order to decrease 
the	number	of	qualified	nurses	needed	for	vaccine delivery sessions.  
• Integration with other outreach activities, spreading HPV vaccine activities over a longer time period, task shifting to lower cadre staff, and/or allowing for longer working days could minimize the impact of HPV vaccine activities on other routine services if human resources are thought to be limited in country. These strategies and/or other strategies should be tested and evaluated. 
7.4 Staff supervision 
7.4.1 Country experienceOnly 28 countries mentioned any detail around supervision during any of their delivery experiences. Of these, 21 countries representing 26 delivery experiences reported whether supervision followed a cascade or centralized approach. A cascade approach, where the national level supervises the provincial/ district level and the district level supervises the health workers, was employed by 11 countries implementing 16 delivery experiences (Countries 1, 3, 12, 13, 14, 15, 17, 30, 33, 37, A). Experience from 3 countries questioned the relative merits of the cascade approach (Countries 3, 37, A) and called for the capacity of all district/ regional supervisors to be strengthened. Checklists and logbooks were 
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mentioned by 15 countries as being useful to keep track of whether supervisory visits had been completed (Countries 1, 3, 15, 12, 17, 18, 21, 30, 37, 26, 28, 31, 33, 36, I). A centralized approach, where national teams visited the districts during HPV vaccination activities, was conducted in different projects/programmes in 10 countries implementing 11 delivery experiences (Countries 3, 21, 24, 29, 31, 33, D, E, F, H). This was reported as an expensive activity during vaccine introduction due to the need for additional transport and per diems and seven countries eventually opted for cascade supervision to reduce costs (Countries 3, 8, 22, 28, 29, 31, 33). HPV vaccination was incorporated into routine EPI supervision visits in four countries by the second year of the project/programme (Countries 3, 8, 31, 33). 
Supervision	specific	to	HPV	vaccine	delivery	
was	largely	done	only	for	the	first	year	of	demonstration projects due to the focus on monitoring and evaluation at this stage and reporting requirements. Overall, supervision followed routine practice, 
although	five	projects/programmes	reported	that they had started with more intensive supervision with higher cadre supervisors than routine supervision because of the novelty of the vaccine and media attention (Countries 11, 14,18, 28, E). Two countries reported the level of supervision “decreased to normal” after the 
first	year	of	introduction	(Countries	3,	28).	Two	countries with projects/programmes run by the MOH decreased the level of supervision for 
the	final	dose	of	their	first	year	due	to	expense	and funding constraints (Countries 24, 31). The impact on data quality and completion of the vaccination activities was not assessed.In cases where the demonstration project was implemented more as a research project, supervision was kept completely separate from routine EPI supervision (Countries 5, 6, 19) or was completed as a joint exercise between the MOH and research team (Country 31).Four countries stated explicitly that supervision was necessary to encourage staff to perform the outreach and motivate them to continue to serve their community despite heavy workloads (Countries 3, 6, 14, 29). A further two countries stated that supervision was useful to build capacity (Countries 8, 33). Just one programme deemed supervision unnecessary due to logistical challenges in travelling to vaccination sites, the expense involved and the experience of the vaccinators (Country 35). One country called for the MOE to become involved in HPV vaccine supervision at schools in order to provide support and reassurance to teachers (Country 6). 
7.4.2 Key lessons learnt and 
conclusionsIn relation to staff supervision key lessons learnt included:
• Supervision is necessary when adding another activity like HPV vaccine introduction to health workers’ workload. It can be motivational, can ensure successful implementation and high quality data collection. 
• Supervision was usually carried out in a cascade from national level to frontline staff. 
• Checklists and logbooks can help to ensure supervision activities are completed if these are audited by higher level supervisors. 
• Supervision using national level representatives was found to be expensive, primarily due to transport and per diems. Non-integrated national level supervision of every new vaccine introduction is not sustainable long-term and use of national level supervisors may not be a realistic option if implementation is scaled up across many districts or nationally.
7.4.3 Key recommendationsIn relation to staff supervision we recommend:  
• Supervision is recommended for HPV vaccine projects/programmes although the intensity could decrease to routine levels over time 
• Supervision could be integrated with routine EPI supervision to decrease costs.
• New vaccine introduction should be used as an opportunity to strengthen the capacity of supervisors at the national, regional and district levels.  
7.5 Staff remuneration 
7.5.1 Country experience The use of per diems to pay health workers for outreach activities was widespread; of 32 projects/programmes run by the MOH, 29 reported having paid per diems; only 3 did not. Policy ranged from just reimbursing a lunch allowance, to varying levels of reimbursement depending on distance travelled or whether the health worker had to stay overnight. Of the three MOH implemented projects/programmes that did not pay per diems, one was a health facility model (Country 13), and the two others viewed the work as “part of the nurses day-to-day job” (Countries 6, 30).The vast majority of countries that reported remuneration information said that 
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remuneration was aligned with existing EPI levels of reimbursement for outreach or campaign activities (13 countries:1, 3, 4, 6, 11, 13, 14, 15, 21, 28, 30, 31, 35). One country reported paying an increased allowance 
to	health	workers,	reflecting	more	intense	activities such as the unusual outreach to schools (Country 18). When it was considered more as a stand-alone project with lower EPI involvement, reports indicate that additional payment was expected and amounts were higher than routine EPI per diems (2 countries: Countries 5; 25.)Four countries reported they had tried or would try in the future to reduce the cost of per diems and allowances to health workers and supervisors during intensive outreach campaigns. Three countries outlined 
that	specific	allowances	paid	within	the	demonstration project would not be sustainable as part of a national programme and suggested, a health facility based delivery model is planned in the future (Countries 8, 31, 33). One country reported it would try to normalize HPV vaccination activities into the health workers routine day-to-day job (Country 18).  Only two countries mentioned giving allowances to teachers in compensation for the extra workload in enumerating the target population and marshalling girls on vaccination days (Countries 8, 31).  
7.5.2 Key lessons learnt  
and conclusions In relation to staff remuneration key lessons included:
• The use of per diems for outreach activities or any activity which involves the health worker leaving their station is widespread. 
• Per diems are a major consideration when countries assess the sustainability of a 
programme	and	have	a	significant	financial	impact on cost per vaccinated girl. 
• Per diems may be a particular challenge in demonstration projects which can be seen as ‘special’ and ‘non-routine’ and may become less of an issue with national roll-out when delivering the vaccine should be normalized into health workers routine responsibilities, especially if they routinely conduct outreach for other services.
7.5.3 Key recommendations In relation to staff remuneration we recommend: 
• The cost impact of staff per diems should not be overlooked when planning HPV vaccine introduction. Making HPV vaccination part 
of routine activities for health workers may avoid or reduce per diem payments for delivery of ‘special’ interventions. 
• Minimising the number of health centre staff needed at the vaccination sites could minimise cost, if other community workers regularly conduct outreach activities as part of their day-to-day job and HPV can be integrated into those activities. 
• Integration with other existing outreach activities or school health programmes could allow the cost of per diems to be shared across multiple different programmes/ health interventions. 
7.6 Adverse events and safe 
injection procedures
7.6.1 Adverse events monitoring  
and reportingMost countries appeared to have standard reporting mechanisms for adverse and serious adverse events (AE/SAEs), though these mechanisms were generally not well described. Reported AEs and SAEs appeared to be below 1% in the 44 countries (representing 56 delivery experiences that provided data (Table 23). AE/SAEs were generally recorded on standardised forms at the vaccination site, although some countries had girls report to health facilities. Most AE were minor and temporary, requiring observation but no or minimal treatment. Spokespeople and/or communication materials were used to dispel community fears and misinformation. Some country discussions indicated that the very low numbers of AE reported at some sites suggested that forms were not being completed properly and that more training/monitoring was necessary. However, the reporting process was generally considered acceptable. 
7.6.2 Injection safety training  
and proceduresOf 17 countries for which health-worker injection safety was discussed, most indicated availability of guidelines and/or training, while 3-4 mentioned there were no standard national guidelines though safe practices were ‘generally adhered to’. One country indicated that despite effective national guidelines, auto-disposal syringes were not available. Another issue reported was cleaning of injection punctures with tap-water in one site of another country, leading to abscesses. Most did not mention availability of emergency kits outside facilities or whether safe-injection 
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procedures were outlined to health-workers, assessed, and followed. However, several indicated that emergency kits were not always available or could not be brought to all vaccine sites. While no problems were reported as a result of this, it was particularly noted that medications and instruction to manage anaphylactic reactions should be made available at vaccination sites. 
7.6.3 Differences from routine practiceOverall, monitoring and response procedures were consistent with those of other EPI vaccines. In terms of differences from standard EPI training and reporting, the main difference noted was greater rigour and monitoring of training and implementation with emphasis on handling and reporting AE. One difference noted was that teachers and parents were also involved in monitoring AE, which was particularly important.
Table 23. Reported adverse events and severe adverse events by country
Country (Experience) AEs per dose (%) SAEs (%) Details (Number of events or %)
1 (2N) 246/132,407 (0.2) 0 (0) Frequent AEs were headache, nausea and 
vomiting, fever, shivering, pain, giddiness, 
fainting.
2
   
(4D) 10/84,429 (0) 0 (0) Immediate reactions after vaccination as pain, 
redness at the vaccination site, or mild headache 
that did not need medical treatment.
(4D) 35/3,888 (0) 1 (0) Reported AEs were headache (3), slight pain 
(24), redness or some bleeding at vaccination 
point (6), those who'd not eaten breakfast, felt 
nauseated (2); SAE was fainting/chills/low BP, 
resolved after 4hrs in hospital.
3
   
  
(5D) NA NA NA
(6D) 3/6542 (0) 0 (0) Reported AEs were pulled muscle (1), shortness 
of breath (1), dizziness (1).
(7N) NA NA NA
4
 
  
(8D) NA NA An additional AEs survey was conducted among 
1,000 girls followed up to 96hrs after injection. 
Common (>10%): irritability/pain, pyrexia, 
erythema, local oedema; Less Common (>1%, 
<10%): diarrhoea, vomiting, myalgia, upper 
respiratory tract infection, cough, toothache, 
fever <38.9C, fever >38.9C, malaise, arthralgia, 
nasal congestion, insomnia; SAEs (>0.01%, <0.1%) 
were pelvic inflammatory disease, headache, 
appendicitis and gastroenteritis.
(9D) 36/4074 (0) 0 (0) Reported AEs were lipothymia with skin paleness 
or sudoresis (11), fever (7), vomiting and nausea 
(5), pain and oedema at injection site (5), 
transient tremors (3), facial oedema (2), skin rash 
(2), headache (2), facial flushing (1), skin spots (1), 
sleepiness (1). No SAEs reported. 
(10N) 1,007 nationally 29 SAEs were 9 cases of anaphylaxis according to 
WHO definition and the rest indeterminate/
unrelated. Local injection site pain and panic 
attacks were also reported nationwide.
5
   
(11D) 95/4,117 (0) 0 (0) AEs were fever, pain at injection site, swelling, 
headache, fainting, rash, urticaria, erythema.
(12D) 724/23,788 NA AEs were fever, urticaria, pain at injection site.
6 (13D) 1/19,164 (0) 0 (0) AE was swelling at injection site.
6 (19) 249/1191 (21%) 0 (0) 21% of those receiving the first dose reported 
that there was some AEs after vaccination; 
However, they were reported as minor 
not necessitating any treatment: pain at 
administration (31%), Fever (23%), headaches 
(19%) and tiredness (14%)
8
  
(16D) NA/15,940 NA NA
(17D) 24/87,042 (0) 0 (0) NA
9 (18D) 3/20,732 (0) 0 (0) AEs were fainting and slight headaches.
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10 (20D) NA/2,884 NA The most common AEs were pain at injection 
site (49% dose 1, 52% dose 2 and 46% dose 3), 
headache (11%), syncope (2 cases), generalized 
rash (1 case).
11
     
(22D) 0/9492 (0) 0 (0) None reported.
(23D) 3/25,016 (0) 0 (0) NA
12
     
(24D) 121/30,809 (0) 4 (0) Common AEs were headache and dizziness. 
SAEs were 2 neurogenic reactions (i.e. giddiness, 
jerky movements) and 2 deaths later attributed 
to snakebite and malaria (in total 7 deaths were 
temporarily associated with HPV vaccine but all 
later found to have a clear alternative cause e.g. 
snakebite, malaria).
(25D) NA NA NA
13
     
(26D) 7/9050 (0) 0 (0) AEs were dizziness/fainting/headaches (4), 
abdominal pain/ nausea (3).
(27D) NA NA NA
14 (28D) 1/1,490 (0) 0 (0) AE was numbness.
15 (29D) 1/NA 1 SAE was an unrelated death.
16
     
     
(30D) NA NA 2 girls reported a minor rash
(31D) NA NA NA
(32N) NA NA NA
17 (33D) NA/4,822 NA No AEs in 2 years
18 (34D) 2/3,169 (0) 1 AEs were vomiting; SAE was unrelated to vaccine.
19 (35D) NA NA 427 AEs in total across 3 doses most injection site 
reactions; no SAEs.
20 (36D) 0/20,722 (0) 0 (0) None reported.
21
     
(37D) 551/30,591 (0) NA Frequent AEs were sore arms, fever, fainting.
(38D) 2/5,904 (0) 0 (0) AEs were mild swelling.
22 (39D) 0/NA (0) 0 (0) AEs monitoring system may not have been 
effectively implemented, according to country 
representatives, as no AEs reports were 
captured.
23
     
     
     
(40D) 34/NA (0.11) NA Frequent AEs were dizziness (13), fainting (7). 12 
AEs occurred in round 1.
(41D) 7/9,566 (0) 0 (0) AEs were fainting (3), dizziness (1), vomiting (1), 
stomach-ache (1), bleeding from injection site (1).
(42D) 5/24,047 (0) 0 (0) AEs were dizziness (3), vomiting (1), fever (1).
(42D) 12/29,946 (0) 0 (0) AEs were dizziness (6), fainting (4), vomiting (1), 
bleeding (1) Fainting/bleeding associated with 
lack of breakfast and nervousness.
24 (43D) NA 0 (0) NA
25 (44D) 0/17,220 0 (0) None reported.
26 (45D) 252/4,344 (0) NA NA
(46D) 195/26,798 (0) 0 (0) Frequent AEs were dizziness.
(47D) NA NA NA
28 (49N) 5/278,756 (0) 0 (0) NA, except ‘reports of hysterical reaction in one 
region’.
30
     
     
(53D) NA NA NA
(54D) 0/5,346 0 (0) None reported.
(55N) 10/340,000 girls 0 (0) AEs were abscess, rash, nausea, fainting, raised 
temp, dizziness, abdominal pain.
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Country (Experience) AEs per dose (%) SAEs (%) Details (Number of events or %)
31
  
   
 
 
 (56D) 11/5,055 3 (0) Some sites reported 0, suggesting forms weren’t 
used appropriately. SAEs were 1 generalised 
rash, 2 unspecified.
(57D) NA NA NA
(58D) 0/52,566 (0) 0 (0) None reported.
(59D) NA NA Approximately 5% of parents reported their 
daughters experienced AE: pain at injection sites 
(38%), fever (22%) and 41% reported AE resolving 
without management.
33
    
     
   
    
(61D) 6/9,725 0 (0) AEs were girls delivering babies after dose 2 (2), 
undescribed (4).
 (62D) NA NA An additional survey indicated that 23% of 
parents reported AE, e.g. pain or swelling at 
injection site (64%), fever (22%), headache (7%).
(63D) NA NA NA
(64D) NA NA NA
(65N) NA NA NA
34 (66D) NA NA NA
35 
     
(68D) NA/2,718 NA 6% had fever and 27% had pain in their arm for 
1-3 days after the first dose. After the third dose, 
26% had pain in the arm and 5% had fever. Other 
recorded side effects were headache, itchiness, 
stomach ache, swollen arms, general body pain 
(1) and chest pain (1).
(69N) NA NA NA.
36
     
     
(70D) 231/1,998 (11.6) 0 (0) A survey indicated AE included pain/swelling at 
site (108), fever (62), tiredness (18), headache 
(17), dizziness (16), other (10). 
(71D) 64/19,145 (0.3) 0 (0) AE: headache, dizziness, vomiting, which 
dissipated shortly after vaccination.
(71D) 32/10,273 (0.3) 0 (0) AE: dizziness, headache (18), sick and nausea (16), 
fainting (1).
37 (72D) 0/24,541 (0) 0 (0) NA
A 0 (0) Minor redness or injection site pain 
B NA/6000 0 (0) Only a few incidents of pain in injection site 
reported, 6 girls fainted and had to sit for a while
D No AEs observed
F 0 (0) No AEs observed
G NA/NA (18%) 0 (0) Among these 42 parents reporting AEs: three-
quarters were swelling or soreness at injection 
site - all parents did nothing or treated the child 
at home; fever (8 events); headache (8 events); 
dizziness (4 events); nausea (2 events), and rash 
(3 events). The rates of reported events per dose 
was estimated at 1.25 per 100,000 doses in HCC 
and 0.7 per 100,000 doses in Isabel.
H 21/NA 0 (0) 21 cases of minor AE: fever or swelling at the 
injection site
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7.6.4 Key lessons learntIn relation to adverse events key lessons included:
• Non-EPI stakeholders, particularly teachers and parents, were a useful resource in monitoring and reporting AE.
• Training and equipment supplied to support AE reporting and response varied among projects/programmes.
• There were noticeable differences among projects/programmes in AE reporting procedures.
7.6.5 Key recommendations  
Based	on	findings	related	to	adverse	events	monitoring, we recommend:
• Non-EPI stakeholders, such as teachers and parents, should be involved in monitoring and reporting AE.
• All countries should have standardized national guidelines and training procedures for reporting and responding to AE/SAEs.
• AE reporting should be standardised globally (e.g. always reported with 
denominators)	for	the	sake	of	comparability. 
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8. Achievements
8.1 Coverage achievements
8.1.1 Data qualityFinal dose coverage estimates are available for 60/92 delivery experiences. Only 17 delivery experiences in 13 countries had available data from coverage surveys; the remainder reported administrative coverage estimates (47 delivery experiences) or were missing data (32 delivery experiences). Requirements for coverage data collection differed by funder and coverage data were not required for country or external partner programme evaluations, e.g. in GAP projects. Gavi-supported projects were required to conduct coverage surveys within 6 weeks 
of	the	final	dose	using	the	WHO	cluster	survey	methodology[6, 23]. However, results from 9 Gavi coverage surveys were received for this study of 10 known to have been completed. Others had either not been completed or the results were not authorised for release. Interpreting administrative coverage data was challenging since these often used estimated target population sizes from planning phases, despite the fact that these had been proven inaccurate during implementation. Reports did not always explain which denominator was used, whether they had included out-of-school girls within it, or how exactly the eligibility criteria for vaccination were enforced on the ground. Coverage of >100% was sometimes recorded due to vaccination of a larger than expected target population, or vaccination of ineligible populations. The administrative coverage estimates presented in this report have a number of caveats and limitations: 
• The numerator, or number of girls receiving a dose, should be interpreted in conjunction with the reported eligibility criteria (usually geographic and age/grade-based criteria). The ‘accuracy of the numerator estimate was 
influenced	by:a. How well the eligibility criteria were communicated to, understood and implemented by vaccinators and teachers/
communities.	This	influenced	both	the	messages delivered to communities about eligibility and what happened on vaccination days.b. How easy it was for health workers, parents and girls to determine eligibility and therefore the accuracy by which they determined whether a girl should be put 
forward for vaccination and consent given, if required.c. How well eligibility criteria were enforced on vaccination day, despite clear and concise messages that were well understood by both vaccinators and recipients. Three separate projects stated ineligible girls petitioned vaccinators for the vaccine on vaccination day.d. The quality of data collection at vaccine delivery for each dose.
• The denominator, or total population targeted to receive the vaccine, was estimated using: a. Census data. These could be at least a few years old, so 
had	to	be	modified	based	on	estimated	population growth. There may not have been a sub-category of 9-13 year olds, so this was sometimes estimated as a proportion of 10-15 year olds.b. National school enrolment data. These could be used with projections of the proportion of in-school and out-of-school girls, but accuracy of these projections were often uncertain and/or the data had not been recently validated.  c. Other target population estimates as calculated prior to vaccination day (see Section 7.2: enumerating target populations).These could be the most accurate, although 
accuracy	was	difficult	to	determine	and often there was still a challenge in enumerating out-of-school girls. Combinations of data were sometimes used, e.g. a headcount of in-school girls as well as census/national school enrolment data to project the expected number of out-of-school girls. Data were missing from 32 delivery experiences (11 Gavi and 21 non Gavi-supported projects/programmes) because the denominator was not recorded, the eligibility criteria were never 
fully	defined	or	adhered	to,	the	coverage	surveys	were not completed or the 2014/15 data were yet to be released.
8.1.2 Country experienceCoverage was assessed as the number of 
girls	receiving	the	final	dose	among	the	
total	identified	target	population.	It	is	worth	noting that in delivery strategies that only 
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targeted schools, administrative coverage estimates measured vaccination coverage in the school-going population only; only coverage surveys took account of the out-of-school population in these scenarios. Among the 92 delivery experiences with at least 6 months of 
experience,	60	(65%)	had	data	on	final	dose	coverage. For some experiences, this was a reported percentage; others reported the 
target	population	and	number	of	final	doses	received. Among the 60 experiences with data, 
50	(83%)	reported	HPV	vaccine	final	dose	coverage of 70% or above (range between 51% to >100%). No experiences reported coverage below 50% (Table 24). These coverage estimates included ten experiences with data on a two-dose schedule; the remaining 50 experiences implemented a three-dose schedule. The dose schedule recommendation change in April 
2014[41,	42]	left	insufficient	time	for	more	data	on two-dose schedules to become available within this review’s timeline. Among the 35 experiences which reported raw data on target 
population	and	final	doses	administered,	mean	
final	dose	coverage	was	88%.	
Uptake	was	defined	as	the	number	of	girls	
receiving	the	first	dose	among	the	identified	target population. Estimates of uptake were available for 56/92 experiences and ranged from 
64% to >100%. Among the 33 experiences which reported raw data on their target populations 
and	first	doses,	mean	uptake	was	93%.
Completion	rates,	defined	as	the	proportion	of	
girls	who	received	the	final	dose	among	those	who started the schedule, were available for 54 experiences. Reported completion ranged from 70% to 99%. All four two-dose experiences with data achieved >85% completion. Mean completion rates among the 35 experiences with raw data for the number of girls who received 
the	first	dose	and	final	dose	was	89%.The estimates of average (mean) uptake, 
completion	and	final	dose	coverage	rely	on	the availability of numerical data for target population and dose delivery. Among the experiences which reported a percentage coverage estimate but no raw data, 9 reported 
>90%	final	dose	coverage,	5	reported	70-90%	and 2 reported <70%. Numerical data did not seem to have been reported more often for  those experiences achieving high coverage.
8.1.3 Case Studies Boxes 4, 5, 6, 7 and 8 illustrate the multiple 
factors	that	contributed	to	the	final	dose	coverage achieved in each country for HPV vaccination. 
Box 4: Case study – institutional refusals resulted in low coverage  
Eligibility criteria were not well understood by health workers, which led to inconsistent and variable adherence to these eg. some staff only vaccinated 10 year olds in the selected school grade while others vaccinated the whole school grade. This could have resulted in an overestimate of the true coverage of 10 year old girls.A grade-based approach needed to be adapted in private school where girls were enrolled at a younger age on average.Late distribution of funds resulted in delayed production of IEC materials. Rumours that the vaccine affected fertility led to a whole school-level refusal. Despite the participation of high 
profile	champions,	school	head	refused	to	allow	vaccinators	access	in	a	number	of	urban	and	private religious schools. Furthermore, there was no clear strategy of how to allow girls to be vaccinated if they changed their minds after they had initially refused. Inadequate transport to implement a predominantly school-based delivery strategy led to health workers walking to outreach sites and may have limited mop-up activities.
The	high	drop-out	of	girls	before	receipt	of	the	final	dose	was	reportedly	due	to	the	vaccine	schedule coinciding with examinations or holidaysThe low uptake and completion among out-of-school girls, who could access vaccination services at health centres and community outreach venues, was attributed to the lack of a clear strategy to identify and mobilise out-of school girls prior to implementation. 
The	country	identified	recommendations	for	future	delivery:1. Microplanning	of	vaccine	supply	needs,	transport,	and	sensitization	(including	identified	challenging groups in urban areas) needs to take place in good time and take events in the school calendar into account2. Strong	collaboration	between	regional	and	district	medical	and	educations	officers	could	result in more effective microplanning and the development of a strategy to mobilise urban private schools with potentially low rates of consent and acceptance before vaccine delivery.
Country 37: Implementation challenges and institutional refusal (coverage 50-60%)
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Box 5: Case study – challenges in urban areas and low coverage 
In	the	first	year	of	HPV	vaccine	delivery	in	schools,	health	facilities	and	through	outreach	activities, average coverage was lowered by the low coverage attained in just one urban area. This had a high concentration of private schools and was more affected by negative media exposure. Within this urban area, private schools attained much lower coverage in comparison to public schools. The areas of higher coverage attributed to their success to good collaboration with the education sector at every level (regional, district and local). Where the project was implemented in rural areas and another urban area, it achieved good coverage (>80%). However, in urban private schools, coverage was only 51%. Despite an intensive social mobilisation strategy which was well targeted and organised, anti-vaccine lobbyists received media exposure.
Box 6: Case study – low completion
During	a	predominantly	school-based	strategy	with	some	community	outreach	sessions,	first	
dose	coverage	was	high	in	all	areas.	However,	final	dose	coverage	was	almost	20%	lower	in	urban	
areas	compared	to	rural	areas.	It	was	felt	that	insufficient	time	had	been	allowed	for	planning.	
Vaccination	venues	were	not	notified	of	vaccine	activities	sufficiently	in	advance.	The	first	dose	
was	delivered	late	in	the	school	calendar	year,	which	meant	that	the	final	dose	was	offered	during	the school holidays. This was likely to be a major cause of the low completion, particularly in urban areas where school children often migrate to rural villages during the school holiday season. Rumours that the vaccine was ‘experimental’ and/or a contraceptive, alongside inadequate social mobilisation with late delivery of IEC materials, may have affected urban areas more than rural areas.Inconsistent adherence to eligibility criteria, uncertainty of the eligibility criteria for out-of-
school	girls	and	variable	use	of	reporting	tools	decreased	the	level	of	confidence	in	the	accuracy	of administrative coverage estimates. 
The	country	identified	recommendations	for	future	implementation:1. Planning	should	start	sufficiently	in	advance	of	vaccination	activities	in	order	that	schools	
and	vaccination	sites	can	be	notified	prior	to	visits	from	health	workers	and	teachers	can	play	a full and active part in social mobilisation activities. 2. Early planning can ensure doses are administered in one school calendar year, which will allow higher completion rates. 3. Communication with parents and involvement of community leaders may help to lessen the impact of rumours.4. Retraining in the use of reporting tools is necessary to improve data quality.
Country 21: Urban challenges and low coverage (coverage category 60-70%)
Country 24: The problem of low completion (survey: 50-70%)   Administrative coverage estimates: Urban:  coverage: 68%; completion: 78% | Rural: coverage 86%, completion 93%Coverage survey estimates: Total: Dose 1 coverage 73%, Dose 2 coverage 52%, Completion 71% 
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Box 7: Examples of high coverage experiences  
Country 18: The application for HPV vaccine support was led by the non-communicable disease department within the MOH, due to limited capacity within EPI. However, both the EPI and reproductive health department attended planning meetings and were involved in technical working groups. All three departments held responsibility over different aspects of implementation. Vaccine activities were well integrated within EPI. A predominantly school-based strategy was used for all girls in grade 4 and out-of-school girls between 9-13 years were invited to health facilities. A single grade was easy and quick to identify in schools and the wide 
eligibility	age	range	enabled	easier	identification	of	eligible	girls	in	the	community	setting	in	comparison to using a single year of age. Social mobilisation had a dedicated budget and included using drama groups, community leaders holding meetings within villages and CHW motivational talks in schools, although most parents reported they had heard information directly from a health worker. Some information was repeated before each dose. Vaccine delivery was completed in teams of CHWs and nurses and this lessened the workload for full time nurses and allowed good coverage of hard-to-reach areas.
Country 2: Collaboration with the media was vital in raising awareness alongside a comprehensive social mobilisation strategy with messages focusing on several cervical cancer 
presented	in	meeting,	videos,	brochures,	posters,	banners,	flipcharts,	frequently-asked-questions	guides, CDs, training workshops. Timely sensitisation and maintaining scheduled vaccination dates was important at schools, clinics and mobile clinic outreach.
Box 8: Case study – a country with a high proportion of out-of-school girls 
In this setting school enrolement was between 60-70%. The strategy selected was to organise 
three	mass	campaigns	in	schools	and	at	specific	sites	for	girls	not	attending	school.	The	aim	of	the strategy was to ensure high uptake in out-of-school girls. Out of the total target population, the proportion of girls vaccinated at school was between 57% and 69% for the urban areas and 35% for the rural areas. The majority of girls, especially in rural areas, had to be vaccinated out of school. This led to an intensive set of activities that included working with village leaders 
to	locate	girls,	communication	with	parents	to	confirm	ages	and,	in	some	cases,	door-to-door	vaccination.
This	complex	set	of	activities	was	demanding	in	terms	of	planning	and	funding	resources.	Specific	challenges encountered included issues with determining the number of girls, challenges in 
following	up	girls	that	had	missed	the	first	dose	and	pressure	of	operational	costs	that	led	to	
insufficient	funding	in	year	2,	notably	in	terms	of	social	mobilisation	activities.
High	coverage	in	two	different	settings	(coverage	category	≥90%)
Country 24: Delivery with a high proportion of out-of-school girls
8.1.4 Analysis of the correlates of 
uptake, completion and final-
dose coverage across delivery 
experiencesA number of programme characteristics were analysed in relation to the uptake, completion (or dropout) and coverage rates achieved. The full list of characteristics can be seen in Tables 24, 25, 26. Among experiences that had data on coverage, seven LIC experiences (37%) achieved 90% coverage or more, compared to 50% of the experiences in LMICs and 33% of the experiences in UMICs (Table 24). The experiences in UMICs with lower coverage were generally small, run by external groups or researchers, with limited EPI involvement. The rates of vaccine uptake followed a similar 
pattern across LAMIC groups. However, a smaller proportion of experiences in LICs (47%) attained high completion compared to those in UMICs (73%; Table 25).  The majority of data are from demonstration projects; only 9 national programmes shared coverage data. National programmes seemed 
to	attain	better	final	dose	coverage	(67%	
attained	coverage	≥90%,	compared	to	37%	
of	demonstration	projects	attaining	≥90%	coverage); however, the number of national programmes is small and four had completed prior demonstration projects, potentially allowing them to modify their strategies to gain higher coverage. There is substantial evidence that delivery strategies including schools as vaccination sites achieve high coverage. Among the 55 
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experiences that involved schools and had data, only 15% attained coverage below 70%. Health facility-only strategies were more likely than mixed or school-based strategies to attain <70% coverage; however, there remains very little evaluation data. We remain unable to conclude the feasibility of high coverage in health facility only strategies.A slightly higher number of MOH-led experiences attained high uptake, completion 
and	final	dose	coverage	when	compared	with	external partner-led experiences. A slightly higher number of MOH-led experiences attained high uptake, completion 
and	final	dose	coverage	when	compared	with	external partner-led experiences. The level of EPI and school sector involvement 
was	classified	as	follows:
• High: the sector was involved in both the planning and implementation of the programme; 
• Moderate: the sector was involved in the implementation but not the planning 
• Minimal to none: the sector did not play a mentionable part in the planning or the implementation of the programme. 
Over	four	fifths	of	the	experiences	were	classed as having high EPI involvement. Those with moderate-low EPI involvement were run parallel to EPI by NGOs or, rarely, the non-communicable disease department/reproductive health department within the MOH. A larger proportion (47%) of those with high EPI involvement attained 90% coverage or more, compared to only 20% of those with minimal or no EPI involvement. The pattern was very similar for uptake and completion rates. Experiences that involved the MOE and schools in the planning and implementation of the programme attained a greater proportion of high coverage results than those with less school involvement (37% attained high coverage compared to 0% of those with minimal-no MOE involvement). Patterns were similar for uptake and completion rates. These 
findings	correlate	with	the	lessons	identified	by	countries themselves in the next section. High coverage was attained in 43% of experiences that implemented an out-of-school strategy compared to 40% of those that did not. However, this must be interpreted with caution given the reported low accuracy of coverage estimates for out-of-school girls. Some interviewees indicated that out-of-school girls were excluded from the coverage estimates but this was not always reported. There were low numbers of out-of-school girls and reportedly 
low uptake within this group even if there was a strategy to reach them. Estimates of the target population for out-of-school girls were largely 
unverified.	As	discussed	in	Section	7.1:	Delivery,	the majority of out-of-school strategies simply supplied the vaccine in health facilities, with few additional activities to identify and mobilise out-of-school girls. The data suggest that experiences with no out-of-school component may attain higher rates of completion than experiences with an out-of-school component, perhaps due to the concentration of resources on school mop-up activities; however, the numbers of experiences contributing data are small. The projects/programmes to date have generally been in countries with high primary 
school	enrolment	figures	(Appendix	A).	It	is	
difficult	to	draw	specific	lessons	from	localities	with low school enrolment; one country with experience in areas with low school enrolment is described in Box 8.Only 6 delivery experiences offered another service to the same target group at the same time as HPV vaccine and reported coverage data by Q1 2016. These achieved good coverage in comparison with other experiences that did not simultaneously offer another service alongside HPV vaccination (The group of ‘other experiences’ included 2 experiences that offered mothers cervical cancer screening services at the same time as offering daughters HPV vaccine; one of these experiences attained very good coverage and one experience was missing coverage data (See Section 10: Integration)). However, the differences in uptake and completion rates could be due to chance as the numbers are small. 
Estimates	of	final	dose	coverage	were	available	from 10 of the 21 experiences that implemented a 2-dose schedule (from 10 countries). There was clear evidence 2-dose schedules achieved high coverage.  There were limited data on the duration of time each dose took to deliver, and as stated in Section 7.3.3 it differed by vaccination team within countries. The small amount of data we have suggests three quarters of the strategies taking 2 weeks or more to deliver each dose gained high coverage, compared to 5/9 (just under 60%) of the strategies that concentrated activity on just a few days of an intensive campaign. Data are too limited to draw conclusions at this stage; all 3 strategies that gained very high coverage with an extended schedule over 2 weeks or more had an existing well-established health infrastructure.   
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Table 24. HPV vaccination final-dose coverage by experience, project/programme and country 
characteristics
Characteristic Experiences 
with data¹  
(92 total)
Number (%) experiences2
Final dose coverage 
≥90%
 Final dose coverage 
70-89%
Final dose coverage 
50-69%
All experiences 60 25 (42) 25 (42) 10 (17)
Country income group³
LIC 19 7 (37) 9 (47) 3 (16)
LMIC 28 14 (50) 9 (32) 5 (18)
UMIC 12 4 (33) 6 (50) 2 (17)
HIC 1 0 1 0
Type of project/programme
Demonstration 
project
51 19 (37) 23 (45) 9 (18)
National 9 6 (67) 2 (22) 1 (11)
Type of support for demonstration projects
GAP/Merck4 22 11 (50) 8 (36) 3 (14)
Gavi 12 3 (25) 6 (50) 3 (25)
Other5 17 5 (29) 9 (53) 3 (18)
Delivery strategy6
School-based 20 8 (40) 11 (55) 1 (5)
Health facility +/- 
outreach  
5 2 (40) 1 (20) 2 (40)
School + health 
facility/ outreach 
35 15 (43) 13 (37) 7 (20)
Ownership of programme7
MOH 43 20 (47) 16 (37) 7 (16)
Non-governmental 
partner
16 5 (31) 9 (57) 2 (12)
EPI involvement8
High 49 23 (47) 20 (41) 6 (12)
Moderate 4 0 2 (50) 2 (50)
Minimal-none 5 1 (20) 3 (60) 1 (20)
Education sector involvement9
High 35 13 (37) 16 (46) 6 (17)
Moderate 15 7 (47) 6 (40) 2 (13)
Minimal-none 2 0 1 (25) 1 (25)
Out-of-school strategy10
Implemented 40 17 (43) 14 (35) 9 (23)
Not implemented 20 8 (40) 11 (55) 1 (5)
Delivery with other interventions
Concurrent delivery11 6 4 (67) 0 2 (33)
None 46 17 (37) 23 (50) 6 (13)
Dose schedule
2-dose 10 3 (30) 6 (60) 1 (10)
3-dose 50 22 (44) 21 (42) 9 (18)
Days spent on dose delivery 
1-6 9 5 (56) 3 (33) 1 (11)
7-13 6 1 (17) 2 (33) 3 (50)
14-28 4 3 (75) 1 (25) 0
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Table 25. HPV vaccination uptake and completion rates by experience, project/programme and country 
characteristics
Characteristic Experiences 
with data¹  
(n=92)
Number (%) Experiences 
with data
Number (%)
Dose 1 
uptake  
>90% 
Dose 1 
uptake 
70-89%
Dose 1 
uptake  
50-69%
Completion 
>90%
Completion 
70-89%
All experiences 56 31 (55) 23 (41) 2 (4) 54 31 (57) 23 (43)
Country income group2
LIC 18 10 (56) 7 (39) 1 (6) 17 8 (47) 9 (53)
LMIC 25 14 (56) 11 (44) 0 26 15 (58) 11 (42)
UMIC 12 7 (58) 4 (33) 1 (8) 11 8 (73) 3 (27)
HIC 1 0 1 0 0
Type of programme
Demonstration 
project
47 26 (56) 19 (40) 2 (4) 48 26 (54) 22 (46)
National 9 5 (56) 4 (44) 0 6 5 (83) 1 (17)
Delivery strategy 
School-based 18 9 (50) 7 (39) 2 (11) 19 13 (68) 6 (32)
Health facility +/- 
outreach  
5 3 (60) 2 (40) 0 5 1 (20) 4 (80)
School + health 
facility/outreach 
33 19 (58) 14 (42) 0 30 17 (57) 13 (43)
Ownership of programme
MOH 41 24 (59) 16 (39) 1 (2) 36 23 (64) 13 (36)
Non-governmental 
partner
14 7 (50) 5 (36) 2 (14) 17 8 (47) 9 (53)
EPI involvement 
High 43 26 (60) 17 (40) 0 42 28 (67) 14 (33)
Moderate 5 1 (20) 2 (40) 2 (40) 4 0 4 (100)
Minimal-none 6 3 (50) 3 (50) 0 5 2 (40) 3 (60)
Education sector involvement
High 31 17 (55) 14 (45) 0 29 18 (62) 11 (38)
Moderate 15 8 (53) 5 (33) 2 (14) 13 9 (69) 6 (46)
Minimal-none 3 2 (66) 1 (33) 0 2 0 2 (100)
Out-of-school strategy
Implemented 37 22 (59) 15 (41) 0 35 18 (51) 17 (49)
Not implemented 18 9 (50) 7 (39) 2 (11) 19 13 (68) 6 (32)
Delivery with other interventions
Concurrent delivery3 7 4 (57) 3 (43) 0 6 3 (50) 3 (50)
None 44 24 (54) 18 (41) 2 (5) 40 25 (63) 15 (37)
Dose schedule
2-dose 13 8 (62) 5 (38) 0 4 2 (50) 2 (50)
3-dose 43 23 (53) 18 (42) 2 (5) 50 29 (57) 21 (43)
1Excludes projects/programmes that started in 2016 or later
2World Bank definition
3This includes experiences that delivered a service at the same time as HPV vaccine (to any age group).
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Table 26. HPV vaccination dropout rates by experience, project/programme and country characteristics
Characteristic Experiences 
with data¹  
Number (%)
Dropout  
<5%
Dropout 
6-10%
Dropout   
11-20%
Dropout   
21-30%
All experiences 54 22 (41) 9 (17) 18 (33) 5 (9)
Country income group2
LIC 17 5 (29) 3 (18) 6 (35) 3 (18)
LMIC 26 12 (46) 3 (12) 10 (38) 1 (4)
UMIC 11 5 (45) 3 (27) 2 (18) 1 (9)
HIC 0
Type of programme
Demonstration project 48 17 (35) 9 (19) 18 (33) 5 (9)
National 6 5 (83) 0 1 (17) 0
Delivery strategy 
School-based 19 10 (53) 3 (16) 4 (21) 2 (11)
Health facility +/- outreach  5 1 (20) 0 4 (80) 0
School + health facility/ outreach 30 11 (37) 6 (20) 10 (33) 3 (10)
Ownership of programme
MOH 36 17 (47) 6 (17) 10 (28) 3 (8)
Non-governmental partner 17 5 (29) 3 (18) 7 (41) 2 (12)
EPI involvement 
High 42 20 (48) 8 (19) 11 (26) 3 (7)
Moderate 4 0 0 3 (75) 1 (25)
Minimal-none 5 1 (20) 1 (20) 2 (40) 1 (20)
Education sector involvement
High 29 10 (34) 8 (28) 9 (31) 2 (7)
Moderate 15 8 (53) 1 (7) 3 (20) 3 (20)
Minimal-none 2 0 0 2 (100) 0
Out-of-school strategy
Implemented 35 12 (34) 6 (17) 14 (40) 3 (9)
Not implemented 19 10 (53) 3 (16) 4 (21) 2 (11)
Delivery with other interventions
Concurrent delivery3 6 3 (50) 0 3 (50) 0
None 40 16 (40) 9 (23) 12 (30) 3 (7.5)
Dose schedule
2-dose 4 2 (50) 0 2 (0) 0
3-dose 50 20 (40) 9 (18) 16 (32) 5 (10)
1Excludes projects/programmes that started in 2016 or later
2World Bank definition
3This includes experiences that delivered a service at the same time as HPV vaccine (to any age group).
Lessons learnt from human papillomavirus (HPV) vaccine demonstration projects 85
8.1.5 Trends in coverage over time Among the seven countries with over a year’s experience and data on coverage in the same target group over time, four had increasing coverage. They mentioned that this occurred simultaneously to increasing EPI involvement (Country 3), better organisation of social mobilisation and increasing familiarity with the vaccine in the community over time (Country 16, Countries 23 and 36). One country implementing a national programme increased its focus on outreach for out-of-school girls over the years, although it is uncertain whether this resulted in an increase in coverage as school enrolment was high across the country and 
HPV	vaccine	coverage	maintained	at	≥90%	(Country 28). One country had a small decrease in coverage due to changes in coordinating staff 
and	collaboration	difficulties	between	the	MOH	and MOE (Country 2). One country’s national programme had oscillating coverage estimates as different delivery strategies were piloted. Within this country the school-based strategy achieved the most reliable high coverage compared to a health facility-based strategy (Country 1). 
8.1.6 Reported lessons learnt in 
attaining good coverage A wide range of factors were reported in the literature and interviews in relation to their effect on HPV vaccine coverage. Statements and recommendations have been summarised in Tables 26a, 26b and 26c. 
• Good coordination between the MOH 
and the MOE at an early stage was the most frequently mentioned factor governing whether high coverage was achieved across the 37 countries. This agrees with the analysis of the correlates of coverage in Table 24 where countries with high MOE and EPI involvement seem to be more likely to attain high coverage compared to those with low EPI and MOE involvement. The next most frequently mentioned ‘lessons’ were the need to respond rapidly to rumours and 
negative	media	exposure	and	the	difficulty	in estimating target population using census projections.
• School-based delivery appeared to appeared to attain high coverage and this 
was	specifically	stated	as	a	lesson	in	4	countries, although one country stated there was no difference in coverage in districts 
implementing school based and those implementing health facility based delivery.  Three experiences reported that drop out between doses was higher if the vaccination was not conducted on the scheduled date(s). Often this occurred if a programme experienced delays in disbursement of funds for mobilisation activities or training, or 
had	difficulties	with	customs	and	transport	of the vaccine to sites. However, consistent availability of the vaccine at facilities helped to ensure more girls were vaccinated even if they were absent from school on the vaccination days.
• Enumeration of the target population was a challenge especially in urban centres (reported by 9 countries). Management of registration lists of eligible girls was mentioned as a key factor in gaining good coverage (Section 7.2: Enumerating vaccine needs).
• Calculating coverage was found to be 
difficult	if	different	eligibility	criteria	were	applied to in school and out-of-school girls (two countries). If a grade based delivery approach was completed in school, age data would also need to be collected in order to assess coverage by age. Grades often spanned multiple age ranges and use of census data for 9-13 year olds to calculate coverage could result in an overestimation 
of	coverage.	It	was	very	difficult	to	calculate	coverage in out-of-school girls without an accurate target population or if eligibility criteria were unclear. The planning of monitoring and evaluation systems should take this into account and record age on all forms.
• Resistance from health care workers could have affected the coverage achieved in certain areas, despite these areas being accessible (not remote rural areas) (two countries). These countries recommended that the medical community should not be ignored during social mobilisation and needs some special attention as they can harbour reservations about new vaccines which hinder coverage (until HPV vaccine becomes routine). 
• Various strategies were mentioned by 
projects/programmes with the aim of 
increasing completion (other than mop-up strategies detailed in Section 7.1.6; Box 9)
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Box 9: Strategies to increase completion
Country 3: >90% completion
• Registration of all schoolgirls and out-of-school girls for vaccination and the use of an attendance register to check dose receipt.
• The close involvement of headmasters and teachers in the process of registration and monitoring coverage of each girl
• Reminders	to	girls	about	return	dates	for	the	next	doses,	at	the	delivery	of	the	first	dose,	in	church announcements and within vaccination cards.
Country 8: 81% completion
• Vaccinators spent time explaining the importance of completion and it was included in mobilisation messages.
Country 11: 98% completion 
• Names, addresses, phone numbers of girls/parents were listed to facilitate follow up for the second and third dose if absent on the vaccination day.
Country 35: 95% completion
• Wristbands with the reminder “Don’t forget to come back for your next shot” in local language and SMS reminders (uncertain effect on completion as rates did not differ in areas with and without the incentive).
Table 27: Reported correlates of coverage from delivery experiences with high coverage
The top 10 reported correlates for high coverage from delivery experiences with >90% coverage Number 
of delivery 
experiences
1 Coordination between MOH and MOE early in the planning process was essential.
This was particularly important to ensure that: • the planned timing of the vaccination accounted for school closing, holidays, exams, 
religious festivals, seasons; • there was good communication and engagement of actors at the provincial and ground 
levels; • teachers and health workers mobilised for the delivery of each dose efficiently with 
optimal use of resources.
A review meeting after the implementation of each round contributed to improved 
coordination between health and education officials. Involvement of district heads in health 
and education in the review meetings strengthen their understanding of their roles in social 
mobilisation and supervision of HPV vaccination resulting in fewer refusals at schools.
Strong political commitment was instrumental to programme success - national level 
stakeholders need to be engaged as early as possible. Endorsement of the programme by 
national, provincial and district officials can increase acceptance at every level of society.
8
2 For school-based immunization in areas with variable age at enrolment to primary school 
(and therefore a wide range of ages within each grade), eligibility criteria based on age were 
often logistically more difficult to implement than class/ grade based immunisation as it 
involved visiting multiple grades within the school.  The relevant grades to vaccinate may be 
lower grades in rural areas where girls start school later in comparison to urban areas.
5
3 In mixed delivery models (school & health facility), presentation of out-of-school girls at 
health facilities for vaccination was rare; specific mobilisation was needed to encourage girls 
to present for vaccination at health facilities or outreach activities were used.
5
4 Negative media exposure could have affected coverage; preparations were made before 
vaccination day to address rumours and potential anti-vaccine lobbyists. Rumours, often 
centred on fertility fears, were tackled when they first arose to prevent them gaining a 
following, strategies to address rumours included: tailored communication messages, 
announcements by high level officials, dissemination of letters detailing WHO or government 
endorsement for the vaccine, one to one or group meetings with the community.
4
5 Strong community commitment in identifying, sensitising and following up girls increased 
vaccination uptake rates. Engagement of community health workers increased community 
acceptance, increased coverage, aided identification of out-of-school girls and girls who 
missed doses.
3
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6 Adherence to the scheduled dates of vaccination minimized drop out between doses. 
Transport of vaccines and personnel to vaccination sites was well planned and timely.
3
7 School-based delivery gave better coverage than a routine Health facility delivery model. 
Long walking distances to clinics in rural areas is a challenge.
3
8 Rural areas attained higher coverage than urban areas. Urban parents and those with 
daughters in private schools required a larger amount of information for acceptance than 
those in rural regions. Coverage in private schools was increased with proof of government 
endorsement for the vaccine.
3
9 Complete vaccine schedule in one school calendar year to enable good completion rates. 2
10 General knowledge about cervical cancer was low in the community; good social 
mobilisation was key to gaining good coverage. “Credible influencers” of community 
opinion, health workers and/or teachers were used to communicate messages about 
the vaccination programme.  Teachers and local community and religious leaders were 
specifically trained to mobilise girls in their communities with accurate messages about the 
HPV vaccine programme.
2
Table 28: Top 10 reported lessons learnt in delivery experiences with average coverage
Top 10 lessons learnt from delivery experiences which attained average coverage (>70%,<90%) Number 
of delivery 
experiences
1 Negative media exposure affected coverage; strategies to address rumours and anti-vaccine 
groups were not always in place before vaccination day. 
Rumours were not always tackled when they first arose, leading them to gain ground in the 
media and within the community. 
Negative media exposure from a neighbouring geopolitical region affected acceptance 
in one country, despite few rumours nationally. Policy makers should be aware this could 
happen and plan a response accordingly.
3
2 If the vaccination days occur outside the school calendar, girls had to be invited back 
to school or door to door follow up was required to complete the three doses, this was 
resource intensive. Moving away/migration during school breaks or between school years 
contributed to low completion. All vaccine doses should be delivered in the same school 
calendar year to achieve good completion.
3
3 Good social mobilisation was key to gaining good coverage. “Credible influencers” of 
community opinion, teachers and/or community leaders, were trained sufficiently in social 
mobilisation and HPV vaccine at least 1 month in advance.
3
4 Engagement of community health workers increased community acceptance, increased 
coverage, helped to identify out-of-school girls or girls who had missed doses.  
3
5 Making doses available after the main vaccination day at the health centre or at schools 
(mop-up doses) increased coverage and was a good alternative to active follow up and 
tracing of individuals who missed the dose if resources are limited. 
3
6 MOE involvement in vaccine delivery led to good uptake and completion of the series. 
A review meeting after the implementation of each round contributed to improved 
coordination between health and education officials. Involvement of district heads in health 
and education in the review meetings strengthen their understanding of their roles in social 
mobilisation and supervision of HPV vaccination and resulted in fewer refusals at schools.
2
7 Rural areas can attain higher coverage than urban areas. Urban parents required a larger 
amount of information for acceptance than those in rural and mountainous regions. 
It was more difficult to attain good coverage in private schools in comparison to 
government schools due to internal decision-making processes. Private schools required 
more time and social mobilisation than government schools. Coverage in private schools can 
be increased with proof of government endorsement for the vaccine.
2
8 For school-based immunization in areas with variable age at enrolment to primary school 
(and therefore a wide range of ages within each grade), eligibility criteria based on age 
was logistically more difficult than class based immunisation as it involved visiting multiple 
grades within the school. Grade based vaccination maybe easier to implement and conduct 
follow up doses. The relevant grades to vaccinate to get good coverage were lower grades in 
rural areas where girls started school later in comparison to urban areas. 
1
9 Endorsement of the programme by national, provincial and district officials increased 
acceptance at every level of society. 
1
10 School-based delivery gave better coverage than a routine health facility delivery model. 
However; if school enrolment is very low, especially in the rural areas, community/ health 
facility-based projects/programmes should be prioritised as the HPV vaccine delivery 
approach.
1
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Table 29: Top 5 reported pitfalls to avoid from countries with low coverage
The top 5 reported pitfalls to avoid 
Reported from countries with <70% coverage (8 delivery experiences)1
1 The power of negative media exposure was under-estimated. Countries were not prepared before 
vaccination day to address rumours and anti-vaccine lobbyists which meant that rumours, were not tackled 
when they first arose and gained a lot of media exposure leading to low coverage. 
2 Poor coordination between the MOH and MOE and delays in the planning processes led to vaccination 
schedules falling on days which were outside the school calendar (school holidays), exams, festivals; this led 
to low completion as girls moved away or were too busy to receive the final dose. Some schools were not 
notified by the MOE which led to some schools refusing to allow vaccinators entry to vaccinate girls. Teachers 
did not know enough detail about the programme to mobilise girls or address parents’ questions. Teachers 
were not engaged in the programme to help to follow up girls who missed doses.  
3 High level political commitment was not in place leading to delays in vaccine importation and fund 
disbursement. This led to delayed preparations e.g. printing of training materials and IEC materials, leading to 
poor social mobilisation and rushed vaccine delivery. 
4 Miscommunication and alienation of community leaders reversed efforts in social mobilisation and caused 
some community leaders to advise against vaccination. Community leaders and teachers were not trained 
or educated about the programme contributing to high refusal rates by parents and girls. Training of national 
stakeholders (e.g. religious leaders) did not necessarily cascade down to local level.
5 Private schools were not engaged early enough in social mobilisation activities. Private schools required 
more information and time to communicate with parents than government schools.
1Each lesson was reported by 2 delivery experiences that attained 50-69% coverage.
8.1.7 Key lessons learnt and 
conclusions  In relation to coverage achievements, key lessons included:
• High HPV vaccine coverage is feasible in L&MICs
• It	is	difficult	to	obtain	meaningful	data	on	vaccine coverage without a well-designed coverage survey. 
• Limitations in administrative data need to be realised by national and international agencies.
• Delivery strategies including a school-based component are likely to achieve high 
uptake,	completion	and	final	dose	coverage,	due to the relative ease of capturing a large number of girls in one place, gaining consent if required and following up girls. However, these strategies are resource intensive. Data on health facility only strategies is limited and the coverage achievements to date have been highly variable.
• Urban areas may be more exposed to negative media, contain more mobile populations and be harder to enumerate than rural areas; it may be harder to achieve high coverage in urban centres for these reasons. 
• High-level political commitment and the involvement of the EPI team or national immunisation programme and the MOE early in the planning process is critical to obtain good coverage. 
• Early collaboration between EPI and education representatives at lower levels 
(provincial, regional or district) can ensure 
efficient	microplanning,	i.e.	the	vaccine	
schedule	is	planned	to	fit	into	the	school	calendar, can aid in enumerating school-based target populations, can coordinate an effective response to vaccine rumours within the community and can help to follow up girls who missed doses – all of these functions can help to ensure high coverage. 
They	can	also	more	efficiently	identify	potentially problematic groups within the target communities e.g. private schools or vocal anti-vaccination groups. 
• EPI/national immunisation team involvement can ensure timely vaccine delivery which is important to maintain interest in vaccination in the community and to reduce drop-out.
• Specific	strategies	are	needed	to	identify	and	mobilise out-of-school girls; the absence of 
specific	strategies	can	result	in	low	uptake	if the vaccine is simply made available at the health centre. 
• We cannot yet draw conclusions on the effect of the change to a 2-dose schedule on completion and coverage rates.
• The 2-dose schedule achieved high coverage, uptake and completion and was reportedly easier and cheaper to implement when compared to the 3-dose schedule. Only one country attempted a 12 month interval between the 2 doses, rather than 6 months, and stated an annual campaign was easier to implement. 
• Delivery of HPV vaccine simultaneously with another intervention to the same target 
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group did not seem to affect HPV vaccine coverage rates. However, few countries attempted to deliver other services with HPV vaccine. Coverage data from experiences which tested delivery of other interventions were only available for 6 countries. 
8.1.8  Key recommendations In relation to coverage achievements we recommend: 
• Strategies including a school-based component achieve high coverage. If school enrolment is low, a mixture of strategies could be important in order to attain good coverage. There is limited data on how to deliver a health facility based strategy successfully.   
• The grade based eligibility criteria in a school programme is the easiest and quickest strategy to implement; however, we recommend taking into account country 
specific	factors	of	acceptability	to	the	target	group and school enrolment statistics. Grade based eligibility criteria can make target population enumeration and coverage calculations challenging; these processes are easier when eligibility criteria are the same for in-school and out-of-school girls. 
• If countries decide to change delivery strategy, the effects on coverage should be carefully monitored and evaluated. 
• Good relationships between the MOH and MOE should be developed. Coordination should begin at an early stage of the planning process, and collaboration should continue during implementation in the districts to ensure the vaccine delivery is planned and carried out within school timetables, 
efficiently,	and	achieves	high	coverage.		
• Planning	should	allow	sufficient	time	for	fund disbursement, customs clearance and preparation activities including planning transport requirements to ensure that scheduled vaccination dates are adhered to and that all vaccine doses are delivered in the same school year. 
• Encourage high-level political commitment to the programme in order to reduce bureaucratic hurdles, to secure ring-fenced funding and ensure timely delivery of the vaccine. 
• Engage the community and community health workers in order to increase acceptance and uptake of the vaccine and aid 
identification	of	out-of-school	girls	or	girls	missing doses. 
• More intense social mobilisation (e.g. more information and over a longer period) should 
be planned for urban areas and private schools as these groups are potentially more exposed to negative media exposure and rumours and more likely to refuse vaccination.
• Out-of-school	girls	should	be	specifically	targeted with social mobilisation messages and provided with an opportunity to access the vaccine either at schools, during vaccination days, health facilities or outreach sessions. 
• An opportunity for girls who missed doses to receive the vaccine should be supplied, either at return visits to schools or referral to health facility or outreach sites, depending on the resources available.  
• Staff may need retraining or refresher training in the use of data collection forms in order to ensure adequate quality administrative data. 
• Different strategies and target populations and integration with other services should be tested in order to gain experience for later implementation.  
8.2 Monitoring and evaluation
8.2.1 Data collection and reporting Data on reporting were available from 42 experiences in 30 countries. HPV demonstration projects were frequently organised so that reporting followed the system used in campaigns (e.g. daily reporting) and could not be tallied with routine reporting structures and timelines. Particular challenges were associated with the complexity of HPV vaccine reporting, including how to trace girls for doses 
2	and	3,	insufficient	space	within	reporting	tools to write girls names, confusion about who should keep vaccination cards between doses, and grade-based vaccination approaches that still needed to report nationally by age. The reporting requirements placed heavy and often confusing burdens on vaccinators, compared with other vaccinations. In some cases there were separate HPV vaccination cards and reporting tools; separate databases were developed in 4 countries. Data reporting tended to be separate from routine EPI reporting, especially during initial phases of demonstration projects. Countries with more experience noted that they planned to gradually integrate HPV data collection into routine reporting processes. For example, two countries that had scaled-up nationally now capture HPV data in the Health Management Information System (HMIS) system and HPV 
vaccine	specific	tools	have	been	incorporated	
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so that each month every health facility reports how many doses have been delivered (Countries 3, 33).Minimal discussion of monitoring and evaluation (M&E) was found, primarily because it seemed to be assumed that countries had some functional means of monitoring implementation. Gavi-supported countries adapted EPI monitoring forms and reporting while several other countries developed new forms and procedures. Sometimes monitoring tools were provided by international partners. All who answered indicated HPV monitoring was more intensive for the demonstration period than would be anticipated for routine immunisation. Data collection at implementation sites was recorded on forms or in register books daily and generally entered into a database at district level for electronic transmission to national level. 
8.2.2 Quality assessment and 
supervision Data quality-checking and supervision were rarely mentioned, except to indicate they had been done. However, a few countries conducted evaluation research to determine programme quality and effectiveness, sometimes implemented by international partners. One concern noted in a few countries was whether schools, girls or health facilities should keep vaccination cards, particularly for girls who switched schools. One programme addressed this by having schools keep cards until all three doses were completed and then returning them to girls. Another programme was advised by the regional EPI team to ask the health facility serving the schools to keep vaccination cards and to issue a second card to girls when they completed the vaccine course (Country 31).
8.2.3 Integration with EPI systemsDiscussions on integration of HPV vaccination reporting with EPI reporting systems indicated that countries expected to integrate it within EPI systems, though this was noted as challenging by some countries due to differences between HPV vaccination and routine EPI vaccines in terms of age of the target 
group,	gender	specificity	of	the	HPV	vaccine	and	different vaccination schedules. One country noted that, while standard HMIS tools were 
not	used,	existing	EPI	forms	were	modified	and	approved by the MOH for use with HPV vaccine (Country 10). Another country questioned the effectiveness of HMIS standard tools (Country 22).
8.2.4 Key lessons learnt and 
conclusions  In relation to monitoring and evaluation, key lessons included: 
• Use of electronic monitoring and reporting systems appeared to reduce errors and, 
in	some	cases,	simplified	the	process	of data recording. For example, at least two countries created a database of girls to be vaccinated in advance so that all forms already had names on them, thus simplifying and speeding data recording (Country 30, 31). Other projects noted 
logistical	difficulties	with	paper	forms	(e.g.	
insufficient	space	on	forms,	difficulty	in	following-up girls who missed vaccinations).
• Vaccinating girls by school grade may have been easier logistically, but had implications for reporting and follow-up if the HMIS was organised by age. If one form per class or school was used, all vaccines - even if given on different dates - were entered on the 
same	form	making	it	difficult	to	document	vaccination of all three doses per individual and complicating registration in summary forms if mistakes were made. 
• Early and thorough training of health-workers in correct and timely recording, reporting, and monitoring procedures was not always given enough attention, which 
caused	later	difficulties	in	timeliness	and	accuracy of reporting.
• More discussion appears warranted on who should hold vaccination cards (e.g. whether this should be health-workers, schools, or girls).
• Reporting workload was not often mentioned, despite the probability that it may have been an issue in some countries.
8.2.5 Key recommendations 
Based	on	findings	related	to	monitoring	and	evaluation, we recommend:
• HPV demonstration projects must include discussion and agreement with EPI personnel at the planning phase about how HPV vaccination will be integrated within EPI structures.
• Monitoring and reporting systems should be standardised, so that issues such as who is responsible for holding vaccination cards can be agreed. Where feasible, electronic systems should be used to improve data collection and tracking.
• Reporting should be consistent with target group selection, i.e. if vaccinating girls by school grade, reporting should also be by school grade and by age if necessary.
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9. Sustainability
9.1 Financing and costs
9.1.1 Financing of demonstration 
projectsFinancial sources of the 66 demonstration projects undertaken in 44 different countries are summarised in Table 30 (2 countries did not complete a demonstration projects and went straight to national implementation).
The	GAP	financed	the	vaccine	in	30	(45%)	of	the projects. The GAP provided free vaccine but a wide range of organisations and ministries of health implementing the demonstration projects were responsible for procuring injection supplies, paying customs duties for the 
vaccine	and	for	financing	all	delivery	costs	e.g.	Partners in Health (Haiti), ACCF (Kiribati and Nepal), Moi University (Kenya), MOH (Georgia, Moldova, Mongolia) [18, 19]. Gavi funded 20 (30%) of the demonstration projects included in this study. Gavi covered the entire cost of vaccines and injection equipment until port of entry. In addition, countries could 
receive	funding	to	partially	finance	delivery	costs for two years. The amount given depended on the size of the targeted population. For the 
first	year	of	the	Gavi	projects,	Gavi	offered	US$ 4.80 per girl, or US$ 50,000, whichever amount was greater. During the second year of 
implementation,	Gavi	financed	US$	2.40	per	girl,	
or US$ 25,000, whichever amount was greater. 
Funding	was	greater	in	the	first	year	to	account	for start-up costs, such as training and social mobilization. In addition, projects could apply for a maximum of US$ 95,000 for evaluation and strategy development, and a maximum of US$ 25,000 for implementation of joint delivery of HPV vaccine with another adolescent health intervention. PATH co-ordinated four of the non-Gavi non-GAP supported demonstration projects in four countries; each country tested 2 different delivery strategies. Merck & Co. or GSK donated the vaccine to PATH and PATH received funding from the Bill and Melinda Gates Foundation to implement the projects. Project implementation costs were paid according to budgets negotiated with governments in the four countries. The Australian Cervical Cancer Foundation (ACCF) funded three demonstration projects during 2008-2014. Jhpiego, an international, 
non-profit	health	organisation	affiliated	with	the Johns Hopkins University, implemented two projects with funding from the Cancer Institute Foundation in the Philippines. Merck & Co. and GSK funded two projects directly in South Africa through the University of Stellenbosch and Uganda through the MOH. Five different organisations funded one project each in their respective countries (Table 30)
Table 30: Financing of HPV demonstration projects 2007-2016
Name of funder1 Number of demonstration 
projects
GARDASIL® Access Program (GAP) 30
Gavi 20
PATH 4
Australian Cervical Cancer Foundation (ACCF) 3
Merck & Co. (Uganda); GSK/ University of Stellenbosch (South Africa) 2
Cancer Institute Foundation/Jhpiego (Philippines and Thailand) 2
World Bank, National AIDS Programme, Botswana 1
MOH, Botswana 1
University of Cape Town, South Africa 1
KwaZulu Natal Provincial Department of Health, South Africa 1
Municipal immunization programme, Brazil 1
Partners in Health, Haiti 1
Total 66
1 Many projects were in fact funded through a variety of sources; however, these listed organisations formed the primary point of contact for the project or programme. These 
organisations had varying roles in implementation. E.g. Four projects were implemented by EPI but primarily supported by PATH who were funded by the Bill & Melinda Gates 
Foundation and obtained vaccine as a donation from either GSK or Merck & Co. 
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Table 31: Financing sources of national HPV programmes
Country Year of national introduction Primary funding source
Bhutan 2010 ACCF (2010-15), Merck & Co. (2015-)
Botswana 2015 Government
Brazil 2014 Government
Chile 2014 Government
Guyana 2014 Government
Honduras 2016 Government
Lesotho 2012 Government
Peru 2013 Government
Rwanda 2011 Merck & Co. (2011-13), Gavi (2014-)
South Africa 2014 Government
Uganda 2015 Gavi
Uzbekistan 2016 (planned) Gavi
Vanuatu 2013 ACCF
9.1.2 Financing of national HPV  
vaccine programmesTwelve national HPV programmes were included in the analysis and had completed at least 6 months of implementation by 1st May 2016. We received data on a further 1 national programme planned to start in 2016 or later. Funding for these 13 programmes are listed in Table 31. The national government is funding national implementation in seven middle-income countries; Botswana, Brazil, Chile, Guyana, Lesotho, Peru and South Africa. 
9.1.3 Key lessons learnt and 
conclusions  Our data showed that several projects found it challenging to secure funds for implementation. The largest proportion of delivery costs was reported to be transportation and per diem costs for health workers and supervisors to travel to schools; in many demonstration projects this was done for both enumeration activities e.g. to register eligible girls, as well as vaccine delivery. Despite Gavi contributing funding towards operational costs of the demonstration projects, several countries had extinguished funding after one year of the project and had to look for additional funding for the second year of delivery. They argued that mobilisation costs, transport and staff costs (including costs related to enumeration of girls) had been higher than anticipated (Countries 22, 24, 29, I). 
Several	countries	found	it	difficult	to	finance	these operational expenses, which were regarded as the main barrier to scaling up to a 
national	programme.	Reported	financing	issues	are summarised in Table 32. 
Of note, one country (country D) stated that they had declined additional support from partners other than Gavi as they did not wanted to implement an expensive programme and thus not have a chance of achieving sustainability.
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Table 32: Examples of financing issues reported
Topic Financing issue
High delivery 
costs
Although the vaccines may be donated, the start-up costs are perceived prohibitive for countries 
to manage.
School based + facility based + outreach proved too costly and unsustainable. Campaign mode 
requires more financial resources. Costs to pay staff meals and lodging could make delivery costs 
very high.
Although vaccines are offered free of charge, custom clearance may be required. Furthermore, 
administrative charges, especially where NGOs are involved, are still high.
Because of logistical difficulties, costs tended to be higher in rural than urban areas. The delivery 
costs through on-going outreaches was much lower.
Costs vary a lot with transport costs. Once it is integrated into the school health system and if 
it is delivered with other vaccines in school, there are no increased costs for implementation. 
“Additional costs are in remote locations - that is where it is difficult to sustain.”
Delivery is too expensive, mainly because cars were needed plus allow-ances for nurses.
Enumeration costs are high, notably where house to house enumeration is carried out
There was inadequate funding for implementation of activities, such as budget for training of 
teachers and waste management. There was a shortfall to implement the second and third dose 
in some districts. There were no funds to print monitoring tools, tally sheets and registers for the 
second co-hort.
Financing 
challenges
Because of Ministerial changes, the financial commitment to procure syringes was not honoured.
Routine budgeting for transportation (car hire) and personnel to travel to schools is difficult to 
sustain.
Funds were not transferred in time
The initial budget was under estimated leading to disruption of some activities especially social 
mobilisation activities.
General 
financing 
comments
Additional resources should be included to sensitize teachers.
Local resource mobilisation is key to bridge the funding gap.
Advocate for allowing the reallocation of certain budget lines to better reflect certain realities  
(allocation of more resources for the enumeration), given that the project is in the demonstration 
phase.
When designing HPV vaccine demonstration projects, country governments and partners should 
consider including different delivery models that vary in the resources required to implement 
them. For example, demonstration projects could test whether a lower-cost option of integrating 
HPV vaccination as part of the routine EPI delivery system is effective.
The vaccine co-financing is not a problem – it is easy for the government to commit to financing 
the vaccine. But routine operation costs are difficult to fund. We need to develop a routine 
programme of visits to schools so that we don’t need to pay lunch allowances and per diems 
for supervisors. It is difficult as Gavi finances some operational cost during the demonstration 
project, but then expect the government to take these on when scaling up to national - it is a big 
jump.
9.1.4 Future plans for financing HPV 
vaccineComments and opinions about future funding for HPV vaccine were available from 28 countries. Only eight countries had 
certainty	about	future	financing	and	tended	to be the countries that had already scaled up nationally and fully integrated the HPV vaccine into their EPI or national school health programmes.  In the remaining 20 countries, there was considerable uncertainty about 
future	financing,	in	particular	with	regard	to	introducing the vaccine nationally. “Affordability will be the main focus (in future decisions around HPV vaccine delivery) as it is possible that some vaccines will have to be dropped from 
the schedule when the country graduates from Gavi”
KI Country 8 after 2 years of HPV vaccine 
experience. Two approaches were reported to facilitate HPV vaccine introduction; seek additional donor funding and/or lobby national government (n=17), and change the vaccine delivery strategy to reduce costs (n=3). Several of the countries 
suggested	specific	strategies	(tobacco	tax,	
lobbying	of	parliamentarians,	a	specific	budget	line for vaccines in the national budget) to increase government funding not only for HPV 
vaccine	financing	but	to	sustain	EPI	financing	more generally.  One country noted that they were planning to domestically produce HPV vaccine to reduce costs. At least 3 countries 
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expressed considerable concerns as to how to 
finance	a	national	programme	such	that	it	may	not be done.
9.1.5 Evidence on costs per dose 
deliveredThe costs of HPV vaccine delivery in demonstration projects have been published in two papers. In a 2012 paper by Quentin et al. [52], the costs of HPV vaccine delivery were estimated for two different school strategies; one targeted a certain age and another 
vaccinated	a	specific	school	grade.	Levin	et	al.[37] reported the costs of HPV vaccine delivery in PATH demonstration projects in Peru, Uganda and Vietnam. Another paper reviewed evidence of HPV vaccine delivery costs [38].In addition to the above studies, costs estimates from the PATH demonstration projects in India were included in this study. However, as the objective of this analysis was to provide evidence to support the Gavi introduction 
grants,	only	recurrent,	financial	costs	were	reported. A paper by Ladner et al. reported 
financial	cost	per	dose	and	full	girl	vaccinated	for 7 of the original GAP funded demonstration project[18, 28]. Finally, we collected costing studies of 5 Gavi demonstration projects.Some of the published cost estimates are summarized in Table 33. These estimates exclude the vaccine costs. The difference 
between	economic	and	financial	costs	is	that	opportunity costs, such as staff salaries, are 
included as economic costs. Financial costs are only the expenses that need to be budgeted for in a new budget, such as per diems. 
Table 33: Published evidence of the costs per dose 
of the costs per dose of HPV vaccine delivery
Country Delivery 
strategy
Financial 
delivery 
costs per 
dose (US$)
Economic 
delivery 
costs per 
dose (US$)
Tanzania Grade-
based 
3.09
Peru School 2.03 3.88
Uganda School 2.10 3.15
Uganda Integrated 
outreach
1.11 1.44
Vietnam School 1.62 2.08
Vietnam Health 
centre
1.55 1.92
There was some consistency across the early 
pilot	programmes	with	financial	cost	per	dose	generally around $2 per dose (Table 33). A further 7 GAP projects reported a mean cost per dose of $2.74 (range 1.35-2.34)[18, 28]. 
However,	financial	costs	tended	to	be	higher	in the 5 Gavi demonstration projects that 
provided	data	(Table	34).	All	five	estimates	of	the cost of delivery from Gavi countries were in experiences predominantly using a school delivery model with some vaccine available in health facilities and during community outreach (although this was reported to be utilised 
variably).	Reporting	financial	cost	of	delivery	per dose ranged from $6.04, $6.90, $6.42 and $9.21 to $3.1.
Table 34: Financial costs of delivery in five Gavi-supported demonstration project costing reports 
Cost category
(% of financial costs)
Country 6 Country E Country 22 Country 17 Country F
Start-up 37% 21% 23% 74% 71%
Microplanning 2% 5% 46% 12% 19%
Training (cascade) 58% 18% 22% 12% 38%
Social Mobilisation 40% 77% 32% 76% 43%
Sub-total 100% 100% 100% 100% 100%
Recurrent costs 63% 79% 77% 26% 29%
Vaccine and injection materials 13% 34% 33% 25%
Service delivery (e.g. staff per diems 
and transport)
57% 71% 23% 24% 18%
Supervision and evaluation 17% 5% 42% 41% 47%
Other (e.g. waste management) 13% 24%* 1% 2% 10%
Sub-total 100% 100% 100% 100% 100%
Cost per dose delivered (USD) 3.1 9.2 6.02 6.9 6.42
Final dose coverage 69% 73% 66% 62% NA
Table does not include investment costs e.g. cold chain equipment; NA: not available; 
all USD estimates were made in 2015.  
*’Other’ included evaluation for this costing report.
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Non-recurrent costs reported for these Gavi demonstration projects varied form 
37%	to	74%	of	total	financial	costs	for	the	demonstration projects. On average, social mobilisation activities were the largest proportion of start-up costs. Service delivery, including per diems to staff and transport costs, was the largest proportion of recurrent costs, followed by supervision costs. These 
findings	are	consistent	with	the	perceived	cost	drivers described in key informant interviews. Implementers additionally mentioned enumeration activities, included here in the microplanning category, as an unexpected and often unbudgeted, expense. The cost of delivery per dose did not necessarily correlate with coverage achievements, which were governed by many other factors. Despite high levels of investment in social mobilisation key informants suggested that this did not always translate into the delivery of communication materials/messages in adequate time prior to vaccination day, and the prevention of rumours. Three costing studies estimated a projection of the possible cost per dose for a national programme and these ranged from 1.99 USD to 2.39 USD. These projections were made using the WHO C4P costing tool, assuming integration into routine EPI systems, with a declining level of investment needed in social mobilisation activities as the programme progresses, but a step increase in the necessary investment in training when preparing to roll-out nationally.  Despite limitations in the way the cost per dose is calculated and the expectation that national scale up would provide economies of scale, these costs were reported to contribute to raising concerns on the affordability of HPV vaccination scale up. 
9.2 Implementation of scale-up 
compared to demonstration 
projects
9.2.1 Factors influencing scale-up 
decisionData from 34 of 44 countries contributed to this section (2 countries went straight to national introduction). Ten of these countries had already scaled-up from demonstration project(s) to national programmes, 11 countries reported not planning to scale-up in the foreseeable future (33%) and 13 countries reported planning to apply to Gavi for a national HPV vaccine introduction grant. Among the 10 countries with experience of scaling up from a demonstration project to national programme, 6 stated the project guided the planning and/or design of the 
national programme (4 LIC/LMIC, 2 UMIC), three stated the demonstration project did not 
influence	the	national	programme	(1	LMIC,	2	UMIC) and one did not provide any information (LMIC). However, among the 6 that stated the demonstration project was useful in planning their national programme, one stated they would have gone straight to national if funding had been available and three reported that although the demonstration projects were important to demonstrate acceptability and encourage political support, they had learnt substantial, far-reaching lessons when rolling out nationally: 
“The	demo	didn’t	influence	[national]	HPV introduction, but it did cause some changes to the routine immunisation system. We would have gone straight to national implementation if it had been possible.” 
KI Country 11.Key informants across the 11 countries not planning to scale up cited the considerable uncertainty around future funding for the vaccine and delivery costs as the predominant/only reason for hesitancy. Four country representatives noted that not, or no longer, qualifying for Gavi support was a major barrier and concerns were not limited to HPV vaccine but included the funding of other recently introduced antigens also. One indicated their country intended to implement a direct agreement with Merck but delivery costs remained a barrier. Demonstration projects were still predominantly cited as useful to indicate the demand and acceptability of the 
vaccine	in	the	community,	which	influenced	political will to continue the programme, but obviously did not govern the decision to scale. Of note, two of the 11 countries indicated that the demonstration projects had actually deterred policy makers from continuing HPV vaccine delivery in national programmes due to the negative media stimulated by anti-vaccine lobbyist groups (Countries 12, 21) and delivery costs (Country 21 only).Among the 13 countries planning to apply for Gavi support for national programmes, 6 indicated remaining uncertainty over funding for delivery expenses and would be testing a ‘routine’ health facility based delivery strategy in their planned national programmes for 
the	first	time.	A	phased	national	roll-out	over	3-5 years was stated as preferable in these countries. Regarding the extent to which experiences from demonstration projects were useful in 
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scale-up discussions in countries that had scaled or were planning scale-up, several indicated that the demonstration had given 
them	additional	confidence	and	that	they	had	learnt useful lessons (See section 11: Value). If done well, demonstration projects could provide vital information for national roll-out (e.g. addressing issues around consent, rumours, population enumeration). One country source indicated that discovering that the school-based strategy exceeded their 80% vaccination goal convinced policy-makers that it was the appropriate approach (Country 4). However, six countries stated they would embark on national programmes with completely new, untested delivery strategies as their demonstration projects had proved expensive and had not tested sustainable delivery strategies. Two of the 34 country representatives suggested that given the option they could have gone straight to national introduction instead of completing demonstration projects (Countries 11, 16). However, at least three countries that had not yet scaled up from their 
demonstration projects indicated that they felt they could not have gone straight to national introduction (Countries 17, 37, I).A few others expressed concern that quality and effectiveness of delivery would deteriorate in national programmes without the additional support and intense interest/participation provided by pilot projects. Integration of planning, communication and social mobilisation was important to ensure the programme was accepted and owned as a ‘public health’ programme, rather than being seen as a vertical EPI or education initiative. Previous small-scale demonstration projects were not well-cited in subsequent applications for Gavi demonstration projects. Some were likely too small or countries chose a different delivery strategy than the one previously tested. However, many applications referred to previous experience of school-based delivery during campaigns and TT vaccinations (Table 34).
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Table 35: Mentioned ‘lessons learnt’ from previous HPV vaccine projects within applications for  
Gavi-supported demonstration projects or national programmes
Country ID Any mention of 
previous project 
Key lessons learnt from previous pilot Other lessons learnt from vaccination 
programmes
Cameroon Yes Mentions coverage of previous 
demonstration project (GAP) but does 
not clearly identify lessons learnt. 
Gavi application proposes a different 
strategy (school-based versus mothers/
daughters). Mentions success of peer-
search strategy used in the previous 
pilot. Mentions no record of severe 
AEFI.
Mentions measles campaign 
implemented in schools in 2012.
Ghana No Mentions communication strategy for 
tetanus vaccination.
Kenya No Report of limited experience with HPV 
vaccination through various research 
settings. 
Success with vaccination of adolescent 
girls using TT through a school-based 
programme covering several counties 
in the eastern part of the country. 
Lessons learnt from the programme 
included the need for community 
engagement and male involvement. 
HPV demonstration can be integrated 
with ongoing school health 
programmes to leverage resources 
and strengthen current projects. This 
will be an inclusive programme carried 
out in collaboration with the different 
departments and partners.
Mali No Mentions experience with other 
campaigns (MenA, measles)
Nepal Yes Very brief comment acknowledging 
previous experience
Mentions the measles-rubella (MR) 
campaign conducted in schools for 9 
months for 15 year-olds
Rwanda No No lessons learnt highlighted despite 3 
years national programme. 
Tanzania Yes Quite detailed, lessons learnt include 
the need to organise mop-up days 
to increase coverage; feasibility and 
effectiveness of school-based delivery; 
need for comprehensive community 
sensitization incorporate messaging 
to explain the target population for 
vaccination, benefits to this population, 
and the reasons for vaccination of girls 
only.
Mentions experience in explaining 
sex-specific vaccination through 
their efforts to vaccinate women of 
reproductive age against tetanus 
toxoid.
Uganda Yes Comprehensive: Importance of 
formative research in identifying the 
key issues for HPV vaccine delivery 
such as delivery strategy elements, 
communication and advocacy 
strategy, training needs, identification 
of stakeholders, assessment of 
the health and education systems 
among others and these needed to 
be addressed before introduction. 
Detailed operational lessons learnt 
about planning, implementation and 
communication.
Uzbekistan No Long-standing experience in 
implementing school-based vaccination 
programme (Booster doses of Td 
vaccine to adolescents administered at 
the age of 7 and 16 years) Previously, 
BCG booster were administered at 
schools at the ages of 7 and 15 until 
removal from the immunization 
schedule. 
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9.2.2 Planning in advance of scale-up Changes made during the pilot or to EPI in advance of scale-up were very contextual among the 8 experiences in 7 countries for which this was mentioned (Countries 1, 4, 8, 26, 33, 34, 35). One source noted government plans should not be too rigid, giving the example of using an abattoir to store HPV vaccine when the cold chain failed. Some commented on the costliness of school-based approaches, one suggesting revising the vaccination schedule to an annual approach if this was feasible, while several indicated the mixed approach of schools and facilities was preferable (e.g. particularly for harder-to-reach remote areas). Six countries cited plans to change from a school-based strategy to a health facility based strategy due to the costs required for school-based delivery. These issues thus need to be explored further prior to scale-up.    
9.2.3 Key lessons learnt from scale-upIn relation to scale-up, key lessons included: 
• Demonstration projects appeared most useful for countries with less experience of rolling-out new vaccines or of vaccinating older children; however, substantial lessons have been learnt during scale-up and national programmes also.
• Some countries indicated they could have gone straight to national or phased national programmes rather than spent time on demonstration projects if funding had been available. 
• Demonstration projects did not appear to 
be	particularly	useful	in	influencing	the	decision of whether to scale to national HPV introduction, which was sometimes already decided or was governed by the availability of funding. However, demonstration projects  
did	appear	useful	in	influencing	plans	for future implementation (e.g. consent, enumeration processes, delivery strategies).
• Continuity of access to Gavi funding was a major concern when considering scale-up and longer-term sustainability.
• A number of sources appeared unaware of 
the	relative	flexibility	of	the	HPV	vaccine	dosing schedule (e.g. several did not know it could be given in two doses one year apart), which could have potential logistical and cost implications.
• While Gavi sources indicated that Gavi will continue to offer vaccine at a subsidised price to countries after they graduate from Gavi support, for some countries that currently no longer qualify for funding, exploration of alternative sustainable funding options could encourage more countries to scale-up HPV vaccination.
9.2.4 Key Recommendations
Based	on	findings	related	to	scale-up	plans	and	experiences, it is recommended that:
• More case study research should be conducted on scale-up experiences.
• Where feasible (e.g. in terms of funding and country experience with introducing vaccines), consider phased national implementation rather than demonstration projects.
• Further research should be conducted on 
the	costs	versus	benefits	of	school-based	delivery approaches within national scale-up.
• Further exploration of sustainable funding alternatives should be conducted and disseminated, to encourage more countries to scale-up demonstration projects.
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10.1 Combining delivery with  
other interventionsTargeted campaign-style delivery provided some opportunities to combine the vaccination with other interventions, which a minority of countries took up. The analysis below was conducted for 38 countries that provided information on whether or not they considered combining the vaccine delivery with any other type of intervention (Table 35). The same countries may have provided combined interventions in multiple programmes or delivery experiences. 
Only	five	countries	mentioned	they	had	an	established school health programme but some admitted that the programme may not have been very operational (Countries 3, 4, 8, 30, 34).
“There is a School Health Education Programme (SHEP) where community health nurses and other public health 
officers	embark	on	scheduled	visits	to	all	schools for integrated health education; physical examination of pupils/students and treatment of minor ailments undertaken. The coordinators of SHEP are teachers; they participate in all immunization and other health activities in the district.” 
KI Country 8. The strategy to integrate activities changed over time; countries would tend to add combined interventions in subsequent rounds of vaccination, having presumably felt more 
confident	in	HPV	vaccine	delivery.	Additionally	some countries mentioned they intended to test combined delivery of services or health education interventions in the future (e.g. TT/Td Booster (Countries 34); child annual health checks, hygiene education and eye screening (Country 13, G); deworming (Country E); male circumcision (Country 37)). Countries with experience of integrated ‘joint’ delivery either delivered another intervention with HPV vaccine to the same target group and at the same time as HPV vaccination, or another intervention was delivered to a different target 
10. Integration with routine 
immunisation and the  
health system
Table 36: Different models of integration of HPV vaccine delivery implemented with other services/
interventions (number in brackets indicates country reference number)
Type of 
integrated 
delivery
HPV vaccination 
integrated within 
an existing 
school health 
programme
HPV vaccination 
integrated to an 
existing delivery
Add-on service 
provided 
alongside to the 
delivery of HPV 
vaccine
Add-on health 
education 
intervention 
provided 
alongside to the 
delivery of HPV 
vaccine
Cervical 
screening and 
HPV vaccination
School-based TT and OPV 
(Country 3)
Td 
(Countries 14, 
30, 35)
Generic 
School health 
programme 
(Country 4, 8, 30)
Child day 
outreach  
(Country 28, 33)
Hepatitis B 
vaccination 
campaign 
(Country 26)
De-worming 
tablets & 
Vitamin A 
supplementation
(Countries 15, 17, 
28, 33)
Reproductive 
health (Countries 
1, 4, 6, 18, 28, 
30, 37)
Hygiene /
screening
(Countries 14, 15, 
28, 30)
Health facility 
based
Mother and 
daughters’ 
programme 
(Countries 1, 6, 
19)
TT: Tetanus toxoid; OPV: Oral polio vaccine; Td: Tetanus diphtheria booster dose
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Box 10. Case study – combining measles and HPV vaccine trainingIn 2015, the government received only 50% of the funds needed to deliver the measles campaign, which was conducted every three years for children aged 5 and below. The other 50% was to be funded by government, which on being unable to raise these funds decided to combine the measles vaccination campaign with the national HPV launch.“At the central level this worked - everyone was trained on both the measles campaign and HPV. However, in the districts it failed.” Despite a training manual combining the two, which supported training on microplanning and catchment area mapping, trainers sent to the districts only focused on measles having concluded that having two disease foci to the training was likely to confuse people. Central government representatives reported surprise, as they “thought people would do what we asked them to do”. Thus, when asked why they had not started HPV vaccination in January 2016, after having received HPV vaccine in December, health-workers stated they were waiting to be trained. Social 
mobilisation	also	faced	difficulties.	The	government	is	now	waiting	for	additional	funds	form	UNICEF to strengthen training and mobilisation for HPV.  “We thought it would be a good thing because we didn’t have funds and it would prevent people [trainers] coming and going twice to the districts. On the money side it worked, but on the implementation side.. it did not work”. (KII, Country 33)In January 2016, HPV vaccine training was added to training for a polio campaign. This time, it spurred delivery to start in some areas - it worked better the second time as the importance of HPV vaccine was emphasised and training was supervised.
group but in the same school or outreach site as that used for HPV vaccine delivery and at the same visit as HPV vaccine delivery. One country provides a good example of both of 
these	scenarios:	at	the	first	school	visit	TT	was	administered to grade 7 alongside HPV vaccine dose 1; at the second school visit of the year oral polio vaccine (OPV) was administered to grade 1 and HPV vaccine dose 2 was administered to grade 7 (Country 3). Combining HPV vaccine delivery with another major vaccination campaign (e.g. Hepatitis B or measles) seemed generally to have been unsuccessful because of organisational challenges, a lack of prioritization of HPV vaccine and reported confusion in messages directed to health care workers and the public (Box 10): “A national campaign to vaccinate all children 2–11 years of age against hepatitis B was conducted at the same time as the HPV vaccination campaign… This hepatitis B campaign involved vaccination at the health facility with community outreach; the hepatitis B vaccination was the main priority and the nurses’ principal concern was reaching the goals for this campaign rather than for the HPV vaccination; Health facilities with fewer personnel had a greater challenge in implementing both vaccination campaigns without neglecting the regular vaccination schedule”
 KI Country 26.
Gavi-supported countries are encouraged and incentivised to provide another intervention that would be tailored to their context alongside HPV delivery [6]. Although all the Gavi demonstration projects included in this review 
are	only	in	their	first	year	of	implementation,	it	seems that, based on the information that this study was able to collect, very few countries plan to take up this opportunity (Table 33). With the caveat mentioned above, overall the Gavi application process does not seem to have fostered innovation in the delivery of combined interventions, notably in reproductive health, which was one of the objectives of the demonstration programme approach.Across all countries (Gavi-supported and non Gavi-supported), most countries that have delivered a combined intervention had such pre-existing programmes (school vaccination programme or existing school de-worming programme). In their reports, countries are not 
specific	about	whether	they	have	considered	adding interventions and whether they have gained lessons from delivery alongside other interventions. In one country it was obviously not a new idea:“In most polio campaigns the vaccine is delivered with deworming or vitamin A supplementation - it is not a new thing. HPV was no different. There were no problems with deworming tablets sometimes causing nausea or sickness.”
KI Country E.
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Table 37. Gavi countries with approved HPV vaccine proposals
Country Type of programme, 
Gavi approval date
Evidence of combined intervention implemented Included in 
this review
Bangladesh Demo 09/03/2015 No data No
Benin Demo 31/1/2014 No data No
Burkina Faso Demo 9/3/2015 No data Yes
Burundi Demo 31/01/2014 No data No
Cameroon Demo 31/01/2014 No Yes
Cote d’Ivoire Demo 31/1/2014 No, but possibly Y2 Yes
Ethiopia Demo 6/5/2015 No, but possibly Y2 Yes
Gambia Demo 31/1/201 No, but possibly Y2 Yes
Ghana Demo 31/1/2013 Mentions generic school health programme but without 
details
Yes
Kenya Demo 31/1/2013 Planned but dropped Yes
Lao PDR Demo 31/01/2013 Planned in the second year  
(Hygiene and oral care messages with eye screening)
Yes
Liberia Demo 31/1/2014 Programme delayed-Ebola affected country No
Madagascar Demo 31/1/2013 Yes deworming and vitamin A (pre-existing programme) Yes
Malawi Demo 31/1/2013 No data Yes
Mali Demo 31/1/2014 Delayed start date to Oct 2015 No
Mozambique Demo 24/05/2013 No  Yes
Nepal Demo 4/11/2014 No data No
Niger Demo 31/1/2013 No, but exploring it (UNFPA) Yes
Rwanda National 15/2/2013 Yes deworming & vitamin A No
Senegal Demo, 31/1/2014 No data No
Sierra Leone Demo, 31/1/2013 Programme delayed-Ebola affected country Yes
Tanzania Demo 31/1/2013 Exploratory work done in Year 1 to identify potential 
interventions[53]. Not implemented
Yes
Togo Demo, 19/3/2014 No, but possibly Y2 Yes
Uganda National, 4/3/2014 Yes included in routine integrated outreach strategy Yes
Uzbekistan National, 4/3/2014 Yes, school programme with Td and OPV starts 2016 Yes (limited as 
future plans)
Zimbabwe Demo, 24/05/2013 No, but possibly Y2 Yes
However, some countries state that they have decided against combining delivery with other interventions pointing to a number of barriers preventing integration including: the absence of an overarching school health programme; no existing/ routinely delivered interventions to this age group; the fragmentation of other existing programmes; the lack of funds 
and	unpredictability	of	financing	for	other	programmes (e.g. deworming); the complexity of delivering multiple interventions and in some cases different types of staff needed; and general front line workload issues. In addition, a few countries noted that the restricted geographical remit of the demonstration 
projects meant that it was more challenging to involve national stakeholders and secure effective involvement of possible national partners outside of immunisation. Two countries wanted to minimise time spent in the schools and therefore disruption to the school day (Country 15, 16). “The decision to integrate all the services together, including HPV vaccine, has to come from the top, with a strong coordinating body to manage the different interventions and partners.”
KI Country 22. 
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10.1.1 Combining service delivery with 
other interventions: Key lessons 
learnt and conclusions
• Inserting HPV into a wider school vaccination programme was not necessarily straightforward, as the target age group and/or schedule of other vaccines could differ from HPV. However when vaccination sessions were planned for other vaccines, this was seen as an opportunity to combine sessions. One country notes:“Currently, school-based vaccination sessions are conducted twice a year (in April and in October). The administration of 
the	first	and	the	third	doses	of	HPV	vaccine will be combined with these existing sessions” 
Uzbekistan Gavi application for a 
three-dose schedule
• Few countries decided to test reproductive health interventions, presumably because the young age of girls to be vaccinated (age 9-11 years old) (Box 9). Countries that implemented reproductive health interventions tended to be UMIC countries that were targeting older age group girls. 
• There was no evidence of any evaluation of the feasibility and cost effectiveness of combined interventions with HPV vaccine delivery. The decision to add on new interventions seemed to be opportunistic.
• Apart from countries with an existing well-established school health programme, generally in UMIC, there was no clear strategy to establish a more structured school-based health programme in which HPV vaccination would be one element. However, a few countries saw HPV vaccination as an avenue to strengthen the weak, existing, school health programme.
• In some cases, countries opportunistically combined already planned activities to the same target group (Hepatitis B vaccine introduction and cervical screening demonstration in one country) but outcomes seemed mixed and limited lessons learnt were reported on the outcomes of this ad hoc combined delivery.
• Several countries noted that a combined intervention was originally planned but this was not implemented highlighting possible organisational challenges.
• Organisational challenges around integration included national level 
coordination of the partners supporting delivery of the different interventions 
including	agreement	over	the	financial	share	of delivery costs between programmes. If delivery costs were borne by just one component of the integrated delivery package, the future of the other components would be at risk if funding is discontinued. 
Box 11. Examples of reproductive health 
interventions implemented by countries
!  Country 4: Sexual health education lessons delivered prior to vaccination days during sensitization (age 11-15).
!  Country 1 & 6: ‘Reproductive Health awareness sessions’ provided in schools.
!  Country 30: Health education on sexuality and puberty, bullying – as part of health education programme for all grade 4 children (Grade 4 and 5).
!  Country 18: HIV prevention and hygiene messages provided to girls (Grade 4).
10.2 Integration with routine 
immunisation programme 
processes and structures
10.2.1 Assessment of integration with routine 
immunisation programmeWe found that HPV vaccination was generally delivered through the routine immunisation programme, with the exception of a small number of earlier GAP demonstration projects set up independently (Countries 5, 6, 19). Exceptions included two countries whose HPV vaccine demonstration project was closely managed by EPI but chaired by a different MoH department (Cancer and reproductive health services) (Countries 6, I). Hence they shared the same programme structures and resources, including staff and logistical capacity as EPI although EPI did not lead the projects. HPV vaccine delivery was consistent with EPI processes in terms of planning, supply chain management, staff management and social mobilisation.  Similar processes to routine immunisation were used in terms of micro-planning, communication, social mobilisation, training strategies, and logistics. However, country reports often commented on the fact that several activities such as planning, social 
Reproductive health education provided with HPV vaccine
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mobilisation and supervision were felt to be more “intense” in terms of resource mobilisation and needed an extended period of preparation time. This tended to be especially 
true	for	the	first	round	of	vaccination.	The choice of the school-based delivery strategy led to more similarities with other vaccination campaigns than with how routine infant vaccines are traditionally delivered. Because of their recurrence, it can be argued that campaigns themselves have been “routinized”. “Mini immunization campaigns will be organized in primary schools of pilot districts with the aim to immunize all girls of primary grade 6”
KI Country 28.A small number of countries had existing school health programmes and HPV vaccination were inserted into this existing programme framework, and aligned with existing processes (e.g. consent, medication distribution and logistics). However, several countries noted that they were re-considering how these other interventions were delivered following HPV vaccine introduction.Roles of staff and community workers generally aligned with other routine immunisation activities. “This [HPV vaccination] was planned around routine work” 
KI Country 17. But new staff were drawn in at least 13 countries to supplement healthcare workers to deliver school vaccination activities. Remuneration levels were generally based on existing country rules and aligned to existing rates (e.g. allowances). Supervision activities and data collection/reporting appeared to be areas that were more often set up for HPV vaccine in parallel to routine processes (Table 37). Workload was considered high for vaccine delivery in schools and reporting activities.  There were instance of reported disrupted activities of routine services, but generally these were reported to be low, probably because of the additional staff resources that were allocated to the vaccination activities. Several countries noted that the health care facilities tend to be understaffed so the campaign mode approach was disruptive to their routine services, with one saying that some facilities had to be closed for the duration of the vaccination. Those countries conducting house to house visits to enumerate girls reported that this activity tended to generate a very high workload for community health workers. A learning curve was mentioned as potentially 
reducing workload over time.Importantly the small size of most of the demonstration programmes, generally circumscribed to a few districts, often failed to permit assessment of the actual integration of HPV vaccination within routine processes. This was particularly the case for cold chain and transport logistics, as 
well	as	planning,	staff	allocation	and	financial	sustainability. The choice of districts to host the HPV vaccination introduction were frequently found to be based on convenience rather than to test more challenging contexts that a national introduction would face (e.g. remote areas, areas with lower school attendance).For the national programmes for which we had 
sufficient	data,	integration	of	HPV	vaccination	
within	the	EPI	tended	to	be	significantly	stronger than with demonstration projects, notably in relation to service delivery, vaccine management, reporting, supervision, and human resources. Delivery models took different forms of integration: (a) with the national school health programmes where HPV would be delivered with other vaccines or interventions; (b) with a national bi-yearly child health day routine programme; and (3) with the routine EPI programme, where districts and facilities would be left to decide how best to reach their target population 
(schools,	fixed	sites	and	integrated	outreach).	There were advantages and drawbacks to each of these, notably predictability of funding for models (a) and (b) while model (c) seemed to introduce more uncertainty and potential weaknesses notably in vaccine management and ascertaining coverage rates in a context where routine outreach services might not be consistently funded.
10.2.2 Coordination and collaboration 
beyond EPICoordination and collaboration with stakeholders outside the routine immunisation programme seemed to be more variable and depended on:
• Formal requirements by funders to set up an integrated cancer strategy; for instance, the Gavi application process requires countries to set up a Technical Advisory Group that will deliver a national inter-agency cervical cancer strategy.
• Ownership of the demonstration programme; for instance, the single (hospital) site programmes did not always involve the EPI, or tended to coordinate with EPI at a later stage of implementation.
• Some EPI led programmes did not refer to the involvement of the Reproductive Health programme and cancer-related departments.
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• All school-based programmes involved the MOE to various degrees, but all acknowledge the critical importance of early involvement of education authorities.
• Unlike for other childhood vaccinations, school staff were considered critical to support the overall HPV vaccination process (notably for enumeration, mobilisation, support, awareness raising, consent, mop up and reporting activities). 
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10.2.3 Key lessons learnt and 
conclusions In relation to integration key lessons included: 
• When EPI was leading the demonstration projects, integration with routine immunisation activities was usually strong and the regular routine human resources and infrastructure was used to deliver the HPV vaccine. HPV vaccination delivery led by EPI shared the processes and resources of the routine infant vaccination programme.
• Smaller scale projects run by entities other than the MOH showed minimal or no integration with routine services, and in some cases were run in parallel to the routine health service, hence limiting understanding of scalability. These projects also ended up using some EPI capacity (e.g. cold chain and logistics), often with minimal or late involvement of EPI, thereby reducing its capacity to integrate activities within the routine programme.
• Many countries used familiar delivery models and therefore the level of integration into standard processes tended to be high (e.g. (repeated) school-based campaign model, with additional mop-up activities in regular health centres). Hence delivery 
shared	practices	specific	to	campaign	delivery (limited duration, additional staff, allowances, intensive supervision and reporting). 
• Many	specific	characteristics	of	the	HPV	vaccination continue to be related to the introduction aspects of the new vaccine 
(significant	initial	investment	in	social	
mobilisation,	specific	vaccine	focused	training, intensive supervision, responding to possible emergence of rumours) and explain processes that tend to remain parallel (supervision, reporting) to the routine immunisation programme practices.
• There were only a limited number of unique traits to HPV vaccination that distinguished it from other routine vaccines. These involved the targeting of older girls, the often-complex enumeration process and the repetitive vaccination campaigns in schools for countries without existing school health programmes. 
• Many aspects of integration with the routine immunisation programme process remained challenging to assess because of the small size of demonstration projects. Scale up may produce new challenges and learning curves and result in changes of strategy.
• Despite reporting high workload, negative  
effects on the routine delivery of other services were rarely commented upon. This may be owing to the small scale of the programmes (Section 7.3.3: Staff workload). 
• A small number of countries had in the past or were envisaging to switch in the future from the campaign-style delivery to a health facility based strategy to foster a more cost-effective and integrated approach. One country that made this change reversed to school delivery because of poor coverage. Countries will have to trade-off the high coverage attainable in campaign style delivery with the more integrated approach to childhood routine vaccination and possible lower coverage outcomes.
• An increasing number of countries originally intended to test combining at least one other intervention with HPV vaccination but few have translated this into actual implementation. None have formally evaluated combined delivery.
10.2.4 Key recommendations
Based	on	findings	related	to	integration,	we	recommend: 
• Rigorous evaluation of combined interventions with HPV vaccine delivery is needed to assess the effect on implementation, coverage, workload and cost. Funding agencies should systematically encourage this.
• Gradual integration of processes into routine processes should be planned and formalised 
after	the	first	round	of	vaccination	is	completed (notably for activities such as communication, reporting procedures and processes, supervision, social mobilisation, remuneration, and human resources management).
• Opportunities to initiate or strengthen existing school health programmes and/or pre-adolescent/adolescent health should be seized through on-going collaboration with partners (e.g. MOE, reproductive health departments).
• HPV vaccine is overwhelmingly being delivered through “routinized” campaigns, it is critical to ensure that other routine health services are not disrupted by recurrent school delivery or that possible disruptions are mitigated, and that this delivery mode is sustainably funded. This needs to be monitored and evaluated.
• Financing of operational costs of school-based delivery needs to be embedded into routine budget cycles. 
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11. Value Added
11.1 Background to demonstration 
projects To examine the value that countries might have placed on the demonstration projects to date, it is necessary to note that access to vaccine for many LICs and LMICs was initially limited 
to	demonstration	projects	and	that	the	first	projects were the result of donated vaccine from the two pharmaceutical companies producing HPV vaccine; Merck & Co. and GlaxoSmithKline Biologicals. These demonstration projects, either a result of a direct vaccine donation to the government or an external partner, or managed through Axios Healthcare Development for the GAP [7], allowed countries to gain experience in 
gender-specific	vaccine	delivery,	and	for	many	countries, in delivering vaccine to a novel target group. At that time, with one exception, vaccine donation for national roll-out was not an option. Thus, to gain experience with HPV vaccination, resource-poor countries had no alternative but to conduct demonstration projects. Rwanda was the only exception, since it received an industry donation through the Merck Qiagen Initiative [54] to start national implementation in its relatively small target population without a demonstration project [55].  In 2012 Gavi announced plans to support HPV vaccination demonstration projects or national programmes if the country had prior experience of HPV vaccination [21]. Gavi demonstration project support was, and is, granted for 2 years to allow countries time to test different delivery strategies, integration of HPV vaccine delivery with other adolescent services, and to prepare an application to Gavi for national programme funding. By early 2016, Gavi had approved demonstration project funding for 25 countries by April 2016, but only three countries had received approval for national programme support (Rwanda, Uganda, Uzbekistan) [21]. Of the 25 countries approved for Gavi demonstration projects, six had conducted at least one previous demonstration project. Only 
two	of	these	initial	projects	had	significant	MOH/ EPI involvement (Countries 8, 23), three were run by partners that actively disseminated lessons to national stakeholders (Countries 6, 19, 31), and one was implemented completely separately from the MOH (Country 13).
Available data from the combined experience of all 66 demonstration projects and 12 national programmes in 46 countries contributed to this 
section;	29	of	the	46	countries	offered	specific	opinions on the value of demonstration projects. These 29 countries include: two countries that did not conduct a demonstration project and stated they had not needed one to introduce nationally; nine of the 10 countries that had experience of scaling up from a previous demonstration project (GAP or other) to a national programme provided information on the value of those initial projects; and 18 countries with only demonstration project experience offered perspectives 
on	the	potential	benefits	and	drawbacks	of	demonstration projects to date. Data were interpreted in conjunction with those in Section 9: Sustainability.
11.2 Value found in demonstration 
projectsReported experience suggests that demonstration projects do allow countries (i.e. national implementers, national implementers supported by external partners, or external partners who then disseminate lessons to national implementers) to gain valuable experience in a number of areas. These 
include	the	significant	planning	and	budgeting	requirements for school outreach, enumeration of the target population, acceptable consent procedures in older children and adolescents, effective mobilisation messages and working with the MOE. Realisation over the cold chain storage and transport requirements for the vaccine were also noted as important. Demonstration projects also allow for the development and piloting of new forms and  IEC materials, and, more recently, practice in using standardised evaluation tools, e.g. the  C4P costing tool [22]. “The demo is really important so we can analyse the results of the delivery to a 
new	target	age	group	of	a	gender	specific	vaccine – routine immunisation usually targets children of less than a year.” 
KI Country H.“Demos elucidated issues around enumerating out of school girls and consent issues around people thinking vaccine is experimental. We wouldn’t have performed to this high coverage in the national if we didn’t do demos.” 
KI Country 3.
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However, lessons have not been restricted to demonstration projects; six countries stated they had learnt substantial lessons during national implementation. A further six stated their preference for continuing after their HPV demonstration projects would be through phased introduction beginning with a few districts in year one with gradual expansion nationally.“There was no need for a demo as we have experience initiating new vaccines.”
KI Country B.“If the funding was adequate, we would have gone directly to phased national introduction, without necessarily going through a demo…. The [demo] will be useful to inform the national programme if it is used to test delivering through facilities only. It is likely the strategy may vary by county.. the country was going to apply for national funding but Gavi recommended [a demonstration project]. the EPI team learnt a lot of lessons. The demo allowed the team to check readiness and capacity and led to the decision over whether to roll-out all at once or conduct a phased introduction.”
KI Country 13.
11.3 Drawbacks of demonstration 
projectsCollated ’lessons learnt’ from the 66 demonstration projects with at least six months of experience are largely a repetition of those 
reported	after	the	very	first	demonstration	projects in 2007-2010. Countries themselves have nuanced experiences and gained from the process of ‘learning by doing’. However, they also experienced a number of drawbacks from conducting small-scale projects in areas that were not always nationally representative. The limited scale of demonstration projects 
means	that	it	is	difficult	to	assess	the	impact	of HPV vaccine on national cold chain capacity and other primary healthcare services, and to demonstrate integration with the health system as national teams have to coordinate the project as a distinct entity. There were 
also	several	specific	concerns	in	implementing	demonstration projects in a small area of the country; three countries mentioned the need to restrict national mobilisation activities to avoid perceptions of inequity among communities not receiving the vaccine and rumours that the project was restricted in scope because it was ‘experimental’ (e.g. Countries 3, 8, C). If demonstration projects are carried out in districts or communities that are primarily selected for convenience, which have higher 
routine vaccination coverage, more extensive infrastructure and better education levels in comparison to national averages, the lessons learnt may not be applicable to national roll-out. Eleven countries stated that the resource-intensive delivery strategies used during their demonstration projects are not sustainable 
without	substantial	financial	support	provided	by international funders for delivery costs (Countries 8, 13, 17, 18, 21, 29, 31, 33, 37, A, I). Some countries indicated that high costing study results from demonstration projects deterred decision-makers from national roll-out (e.g. Countries A, 8, 21). Only one country is testing a more ‘routine’ delivery approach in their Gavi demonstration project, another is conducting a third demonstration project in order to test a routine delivery approach, six more plan to test the new ‘routine’ delivery strategy in phased national introduction. Among the 32 countries that shared opinions about the future funding availability for HPV vaccine delivery, sources from 18 stated considerable uncertainty. Importantly, a number of countries seem to have stalled in terms of expanding HPV vaccination after delivering a demonstration project/s; projects were completed in 2010-11 
in	five	countries	that	have	now	ceased	HPV	vaccine activities (Countries 5, 12, 20, 21, 36). These countries report valuable lessons learnt and could be ready for national roll-out, but no move has been made to source funding. Two other countries have done 3-4 GAP/other demonstration projects between 2010 and 2014 with no known plans for national roll-out (Countries 2, 23). There is some concern that, in several countries, demonstration projects could be used to delay decision making for national scale-up or discourage countries from a national HPV vaccination programme because of the cost of delivering vaccine in the project. For example, some countries reported 
finishing	demonstration	project	funding	allocated for 2 years, in just 1 year, for several reasons (see Table 32). Preparing applications and reports for Gavi demonstration projects and a subsequent application for national roll-out is time-consuming (although this was 
not	specifically	discussed	in	our	interviews).	Political commitment secured in order to begin an HPV vaccine demonstration project can wane over time and with high staff turnover institutional memory can be lost, potentially before national roll-out can commence.
11.4 Increasing the value of 
demonstration projects The value of demonstration projects could be increased if countries used the opportunity 
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to test different delivery strategies in order to ensure that they gain experience in one that is both sustainable and effective. The implementers of only 7 projects purposefully selected areas that included more challenging or hard-to-reach target groups (Countries 2, 8, 12, 22, 36).  Projects in only 2 countries simultaneously tested different vaccination venues (Uganda, Vietnam), one country tested different timings (India) [50] and only 2 others simultaneously tested different eligibility criteria (Tanzania, Uganda) [50, 51]. The opportunity to test the delivery of combined interventions with HPV vaccine has also been missed to date. Of 38 experiences that discussed combining HPV vaccination delivery, only a minority of countries have gained experience in simultaneous delivery with TT vaccine, deworming, vitamin A supplementation, and various health education messages (Section 10 Table 35).  It is worth noting that three countries, which are conducting second demonstration projects through Gavi, having completed GAP projects with well-documented lessons learnt, are using the second demonstration project to try different delivery strategies (Countries 8, 13, 31). The rationale for other countries to complete second, third or fourth demonstration projects is unclear. One concern, which remains unanswered, is whether demonstration projects can actually 
discourage	or	significantly	delay	countries	moving to national scale-up. 
11.5 Scaling-up to national 
programmes and 
demonstration project 
contributionsThe 20 Gavi demonstration projects for which we have at least six months of data continue to implement vaccination in 2016.  As there is no available experience in transitioning from Gavi demonstration project to national 
implementation,	it	is	difficult	to	draw	conclusions on whether Gavi demonstration projects inform scale-up as intended and whether two-year demonstration projects are valuable. Most non Gavi-supported projects were only one year initiatives, although six countries elected to conduct multiple sequential non-Gavi projects (Bolivia, Georgia, Honduras, Lesotho, Nepal, and Uganda). Nine of the ten countries with experience of scaling up from demonstration project to national implementation provided data on whether the demo informed their national programmes (Countries 1, 3, 4, 11, 16, 26, 30, 33, 35). Of these, two out of four UMIC’s reported that the demonstration project informed the national programme (Country 
3, 26). The high coverage achieved during the demonstration projects was important for political advocacy and lessons around consent and enumeration were learnt. One UMIC conducted demonstration projects with MOH involvement and reported more important 
lessons	were	learnt	during	the	first	year	of	their	
national	programme	(Countries	4).	The	final	UMIC indicated that the demonstration project led by a provincial health department did not contribute to decision making for national introduction as information was not deemed useful in national planning (Country 30). 
Among	five	LIC/LMICs	that	transitioned	from	GAP/other projects to national introduction, two reported that the demonstration was useful to prove high vaccine acceptance in the community and had illustrated some challenges (Countries 1, 16). Another two indicated the demonstration projects had been vital to learn how to coordinate with the MOE (Country 35) and in testing different delivery 
strategies	(Country	33).	The	fifth	indicated	
the	demonstration	projects	had	not	influenced	the design of the national programme and they would have gone straight to national introduction if possible (Country 11). In 2015-16, two LMICs, Uganda and Uzbekistan, began scale-up to a Gavi-supported national programme after conducting demonstration projects with MOH involvement in 2008-9. Both planned national delivery strategies that were not tested in their previous demonstration projects. Lessons from the demonstration 
phase	were	specifically	referenced	by	one	of	the	country representatives involved in national planning, particularly for target enumeration, communications, and consent procedures. However, this does indicate that delivery strategies can be equally tested during national roll-out and may even yield more valuable lessons than during a demonstration project, given the more representative experience.  
11.6 Conclusion If designed well, demonstration projects can be used to test different delivery strategies, delivery in areas with particular challenges, and integration with national systems. A number of country representatives described them as useful practice. However, they can also distract countries from planning for the future and may cause a loss of momentum around HPV vaccine introduction. Given that many countries seem to learn many of the same lessons through demonstration projects but appear to need initial experience in vaccine 
delivery	to	fine-tune	the	social	mobilisation	and delivery strategies, there is potentially no reason why the lessons learnt in demonstration 
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projects could not be gained in a phased national roll-out. Phased national roll-out might maintain political commitment to scale-up implementation and avoid demonstration projects being set aside from national health systems as distinct entities. Demonstration projects were valuable when HPV vaccine had very recently become available to LMICs and support for national implementation was not accessible. However, as lessons learnt have been documented and few new lessons have been observed in recent demonstration projects, and as support for national programmes has become available, the value of conducting a demonstration project has decreased. Furthermore, as many countries come to the end of their Gavi demonstration projects in 2016 and have not submitted applications for national programmes, there are urgent questions over how to facilitate a transition phase in order to avoid loss of institutional memory. Future new vaccine introductions including new target groups or delivery strategies may 
benefit	from	framing	experiences	around	phased national introductions rather than demonstration projects.  If phased national roll-out of a future new vaccine is not economically 
feasible	when	the	new	vaccine	first	becomes	available, policy around demonstration projects should be regularly re-evaluated and 
made	more	flexible.	Some	countries	may	elect	to conduct a demonstration project, but the opportunity to obtain support for a phased national roll-out should be made available as soon as possible.  
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12. Pitfalls experienced in  
projects/programmes
Review	findings	confirmed	that	HPV	vaccine	delivery is feasible in L&MIC. However, gathering lessons learnt included gaining valuable experience of strategies which did not work as well and could potentially cause an HPV vaccination project/programme to struggle or even fail.
12.1 Preparations
• District/sub-national areas selected 
for demonstration projects are chosen 
areas with better than average DTP3 
performance, infrastructure, and 
education levels  
Consequences: While it is understandable that countries want to demonstrate HPV vaccine delivery in convenient districts to more easily coordinate monitoring and evaluation activities, this choice of ‘easy’ districts and ‘easy’ to access target populations reduces learning. It can lead to achievement of unrealistic coverage rates, which cannot necessarily be replicated elsewhere in the country or during national programmes.
• Limited/lack of EPI involvement 
Consequences: Delays in vaccine importation, 
insufficient	cold	chain	capacity,	inadequate	vaccine transport, implementation of parallel systems of vaccination reporting (dose delivery, AE, stock management).
• Limited/lack of education sector 
involvement 
Consequences: Inaccurate enumeration of girls can result if MOE representatives are not involved in the planning of the project, or feel a lack of ownership and motivation to obtain the correct number of girls (e.g. through headcounts or through register book completion) and if they do not understand who is eligible for vaccination. The MOE may not make school heads aware of the project leading to refusal to cooperate with vaccinators in terms of allowing entry to school premises or organisation of eligible girls. Vaccination may be targeted at a school grade with a low proportion of eligible girls in comparison to a higher or lower grade. The vaccination schedule may be planned without taking into account school events, examinations and holidays; this can 
significantly	affect	rates	of	completion	of	the	vaccine schedule.
• Insufficient time allowed for planning 
Consequences: Different collaborating ministries (e.g. MOH and MOE) may delay the start of the project as they require more time than expected to complete administrative/ bureaucratic tasks; transport may not be well coordinated e.g. one country did not allow enough time to plan transport and vaccinators had to walk long distances to schools; social mobilisation activities may be delayed due to delayed training leading to inadequate communication before vaccination days. Planning can take at least 9 months.
• Limited/lack of supervision of training 
Consequences: : Information is inadequately 
transferred down the ‘cascade’ from national 
to district to facility staff; misinformation or 
a lack of knowledge amongst health workers 
perpetuates vaccine refusal in parents; 
integration with training around other 
vaccines is not effective and only parts of the 
training are completed. 
12.2 Communications
• Insufficient collaboration between MOH 
and MOE 
Consequences: In the most successful projects, rumours were addressed as soon as they arose. However, lack of collaboration 
between	the	MOH	and	MOE	led	to	difficulties	in disseminating messages and rumour detection and response.
• Ineffective cascade training of educators/
communicators 
Consequences: While cascade training was 
often	used	as	it	can	be	efficient,	variable	levels of monitoring and supervision meant that it was not successfully implemented in some countries leading to ineffective community mobilisation.
• Insufficient time allowed for 
communications 
Consequences:	Countries	reported	difficulties	when messages were disseminated less than a month before vaccination dates. Health workers reported feeling rushed in disseminating messages. Schools, especially private schools, reported needing more time to contact parents.  
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• Lack of adequate mobilisation of private 
schools 
Consequences: Parents of girls in private schools often need more information and more time to process information regarding a new vaccine. Not allowing for this during implementation could result in not being able to vaccinate girls attending private schools. 
• Unnecessary/ lengthy consent procedures 
Consequences: Communities may become suspicious that the vaccine is ‘experimental’ or unsafe if consent is not usually required for other routine immunisations; rumours may start which reduce uptake or completion of the vaccine schedule. Lengthy or over-complicated consent procedures may reduce uptake due to the inconvenience for parents. 
12.3 Delivery
• Attempting to use age-based eligibility 
criteria when age is not commonly known 
or documented 
Consequences: parents/ teachers and health workers will have considerable uncertainty over eligibility, potentially lowering uptake, confusing coverage estimates, and/or causing vaccination activities to take much longer.
• Not providing a vaccination opportunity 
for out-of-school girls OR assuming out-of-
school girls will come to health facilities 
with no strategy to identify or mobilise 
girls 
Consequences: low uptake among out-of-school girls and low equity of coverage. 
• Lack of coordination with teachers 
Consequences: Teachers may not understand the aims of the project/ eligibility criteria. Teachers may send girls home on vaccination day. Registers of eligible girls may not be accurate leading to too few or too much vaccine being transported to the school. Mobilisation of girls may not occur before vaccination day meaning absenteeism is high on vaccination day. If consent is needed it may take longer. Teachers may not assist following up girls absent from school or aid in reporting adverse events. 
12.4 Achievements
• Inaccurate enumeration of target 
population OR inaccurate implementation 
of eligibility criteria 
Consequences: Relying on inaccurate enumeration data due to lack of time/ planning, or inadequate training or project/programme design resulting in inaccurate use of eligibility criteria, may mean coverage achievements cannot be correctly calculated. 
• Lack of provision for out-of-school girls 
Consequences: Reduced vaccination uptake.
12.5 Sustainability
• Testing a resource intensive delivery 
strategy without planning for future 
sustainability 
Consequences: High coverage may be 
achieved	for	the	first	year	or	two;	however,	another strategy will then have to be tested for feasibility when initial funding runs out. 
• Not involving the MOF from the beginning 
Consequences: Lack of MOF involvement often 
meant	insufficient	or	poorly-timed	funding	
and	insufficient	budgeting	for	subsequent	years of the programme.
• Negative media exposure 
Consequences: Politics	(e.g.	influence	of	anti-vaccination groups) and fears could be manipulated by local and national media leading to the spread of rumours and misinformation and potentially reduced vaccination uptake and/or the project/programme ceasing prematurely. 
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13. Summary of recommendations
Section Recommendations
Preparation Planning• Strong inter-sectoral coordination is facilitated from the beginning, so that all decision-
making and planning includes, at a minimum, national-level decision-makers from 
MOH, MOE, and MOF.• Sufficient time must be allowed in project/programme timelines for decision-making 
and planning at national and sub-national levels (e.g. this can take at least 9 months).• While EPI does not have to lead each demonstration project/programme, EPI must 
feel ownership of any HPV vaccination project/programme, as its active support and 
participation in planning and delivery phases is necessary for effective vaccine delivery.
Vaccine management • The HPV vaccine should be transported together with the other EPI vaccines. This 
reduces the risk of temperature fluctuations by using established EPI systems and 
integration is cost efficient. HPV vaccine delivery timing needs to be coordinated with 
routine EPI vaccine delivery timings.• This is one of the key reasons why it is important to integrate HPV vaccine delivery with 
the EPI programme.• Appropriate cold storage can best be achieved when HPV vaccine delivery is closely 
integrated with the EPI programme. • Implementers of demonstration projects outside of the EPI should not assume that 
the EPI cold chain is adequate and working optimally, or available to be used for new 
vaccines.
Staff training • General knowledge of HPV and cervical cancer is low among healthcare workers and 
the community. Careful training is necessary in order to explain the efficacy of the 
vaccine, the eligibility criteria and appropriate social mobilisation messages. • Adequate training is needed in order that staff can resist pressure to deviate from 
eligibility criteria and to ensure that coverage estimates are accurate. • Cascade training is likely to be more efficient and less expensive than a centralized 
training session (where all frontline staff are trained by a national ‘trainer’). However, 
cascade training should be monitored and evaluated by national level staff to ensure 
consistency of messages. • Teachers and all healthcare workers, including those not delivering the vaccine, should 
be included in training. • Training should be conducted at least two months before vaccine delivery. 
Communications • A communication plan should be developed during preparation, to include specific 
strategies to ensure messages are delivered to out-of-school and hard-to-reach girls 
and their parents and communities.• Specific strategies to prevent and manage rumours should be outlined in the 
communication plan. • Teachers, health-workers, and community leaders should be trained to mobilise girls. 
Social mobilisation training should occur well before vaccination. • Face-to-face mobilisation meetings should be prioritised where possible. • Social mobilisation in communities should begin at least one month before vaccination, 
earlier if possible, especially for new projects. Time required (e.g. funds disbursement, 
printing) should not be underestimated. • High-level officials from MOH and MOE should address rumours as quickly as possible.• Schools, health-workers, community groups and media should be engaged with in 
the early stages of planning, as knowledge about HPV and vaccination may be low. If 
feasible, press kits and media sessions can be useful to engage the media. • Additional formative research may not be needed to identify key messages because 
there is consistency in the use of messages across projects/programmes that attained 
high coverage.
Lessons learnt from human papillomavirus (HPV) vaccine demonstration projects114
• Message development should focus on: cervical cancer prevention; safety and 
efficacy, including lack of fertility impact or long-term adverse effects, government 
endorsement, delivery timing and venues and the need to return for a second dose. • Consent should be opt-out where feasible, ensuring consistency with existing EPI 
consent policy. If opt-in consent is chosen for HPV vaccination, processes should be 
streamlined and reasons clearly explained to parents and communities.• Intensity of social mobilisation should be assessed after the first year and potentially 
reduced, if high acceptance has been achieved in targeted communities.
Delivery Experience• Countries should select a delivery strategy based on a combination of country 
specific factors:  the proportion of the target group enrolled in school, absenteeism, 
operational costs, desired/adequate coverage, and programme sustainability. • Including a component of school-based delivery can yield high coverage. • Projects/programmes should be evaluated periodically in order to monitor the 
performance of the chosen delivery strategy and test different approaches in terms of 
coverage and cost.• A combination of delivery strategies rather than a single strategy alone is essential to 
achieve high coverage if school enrolment is low. Countries with limited resources may 
decide to minimise outreach if it does not give significant additional impact.• If school-based delivery is planned, microplanning should include an exercise to 
enumerate all schools including non-registered schools.• A specific mobilisation strategy for out-of-school girls to encourage them to attend 
vaccination days at schools, outreach sites or the nearest health centre should be 
implemented. • If resources allow, active follow up of girls who missed doses can yield high coverage 
and successfully use mobile phones or utilise teachers and CHWs. However, during 
planning, the expense and time required must be realised. • Poorly executed mop-up activities can cost more than their incremental benefit 
justifies. When planning with limited resources, the cost-effectiveness of mop-up 
activities should be assessed; a threshold of coverage is a transparent strategy in which 
to limit mop-up activities to those areas where they will be the most efficient e.g. only 
conducting a return visit to a school if <80% of girls received the dose on the first day. 
However, an opportunity for all girls who have missed doses to obtain vaccine should 
be provided – social mobilisation should include messages on the nearest health centre 
where the vaccine can be accessed.• Staff should be trained on how to deal with the presentation of newly eligible girls at 
the vaccination site when returning to deliver the second/ third dose. • If resources allow, planning a two-stage delivery of each dose can be successful in 
reaching those girls who initially refused vaccination, especially when implementing 
HPV vaccination for the first time.
Target population enumeration • Given the data difficulties, it should be accepted that there are considerable 
uncertainties with the number of doses needed. If good records are kept for the first 
dose, vaccine needs can be adjusted for the second dose and for future cohorts.• Countries should allow for a buffer stock when ordering vaccines so that undercounting 
of eligible girls does not result in restricted access to vaccine.• As many schools are not registered by the MOE, local validation of the number of 
schools is needed.• A system of pre-registration of girls at school needs to be implemented a few weeks 
before vaccine delivery to ensure that the vaccination team brings the appropriate 
number of doses. • If teachers are asked to count girls, clear instructions need to be given to them on the 
eligibility criteria.• School absentee rates should be accounted for in the vaccine needs estimates.• During implementation of the first dose, a robust records system should be established, 
which should be used for future target group calculations.   
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Availability of staff • Vaccination team size should be decided during microplanning, after a human resources 
capacity assessment in each area. Team size should vary depending on the size of 
schools in the catchment population, or the number of schools necessary for each team 
to visit, in order to maintain efficiency.• Teams can include teachers and CHWs in order to decrease the number of qualified 
nurses needed for vaccine delivery sessions.  • Integration with other outreach activities, spreading HPV vaccine activities over a 
longer time period, task shifting to lower cadre staff, and/or allowing for longer working 
days could minimize the impact of HPV vaccine activities on other routine services if 
human resources are thought to be limited in country. These strategies and/or other 
strategies should be tested and evaluated.
Staff supervision • Supervision is recommended for HPV vaccine projects/programmes although the 
intensity could decrease over time and supervision could be integrated with routine EPI 
supervision to decrease costs. • New vaccine introduction should be used as an opportunity to strengthen the capacity 
of supervisors at the national, regional and district levels.  
Staff remuneration • The cost impact of staff per diems should not be overlooked when planning HPV 
vaccine introduction. Making HPV vaccination part of routine activities for health 
workers may avoid or reduce per diem payments for delivery of ‘special’ interventions. • Minimising the number of health centre staff needed at the vaccination sites could 
minimise cost, if other community workers regularly conduct outreach activities as part 
of their day-to-day job and HPV can be integrated into those activities. • Integration with other outreach activities could allow the cost of per diems to be shared 
across multiple different programmes/ health interventions. 
Adverse event (AE) monitoring and reporting • Non-EPI stakeholders, such as teachers and parents, should be involved in monitoring 
and reporting AE.• All countries should have standardized national guidelines and training procedures for 
reporting and responding to AE/SAEs.• AE reporting should be standardised globally (e.g. always reported with denominators) 
for the sake of comparability.
Achievements Coverage• Including a component of school-based delivery can yield high coverage and is 
recommended if resources allow. If school enrolment is low, a mixture of strategies 
could be important in order to attain good coverage. There is limited data on how to 
deliver a health facility based strategy successfully.   • The grade based eligibility criteria in a school programme is the easiest and quickest 
strategy to implement; however, we recommend taking into account country specific 
factors of acceptability to the target group and school enrolment statistics. Grade 
based eligibility criteria can make target population enumeration and coverage 
calculations challenging; these processes are easier when eligibility criteria are the 
same for in-school and out-of-school girls. • If countries decide to change delivery strategy, the effects on coverage should be 
carefully monitored and evaluated. • Good relationships between the MOH and MOE should be developed. Coordination 
should begin at an early stage of the planning process, and collaboration should 
continue during implementation in the districts to ensure the vaccine delivery is 
planned and carried out within school timetables, efficiently, and achieves high 
coverage.  • Planning should allow sufficient time for fund disbursement, customs clearance 
and preparation activities including planning transport requirements to ensure that 
scheduled vaccination dates are adhered to and that all vaccine doses are delivered in 
the same school year.• Encourage high-level political commitment to the project/programme in order to 
reduce bureaucratic hurdles, to secure ring-fenced funding and ensure timely delivery 
of the vaccine.
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• Engage the community and community health workers in order to increase acceptance 
and uptake of the vaccine and aid identification of out-of-school girls or girls missing 
doses.• More intense social mobilisation (e.g. more information and over a longer period) 
should be planned for urban areas and private schools as these groups are potentially 
more exposed to negative media exposure and rumours and more likely to refuse 
vaccination.• Out-of-school girls should be specifically targeted with social mobilisation messages 
and provided with an opportunity to access the vaccine either at schools, during 
vaccination days, health facilities or outreach sessions. • An opportunity for girls who missed doses to receive the vaccine should be supplied, 
either at return visits to schools or referral to health facility or outreach sites, 
depending on the resources available.  • Staff may need retraining or refresher training in the use of data collection forms in 
order to ensure adequate quality administrative data. • Different strategies and target populations and integration with other services should 
be tested in order to gain experience for later implementation.  
Monitoring and Evaluation • HPV demonstration projects must include discussion and agreement with EPI personnel 
at the planning phase about how HPV vaccination will be integrated within EPI 
structures.• Monitoring and reporting systems should be standardised, so that issues such as who is 
responsible for holding vaccination cards can be agreed.• Reporting should be consistent with target group selection, i.e. if vaccinating girls by 
school grade, reporting should also be by school grade and by age if necessary.• Where feasible, electronic systems should be used to improve data collection and 
tracking.
Sustainability Scale-up • More case study research should be conducted on scale-up experiences.• Further research should be conducted on the costs versus benefits of school-based 
delivery approaches within national scale-up.• Further exploration of sustainable funding alternatives should be conducted and 
disseminated, to encourage more countries to scale-up demonstration projects.
Integration of HPV 
vaccine with EPI and 
the health system
• Rigorous evaluation of combined interventions with HPV vaccine delivery is needed to 
assess the effect on implementation, coverage, workload and cost. Funding agencies 
should systematically encourage this.• Gradual integration of processes into routine processes should be planned and 
formalised after the first round of vaccination is completed (notably for activities 
such as communication, reporting procedures and processes, supervision, social 
mobilisation, remuneration, and human resources management).• Opportunities to initiate or strengthen existing school health programmes and/or pre-
adolescent/adolescent health should be seized through on-going collaboration with 
partners (e.g. MOE, reproductive health departments).• HPV vaccine is overwhelmingly being delivered through “routinized” campaigns, it 
is critical to ensure that other routine health services are not disrupted by recurrent 
school delivery or that possible disruptions are mitigated, and that this delivery strategy 
is sustainably funded. This needs to be monitored and evaluated.• Financing of operational costs of school-based delivery needs to be embedded into 
routine budget cycles.
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14.  Study limitations 
Due to the timing of the study, we were able 
to	collect	data	from	the	first	year	of	19	of	20	of the Gavi demonstration projects included in the review (we could not interview an EPI representative from Mali about their new Gavi project). Seven of the 20 Gavi projects had delivered a second year and we were able to conduct 5 interviews about the second year of implementation. There may be many more documented lessons when all of these projects have been completed (after their second year). Only 12 Gavi projects had an estimate of coverage available; nine coverage surveys and three administrative estimates from Gavi projects; this was largely due to delays in evaluation teams conducting coverage surveys 
or	finalising	results	(only	one	further	coverage	survey was known to be completed but the results were not available for our review). Reporting of data and experiences in the literature and in interviews was highly variable across countries and projects/programmes. 
The information presented here is biased by the availability of data, which may have been lower for less successful projects/programmes. Representatives from four countries did not respond or refused to be interviewed and this limits our learning from these project/programme experiences. Interviewees committed varying amounts of time for the interview and follow-up questions, although most consented to at least one hour of interview. During the interview, they provided variable levels of detail. The level of recall varied when projects/programmes were undertaken a number of years ago, and, in two instances, the key focal person who was the project manager, had left the organisation and was not contactable (Countries 10, 16). Information was then obtained from the staff who remained but who had not been in charge of the project and who may not have remembered or known 
various	specific	details	about	the	project	set-up	and implementation.  
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15.  Conclusions 
Considerable experience in HPV vaccine delivery is now available from LAMIC. The 
documented	lessons	learnt	and	key	findings	are applicable across world regions and are 
very	similar	to	the	key	findings	documented	
during	the	first	demonstration	projects	in	2007.	Many lessons have been learnt that should make it easier for countries still considering HPV vaccination to plan their projects/programmes and perhaps deliver HPV vaccine through phased national delivery rather than demonstration projects. Recommendations need broad dissemination to improve HPV vaccine introduction, delivery, and scale-up  and encourage best practice. Among Gavi eligible or graduating countries, the availability of funding is the most cited factor governing the perceived sustainability of the 
programme. Countries need more information on future funding opportunities for HPV 
vaccine	delivery,	after	their	first	demonstration	projects. Countries eligible for HPV vaccine support, but that have not yet applied to Gavi for support, are aware of the support being available but often have competing priorities with other new vaccine introductions and limited capacity at the national level to introduce multiple new vaccines in the same time period.  Limited data are available and further evaluation is needed on a number of topics including: catch-up strategies, scale-up to national programmes, delivery of HPV vaccine alongside other interventions, integration with existing health system structures and the key drivers of project/programme costs.
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16.  Appendices 
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Appendix B: Example Medline search results
1 Papillomavirus Vaccines/ 5085
2 hpv.ab,ti. 26945
3 human papillomavirus.ab,ti. 23071
4 human papilloma virus.ab,ti. 3661
5 exp Immunization Programs/ 10517
6 exp Vaccination/ 70018
7 immuni$.ab,ti. 229073
8 vaccin$.ab,ti. 225394
9 2 or 3 or 4 33568
10 Immunization/ 46296
11 5 or 6 or 7 or 8 or 10 415268
12 9 and 11 7745
13 1 or 12 8441
14 gambia/ 2133
15 gambia.ab,ti. 1774
16 14 or 15 2621
17 limit 16 to yr="2014-Current" 150
18 13 and 17 0
19 senegal/ 4852
20 senegal.ab,ti. 4103
21 19 or 20 6035
22 limit 21 to yr="2014-Current" 376
23 13 and 22 2
24 zimbabwe/ 4890
25 zimbabwe.ab,ti. 3737
26 24 or 25 5778
27 limit 26 to yr="2014-Current" 299
28 13 and 27 0
29 chile/ 10403
30 chile.ab,ti. 8360
31 29 or 30 12887
32 limit 31 to yr="2014-Current" 990
33 13 and 32 6
34 burkina faso/ 2398
35 "burkina faso".ab,ti. 2409
36 34 or 35 2980
37 limit 36 to yr="2014-Current" 316
38 13 and 37 0
39 "cote d'ivoire".ab,ti. 1431
40 cote d'ivoire/ 2595
41 39 or 40 2969
42 limit 41 to yr="2014-Current" 195
43 13 and 42 1
44 ethiopia/ 7873
45 ethiopia.ab,ti. 6694
46 44 or 45 8911
47 limit 46 to yr="2014-Current" 1268
48 13 and 47 1
49 "solomon islands".ab,ti. 508
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50 solomon islands/ 892
51 49 or 50 1072
52 limit 51 to yr="2014-Current" 62
53 13 and 52 0
54 togo/ 870
55 togo.ab,ti. 942
56 54 or 55 1134
57 limit 56 to yr="2014-Current" 89
58 13 and 57 0
59 bhutan/ 240
60 bhutan.ab,ti. 288
61 59 or 60 361
62 limit 61 to yr="2009 -Current" 188
63 13 and 62 5
64 bolivia/ 2013
65 bolivia.ab,ti. 2108
66 64 or 65 2792
67 limit 66 to yr="2009 -Current" 939
68 13 and 67 2
69 botswana/ 1275
70 botswana.ab,ti. 1364
71 69 or 70 1648
72 limit 71 to yr="2013 -Current" 283
73 13 and 72 3
74 brazil/ 62883
75 (brazil or brasil).ab,ti. 48616
76 74 or 75 75353
77 limit 76 to yr="2010 -Current" 29830
78 13 and 77 55
79 cambodia/ 2388
80 (cambodia or cambodge).ab,ti. 2169
81 79 or 80 3029
82 limit 81 to yr="2009 -Current" 1277
83 13 and 82 5
84 (cameroon or cameroun).ab,ti. 4286
85 cameroon/ 4051
86 84 or 85 5216
87 limit 86 to yr="2010 -Current" 1691
88 13 and 87 7
89 georgia/ 9405
90 (georgia or Sakartvelo).ab,ti. 6753
91 89 or 90 12915
92 limit 91 to yr="2010 -Current" 2609
93 13 and 92 18
94 ghana/ 5275
95 ghana.ab,ti. 5071
96 94 or 95 6357
97 limit 96 to yr="2013 -Current" 1228
98 13 and 97 1
99 guyana/ 562
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100 guyana.ab,ti. 623
101 99 or 100 897
102 limit 101 to yr="2012 -Current" 126
103 13 and 102 0
104 haiti/ 2504
105 haiti.ab,ti. 1958
106 104 or 105 2948
107 limit 106 to yr="2009 -Current" 1325
108 13 and 107 9
109 honduras/ 907
110 honduras.ab,ti. 1125
111 109 or 110 1361
112 limit 111 to yr="2011 -Current" 265
113 13 and 112 7
114 india/ 82017
115 india.ab,ti. 53099
116 114 or 115 96520
117 limit 116 to yr="2009 -Current" 32162
118 13 and 117 100
119 kenya/ 12121
120 kenya.ab,ti. 11071
121 119 or 120 14645
122 limit 121 to yr="2011 -Current" 3798
123 13 and 122 13
124 kiribati/ 1003
125 kiribati.ab,ti. 110
126 124 or 125 1059
127 limit 126 to yr="2011 -Current" 163
128 13 and 127 0
129 (laos or lao).ab,ti. 2008
130 laos/ 1391
131 129 or 130 2431
132 limit 131 to yr="2013 -Current" 404
133 13 and 132 0
134 lesotho/ 311
135 lesotho.ab,ti. 422
136 134 or 135 481
137 limit 136 to yr="2009 -Current" 157
138 13 and 137 1
139 madagascar/ 2581
140 madagascar.ab,ti. 3029
141 139 or 140 3543
142 limit 141 to yr="2013 -Current" 549
143 13 and 142 0
144 malawi/ 3555
145 malawi.ab,ti. 3743
146 144 or 145 4441
147 limit 146 to yr="2013 -Current" 934
148 147 and 13 3
149 mali/ 1862
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150 mali.ab,ti. 2281
151 149 or 150 2754
152 limit 151 to yr="2012 -Current" 569
153 152 and 13 5
154 (moldova or moldavia).ab,ti. 516
155 moldova/ 604
156 154 or 155 882
157 limit 156 to yr="2013 -Current" 98
158 157 and 13 2
159 mongolia/ 1306
160 mongolia.ab,ti. 2126
161 159 or 160 2647
162 limit 161 to yr="2012 -Current" 747
163 162 and 13 1
164 morocco/ 4302
165 morocco.ab,ti. 3413
166 164 or 165 5304
167 13 and 166 6
168 mozambique/ 1622
169 mozambique.ab,ti. 1974
170 168 or 169 2323
171 limit 170 to yr="2014 -Current" 302
172 171 and 13 0
173 nepal/ 5554
174 nepal.ab,ti. 5146
175 173 or 174 6611
176 limit 175 to yr="2008 -Current" 3107
177 176 and 13 6
178 niger/ 947
179 niger.ab,ti. 8535
180 178 or 179 8706
181 limit 180 to yr="2014 -Current" 692
182 181 and 13 0
183 papua new guinea.ab,ti. 3512
184 papua new guinea/ 2964
185 183 or 184 4294
186 limit 185 to yr="2012 -Current" 570
187 186 and 13 1
188 peru/ 6144
189 peru.ab,ti. 6012
190 188 or 189 8298
191 limit 190 to yr="2007 -Current" 3606
192 191 and 13 26
193 (philippines or pilipinas or filipinas).ab,ti. 5438
194 philippines/ 6935
195 193 or 194 8853
196 limit 195 to yr="2010 -Current" 1830
197 196 and 13 4
198 rwanda/ 1649
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199 rwanda.ab,ti. 1532
200 198 or 199 2072
201 limit 200 to yr="2011 -Current" 617
202 201 and 13 8
203 sierra leone.ab,ti. 1053
204 sierra leone/ 948
205 203 or 204 1290
206 limit 205 to yr="2013 -Current" 377
207 206 and 13 0
208 south africa.ab,ti. 19388
209 south africa/ 33165
210 208 or 209 37735
211 limit 210 to yr="2011 -Current" 8784
212 211 and 13 36
213 tanzania/ 8464
214 tanzania.ab,ti. 7676
215 213 or 214 9927
216 limit 215 to yr="2010 -Current" 3322
217 216 and 13 17
218 thailand/ 21183
219 thailand.ab,ti. 17744
220 218 or 219 26226
221 limit 220 to yr="2010 -Current" 7834
222 221 and 13 37
223 uganda/ 8601
224 uganda.ab,ti. 8087
225 223 or 224 10265
226 limit 225 to yr="2008 -Current" 4692
227 226 and 13 32
228 uzbekistan/ 1804
229 uzbekistan.ab,ti. 856
230 228 or 229 1999
231 limit 230 to yr="2009 -Current" 242
232 231 and 13 2
233 vietnam/ 9403
234 vietnam.ab,ti. 8707
235 233 or 234 12413
236 limit 235 to yr="2008 -Current" 4654
237 236 and 13 27
238 zambia/ 3347
239 zambia.ab,ti. 3148
240 238 or 239 4135
241 limit 240 to yr="2013 -Current" 640
242 241 and 13 3
243 18 or 23 or 28 or 33 or 38 or 43 or 48 or 53 or 58 or 63 or 68 or 73 or 78 or 83 or 88 
or 93 or 98 or 103 or 108 or 113 or 118 or 123 or 128 or 133 or 138 or 143 or 148 or 
153 or 158 or 163 or 167 or 172 or 177 or 182 or 187 or 192 or 197 or 202 or 207 or 
212 or 217 or 222 or 227 or 232 or 237 or 242
398
244 developing countries/ 65420
245 limit 244 to yr="2007 -Current" 17905
246 245 and 13 142
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247 GAVI.ab,ti. 238
248 limit 247 to yr="2007 -Current" 213
249 248 and 13 31
250 (Low-income countries or LIC).ab,ti. 3274
251 limit 250 to yr="2007 -Current" 2510
252 251 and 13 19
253 (Low-middle income countries or LMIC).ab,ti. 456
254 limit 253 to yr="2007 -Current" 445
255 254 and 13 2
256 243 or 246 or 249 or 252 or 255 545
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Appendix C: Interview topic guide 
for countries with HPV experience 
Key Informant Interview Topic Guide: 
Countries with experience of HPV 
vaccination in a demonstration/ pilot 
project or national roll-out.The interview will involve structured and open questions on a selection of the following topics dependent on what information is obtained from the published and grey literature review:
Decision making at the national/ regional 
level: 
• How was the decision made to conduct the HPV vaccine demonstration project/ national* programme? (*delete as appropriate and use this phrase for the remainder of the interview)
• What	information	influenced	the	decision	and planning? (e.g. information from other countries/ info from a previous pilot?
Planning:
• Was there a planning committee? 
• Who was involved in the planning committee? (e.g. representatives from Reproductive Health, Adolescent Health and Cancer services on the National Immunization Technical Advisory Group (NITAG) or Technical Advisory Group (TAG) for the HPV vaccine projects?)
• How was planning integrated with other sectors e.g. EPI / education sectors? 
• Is there a national cervical cancer control programme? How was the introduction of HPV vaccine integrated with the national cervical cancer control programme and screening services? 
• Were	there	specific	challenges/benefits	in involving the stakeholders you have mentioned/ developing these collaborations? 
HPV vaccine delivery strategy:
• What was the target population for HPV vaccine delivery? 
• Vaccination venues? 
• Timing of vaccination – was HPV vaccination 
performed	on	specific	days	or	was	it	introduced as a routine vaccine available at 
any	time?	If	it	was	provided	on	specific	days	- How many days? How were girls who were 
absent on the day of vaccination accessed (were there ‘mop-up’ activities?)? 
• Was	there	a	specific	delivery	strategy	for	
out-of-school	girls/	identified	hard-to-reach	girls (married/ nomadic/ lower SES girls?)? What was this strategy?
• How was delivery of HPV vaccine integrated with the EPI programme? Was this 
beneficial/	problematic?
• How did health workers/ the government 
health	officials	coordinate	with	schools/	education sector (IF vaccine was delivered in schools/ on school days) / other vaccination venues? Was this advantageous/ problematic? What were the lessons learnt from this? If schools delivery was used what was the role of teachers and educational staff in the delivery (organising, consent taking, follow-up of absentees, completing reporting forms?)?
• Was HPV vaccine delivered with any other services (e.g. other vaccines/health education/ child health interventions…)? Lessons learnt from this?
• Has the pilot continued for >1 year? 
• Has the delivery strategy changed over the years of pilot/introduction? Why was the strategy changed? (What happened and what effect did it have on the delivery strategy?)
• What were the main challenges experienced?
Vaccine management:
• Prior to vaccine delivery, how was the amount of vaccine required, calculated? How was a denominator estimate made for both in-school and out-of school girls? Did this estimate prove accurate? 
• How was vaccine supplied to the delivery sites? How did the supply chain differ from that used for other EPI vaccines?
• Did more girls than expected present at any of the venues? How was this managed in terms of vaccine/syringe supply? Were 
there	sufficient	supplies	of	vaccine	and	consumables at each venue?
• How was the waste generated by vaccination managed and disposed? Was it monitored? Was it done safely? How did this differ from the management of EPI vaccines?
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Cold Chain: 
• Was an assessment of cold chain capacity completed before implementation (of the demo/ national programme)?
• Were changes needed and made to the cold chain facilities for HPV (before, during or after HPV vaccine delivery)?
• How did the HPV cold chain differ/ was it different from systems used for other EPI vaccines? 
Quality/ Safety of care:
• Immunization safety: How were AE/SAE reported? Were there any AE/SAEs? How were these dealt with?
• If the vaccine was delivered outside of the health facility, were emergency kits present at delivery of all vaccination rounds? 
• Safe injection procedures – were they outlined to health workers, were they assessed? 
• How were safety processes for HPV vaccine (AE/SAE reporting and safe injection procedures and training) different from what is done in the EPI program (policies, procedures, reporting, etc)? 
Social mobilisation:
• Was there a plan to carry out social mobilisation/ an educational campaign prior to HPV vaccine delivery? Was it done?
• What were the key messages and communication materials used?
• How the messages were delivered (radio/ drama/ newspaper?)?
• Who delivered the key messages about HPV vaccine (was it a MOH spokesperson/ community leaders/ religious leaders?) 
• Who was the target audience?
• When/ how often was social mobilisation done and how far in advance of vaccination with each dose?
• Were vaccine recipients given incentives to attend the vaccination venue? 
• Were messages delivered during social mobilisation integrated with educational messages about other health interventions/ other vaccines e.g. EPI vaccines? Have there been any indications that HPV vaccine delivery increased demand for other routine vaccines?
The consent process:
• How did parents give permission to vaccinate? Opt-in or opt-out? 
• How were parents informed about vaccination activities for opt-out consent/ how were parents accessed for opt-in consent? 
• Was the process the same as for other routine vaccinations e.g. infant vaccinations or TT boosters in older children? 
Coverage/ acceptability of HPV vaccine: 
• Do you have information on acceptability of vaccination/ refusals? How were issues overcome? What did parents say were factors that made them get their daughters vaccinated/ prevented them getting their daughters vaccinated?  What were the reasons for non-vaccination?  What were the reasons for not completing the 3-dose series?
• Coverage of dose 1, 2, 3 for each year of implementation? In school girls and out-of-school girls? How were these calculated – what was the denominator used?
• Completion rate
Availability of healthcare staff: 
• How many staff were used to deliver the vaccine/ how many used at each vaccination session? Did this differ between sessions at the health centre/ school/ other outreach site?
• Were staff the same staff as those used to deliver EPI vaccines?  
• What was the distribution of staff – how many were allocated to HPV vaccine delivery per facility/ per school/ per community? How many individuals/schools/ communities would one HW cover?
• What was staff workload like during the vaccination? Did it affect normal day-to-day health worker activities? How long did vaccination activities take? 
• Is there any evidence of the extent to which routine healthcare activities including routine EPI were disrupted during HPV vaccine activities? 
• Did HPV vaccination and social 
mobilisation	activities	influence	the	relationships between local health workers and the community/ schools?
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Training of staff: 
• Who participated in training (District representatives/ Number of HWs/ teachers/ community members?)? Did they train others?
• Did training reach the numbers expected/ was more training necessary?
• When was it (how long before vaccination)?
• How long was it? Is it now routine training or was it a one-off?
• Who conducted training?
• Was it integrated with training for routine EPI program?
Remuneration of staff:
• Were per diems used to pay staff for vaccine delivery/ to attend training/ to conduct social mobilisation activities?
• Were incentives to staff used/ helpful/ necessary for quality of care?
• Are processes for remuneration similar to EPI vaccines? Were per diems the same amount as given for routine EPI vaccine delivery?
Performance and supervision of staff:
• What support and supervision of staff was conducted  during HPV vaccine implementation?
• Was supervision integrated with other EPI/ health facility supervision?
• Did the level of supervision differ from routine EPI vaccine delivery? Why?
Monitoring & Evaluation – Reporting 
systems
• How was data collected at the site of delivery on the number of girls vaccinated/ the number who received dose 2 after dose 1? 
• Was the quality of data collection assessed or supervised? 
• Were data collection forms and subsequent data management processes integrated with the national HMIS / the routine EPI reporting systems? 
Financial support for HPV vaccine and 
sustainability:
• Who	financed	the	vaccine?
• Who	financed	the	delivery	costs?
• What	are	plans	for	financing	the	HPV	programme in the future?
• Has a costing study been undertaken of the demonstration project/ national programme? Details?
If the country performed a demo/ pilot 
programme; has there been scale-up after 
the demo to more regions or national roll-
out? 
If yes: 
• How was the decision made to scale-up from pilot/ demo to a national programme? 
• Did the experience/results from the pilot/
demo	influence	the	decision	to	scale	up? Which experiences/ what results 
influenced	the	decision?
• Which	factors	perceived	to	influence	successful demonstration projects can help ensure “success” when going national? 
• What problems that occurred during the demonstration phase have/ will inform strategy for national scale up? 
• Key differences between demonstration projects and national program and key challenges in scaling up. E.g. Were the activities the same or different? How involved was the EPI program for each? Did that make a difference? 
• Were there changes in strategy for year 2 of demonstration project or national scale-
up	and	rationale	for	this	(e.g.	influence	of demonstration project results on the national delivery strategy)?
• What aspects of EPI functions are expected to change with the scale-up of HPV demonstration projects?  
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Appendix D: Interview topic guide 
for countries with no HPV vaccine 
experience
Key Informant Interview Topic Guide: 
Countries who have not yet implemented 
HPV vaccine demonstration projects.The interview will involve structured and 
open	questions	around	factors	influencing	the	decision to implement/ not-implement HPV vaccination:
• The interviewee’s role and experience in the immunization services in general and in decisions related to the HPV vaccination 
programme	specifically.	
• Factors	influencing	the	decision	on	HPV	vaccine introduction
• Do you feel cervical cancer rates are a health priority for the country? 
• How can cervical cancer be prevented? Are you aware that there is a vaccine against HPV?
• Are you aware that HPV vaccine is available through GAVI funding (free for a demonstration project, subsidised for a national programme)?  
• In your view, what are the key reasons why HPV vaccine has not yet been introduced/ an application to GAVI for funding for introduction of HPV vaccine has not been made? 
• Are there other interventions which are/will be prioritised before HPV vaccine? For what reasons?
• Have there been discussions in the MOH on the opportunity to introduce HPV vaccine? Who has been involved in these discussions (roles/ titles (not names))? What have been the outcomes of these discussions/ what are the key points raised by different stakeholders?
• If so, what information was needed in those discussions or what would be needed now if discussions were to take place about introducing HPV vaccine in a pilot/ national programme? 
• Does the country have experience of GAVI Alliance funding? What was the experience 
(were	there	particular	benefits/	drawbacks	that you know of?)
Decision processes How are decisions made on whether to introduce new vaccines? (Probes: are there committees e.g. an immunization advisory committee? Who is involved? Are stakeholders from outside the MOH involved?) Which vaccines have been introduced into the national vaccination programme/ introduced 
in	demonstration	projects	in	the	last	five	years? What information was required in order to introduce these new vaccines? How 
was	the	final	decision	arrived	at?	What	factors	
influenced	these	decisions?	
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Appendix E: Data collected in each of the two data collection periods 
Original grant; data collection 
period Nov 2014-April 2015
Supplement grant; data 
collection period Nov 2015-
1st May 2016
Total
Total countries 
targeted for data 
collection 
37 LAMICs with at least 1 year 
of HPV vaccination experience 
in demonstration projects or 
national pro-grammes
30 countries: 9 new countries 
with new projects since May 
2015; 8 that we were unable 
to reach in the first phase 
of data collection; 5 with 
year 2 Gavi project data; 5 
with data on new projects/
programmes.
46
Demonstration 
projects 
55 11 additional 66
National  
programmes
8 4 additional 12
Scale-up 
experiences 
7 3 additional 10
Published 
literature full 
texts
41 full texts and 9 conference 
abstracts
20 extra full texts and 2 
conference abstracts
61 full texts and 11 
conference abstracts
Grey literature 124 reports from 35 countries 
Including: 4 Gavi PIE, 1 Gavi 
costing report, 2 Gavi coverage 
surveys, 16 GAP final reports
64 further reports from 26 
countries Including: 5 Gavi 
PIE, 6 Gavi costing reports, 4 
Gavi coverage surveys, 
188 reports, presentations, 
datasets, etc. from 44 
countries Including: 9 Gavi 
PIE, 7 Gavi costing reports, 
6 Gavi coverage surveys, 16 
GAP final reports. 
Key informant 
in-terviews 
27 interviews regarding 23 
countries (of 33 targeted for 
interview)
29 further interviews in 27 
countries (of 30 targeted for 
interview)
56 interviews regarding 40 
countries
Lessons learnt from human papillomavirus (HPV) vaccine demonstration projects 139
Appendix F: Gaps in analysis  
and unanswered questions 
There are a number of areas where the 
data are limited but where more data 
will come available in the next year(s):
• Delivery  a.  Evaluation of catch-up campaignsb.  Evaluation of a 2 dose strategy with a 12 month interval e.g. Chilec.  Evaluation of the decentralised approach where localities choose the most convenient outreach or health facility based strategies for them (does this result in predominantly school based delivery anyway? Implications for target population enumeration and coverage?) e.g. Brazil, Uganda, Tanzania. d.  Data on national programmes, phased national roll-out, or transitional periods after the demonstration period but before a national programme.  e.  Long-term coverage achievements once the initial concentration of resources during the demonstration project has waned.
f.			Specific	delivery	challenges	in	urban	areas	and best practices for enumeration to cope with migration, communication, anti-vaccine lobbyists.  
• Social mobilisation a. Media engagement – best practices?b. What was done versus what was reported to have been done and which messages or methods were most accessed by the community 
• Integration of HPV vaccine delivery with 
other interventions
• Scale-up processes from demonstration 
project to national programme
• The value of demonstration projects
• Key drivers of programme costs and 
sustainability 
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